ÀDOCTYPE HTML PUBLIC "-å]ï0Ã0È0—e/DTD HTML 4.01 Transitionaîv/EN" "httpa_/www.w3.or’uTR/html4/loose.dtd"> ; </span><span class="naked_aural">(èlŠ)</span>charset=UTF-8"> å­å®®é ¸ãŒã‚“（cervical cancer）ワクãƒãƒ³æŽ¥ç¨®å•é¡Œï¼ã‚’ã‚ãる言説Ã_title> <link rel="stylesheet" type="text/css" href="../css/default.css" media="all"> <meta name="keywords" content="å­å®®é ¸ç™Œ,ワクãƒãƒ³,医療被害">À-- Global site tag (gtag.js) - Google Analytics --> <scrip4�async src="httpsa_/www.googletagmanager.coÛwgtag/js?id=G-4QQQX(�åe)�BFL"></script> <script> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', ne7�Date()); gtag('config', 'G-4QQQX02BFL'); Ã_script> <meta name="viewport" content="width=device-width,initial-scale=1"> Ã_head> <body> À--↓Facebook↓--> <div id="fb-root">Ã_div><scrip4�charset="utf-8" src=".Û]cstzfb.js"></script> <!--↑facebook↑--> <a name="top">Ã_a> <di6�class="s"><a href=".Û]index.htm">HOME</a �>Ã_div> <hr><di6�class="c"> <È> å­å®®é ¸ãŒã‚“（cervical cancer）ワクãƒãƒ³æŽ¥ç¨®ï¼HPV vaccine å•é¡Œï¼ã‚’ã‚ãる言説 </h1> cervical cancer vaccine <a href=".Û](ums.htm">医療ã¨ç¤¾ä¼š</a>ï¼<a href=".Û](up05.htm">予防接種</a> Ã_div><hr> À--↓Twitter, Facebook↓--> <di6�class="flt-l"> <a href="https:å]twitter.coÛwshare" class="twitter-share-button" data-via="ShinyaTateiwa">TweetÃ_a><scrip4�charset="utf-8" src=".Û]cstztwt.js">Ã_script> <div class="fb-like" data-href="httpa_/www.arsvi.com/d/hpvv.htm" data-layout="button_count" data-action="like" data-show-faces="true" data-share="true">Ã_div> </div> À--↑Twitter, Facebook↑--> <di6�class="sr">las4�update: 20Õ0¡0é0Ã0É00715Ã_div> <di6�id="text"> <1�6�¹p>○本ファイル内目次Ã_1�6�¹p> 　■<a href="#1">（関連ã™ã‚‹ï¼‰æ–‡çŒ®</a> 　　◆<a href="#11">日本語Ã_a> 　　　◇<a href="#110">当事者ã®èªžã‚ŠÃ_a> 　　　◇<a href="#1�">書ç±Ã_a> 　　　◇<a href="#1(�*h)�">è«–æ–‡Ã_a> 　　◆<a href="#(�*h)�">英語Ã_a> 　　　◇<a href="#1">書ç±Ã_a> 　　　◇<a href="#1(� g)�">è«–æ–‡Ã_a> 　■<a href="#2">引用</a> 　■<a href="»0ó0È0">2016年以å‰ã®æŽ²è¼‰æƒ…å ±Ã_a> <h3>○生存学HP内関連ファイル</h3> 　　■人 　　■事項 　　■全文掲載 <hr> <1�6�¹p id="0">■関連サイトãªã©Ã_1�6�¹p> è–¬ã®ãƒã‚§ãƒƒã‚¯ httpsa_/npojip.or’u <h2 2 id="1">■文献等</h3> <h4 id="11">◆日本語</h4> <h4 id="110"><span style="color:dimgrey;">â– Ã_span>当事者ã®èªžã‚Š</h4> <span style="color:cornflowerblue;">â—†</span>森　ã‚ã‹ã­ã€€2020　「HPVワクãƒãƒ³ã‚’接種ã—ã¦ã‹ã‚‰ã“ã‚Œã¾ã¦?ã®ã“ã¨ï¼Œãã—ã¦ä»Šã®æ€ã„ã€,　『社会臨床雑誌ã€W8-3:70-79.　<a href="https:å]www.jstage.jst.go.jp/article/shakairinshów28Ô0¯0ë0(�W)�8___article/-char/jæt">[外部サイト]</a> <span style="color:cornflowerblue;">â—†Ã_span>黒崎　未知å­ã€€2020　「ワクãƒãƒ³è¢«å®³è€…ã«ãªã‚‹ã¨ã„ã†ã“ã¨ã€€ãƒ¼ãƒ¼ç§ã®å¨˜ã®é—˜ç—…体験ã¨æ”¯æ´ä½“制ã®ç¾çŠ¶ã‚’中心ã«ã€,　『社会臨床雑誌ã€W8-3:19Ð0ü0ì0ë04.　<a href="https:å]www.jstage.jst.go.jp/article/shakairinshów28Ô0¯0ë0(�W)�8_ô^_article/-char/jæt">[外部サイト]</a> <h4><span style="color:dimgrey;">â– </span>ＨＰＶワクãƒãƒ³è–¬å®³è¨´è¨Ÿå…¨å›½å¼è­·å›£Ã_h4> https:å]www.hpv-yakugai.neËz <h4><span style="color:dimgrey;">â– Ã_span>厚生労åƒçœè³‡æ–™Ã_h4> 全国疫学調査（å­å®®é ¸ãŒã‚“ワクãƒãƒ³ã®æœ‰åŠ¹æ€§ã¨å®‰å…¨æ€§ã®è©•ä¾¡ã«é–¢ã™ã‚‹ç–«å­¦ç ”究 https:å]www.mhlw.go.jp/fil0u05-Shingikai-10601000-Daijinkanboukouseikagakuka-Kouseikagakukæt000016Ó0ë0(�yr)�.pdf http:å]www.mhlw.go.jp/fil0u05-Shingikai-10601000-Daijinkanboukouseikagakuka-Kouseikagakukæt0000147016.pdf 第２３回厚生科学審議会予防接種・ワクãƒãƒ³åˆ†ç§‘会副å応検討部会ã€å¹³æˆï¼’８年度第９回薬事・食å“衛生審議会医薬å“等安全対策部会安全対策調査会　資料 httpsa_/www.mhlw.go.j:yst‹ushingir^0000147015.html <h4 id="1�"><span style="color:dimgrey;">â– Ã_span>書ç±</h4> <span style="color:cornflowerblue;">â—†</span>種田 åšä¹‹ã€€20Õ0¡0é0Ã0É0　「『å­å®®é ¸ãŒã‚“ワクãƒãƒ³ã€æŽ¥ç¨®å¾Œã®æœ‰å®³äº‹è±¡ãªã„ã—å¥åº·è¢«å®³ã€ï¼Œæœ¬éƒ· 正武・ä½è—¤ 哲彦 編著　『薬害ã¨ã¯ãªã«ã‹â”€â”€â”€æ–°ã—ã„薬害ã®ç¤¾ä¼šå­¦ã€ï¼ŒãƒŸãƒãƒ«ãƒ´ã‚¡æ›¸æˆ¿. <h4><span style="color:dimgrey;">â– </span>書ç±ï¼ˆè‹±èªžï¼‰Ã_h4> <h4 id="1(�*h)�"><span style="color:dimgrey;">â– Ã_span>論文（日本語ã®ç ”究）</h4> <span style="color:cornflowerblue;">â—†</span>種田 åšä¹‹ã€€20　「HPVワクãƒãƒ³æŽ¥ç¨®å¾Œã®æœ‰å®³äº‹è±¡ï¼å¥åº·è¢«å®³ã‚’ã‚ãる係争　ーースティグマã®è¦–点よりã€,　『関西学院大学先端社会研究所紀è¦ã€18:1-16.　<a href="httpsa_/www.jstage.jst.go.j:yarticl0uiasr/1_ñ]18q/_articl0u-cha¾yja.".">[外部サイト]Ã_a> <span style="color:cornflowerblue;">â—†</span>井上 芳ä¿ã€€ã€Œå…ˆåˆ¶åŒ»ç™‚ã¸ã®æ„å¿—ã¯ã€Œæ­£å¸¸ç—…ã€ã®ç—‡çŠ¶ã‹ã‚‚ã—ã‚Œãªã„　ーーHPVワクãƒãƒ³æŽ¥ç¨®è¢«å®³äº‹ä»¶ã‚’糸å£ã«ã—ã¦ï¼ˆã‚·ãƒ³ãƒã‚¸ã‚¦ãƒ ã€Œç—…ã‚’ã‚ãã‚‹Contestation――本態・病因・治療法を論点ã¨ã—ã¦ã€ï¼‰ã€,　『ä¿å¥åŒ»ç™‚社会学論集ã€28(�(g)�:44-Õ0é0ó0.　<a href="httpsa_/www.jstage.jst.go.j:yarticl0ujshmtz28(�W)�(�W)�8_28(�åe)�06/_articl0u-cha¾yja.".">[外部サイト]Ã_a> <span style="color:cornflowerblue;">â—†</span>平岡 厚ã€�N(�åe)�0　「HPV ワクãƒãƒ³è«–争をå†è€ƒã™ã‚‹ã€€ãƒ¼ãƒ¼æŽ¨é€²æ´¾ã®ä¸»å¼µã®å•é¡Œç‚¹ã‚’中心ã«ã€,　『社会臨床雑誌ã€28Ô0¢0¹0È0ë0°05-1Ó0ë0.　<a href="httpsa_/www.jstage.jst.go.j:yarticl0ushakairinsho(�W)�_z^28qz^_article/-char/jæt">[外部サイト]</a> <span style="color:cornflowerblue;">â—†Ã_span>隈本 邦彦ã€�N(�åe)�0　「"åå¤å±‹ã‚¹ã‚¿ãƒ‡ã‚£ã¨ã„ã†ç–«å­¦ç ”究ã¯å­˜åœ¨ã—ãªã„　ーー自由記載欄ã«ã“ãã‚る真実ã«ç›®ã‚’å‘ã‘ã‚‹ã¹ãã§ã‚ã‚‹ã€,　『社会臨床雑誌ã€W8-3:AS-87.　<a href="https:å]www.jstage.jst.go.jp/article/shakairinshów28Ô0¯0ë0(�W)�8_P__article/-char/ja">[外部サイト]Ã_a> <h6><span style="color:dimgrey;">â– </span>論文・医学（日本語）Ã_h6> <span style="color:cornflowerblue;">â—†</span>平井 利明・黒岩 義之　20(� g)�　「環境éŽæ•ç—‡ã€€ãƒ¼ãƒ¼HANSã®ç—‡å€™ï¼Œè‡ªç„¶å²ï¼Œè‡ªå¾‹ç¥žçµŒæ©Ÿèƒ½æ¤œæŸ»ç­‰ã‹ã‚‰å…¨ä½“åƒã‚’考察ã™ã‚‹ã€,　『自律神経ã€59.1:60-.　<a href="httpsa_/www.jstage.jst.go.j:yarticl0uantz59/1/59_0/_articl0u-cha¾yja.".">[外部サイト]Ã_a> <span style="color:cornflowerblue;">â—†</span>鈴木 富雄　20　「Empirical EYE　ーーç§ã®å®Ÿè·µãƒ»çµŒé¨“知「HPV ワクãƒãƒ³æŽ¥ç¨®å¾Œã€ã®ç—‡çŠ¶ã«è‹¦ã—む患者ãŒå—診ã—ãŸæ™‚，ç·åˆè¨ºç™‚医ã¨ã—ã¦ã§ãã‚‹ã“ã¨ã€,　『Journal of generalis4�medicine　ーージェãƒãƒ©ãƒ«ã«è¨ºã‚‹ã“ã¨ãŒæ±‚ã‚られる時代ã®è‡¨åºŠèªŒã€ªÔ0¢0¹0È0ë0Ú0ó0¹0(�yr)�Ð0ü0ì0ë055.　<a href="httpsa_/webview.isho.jp/journal/detaiîvabtz10.11477/mf.1429203067">[外部サイト]</a> <span style="color:cornflowerblue;">â—†Ã_span>鈴æœR�s�富雄ã€�N(�åe)�1　「Empirical EYE　ーーç§ã®å®Ÿè·µãƒ»çµŒé¨“知「HPV ワクãƒãƒ³æŽ¥ç¨®å¾Œã€ã®ç—‡çŠ¶ã«è‹¦ã—む患者ãŒå—診ã—ãŸæ™‚，ç·åˆè¨ºç™‚医ã¨ã—ã¦ã§ãã‚‹ã“ã¨ã€,　『Journal of generalist medicine :ジェãƒãƒ©ãƒ«ã«è¨ºã‚‹ã“ã¨ãŒæ±‚ã‚られる時代ã®è‡¨åºŠèªŒã€ªÔ0¢0¹0È0ë0Ú0ó0¹0(�yr)�Ð0ü0ì0ë055.　<a href="httpsa_/webview.isho.jp/journal/detaiîvabtz10.11477/mf.1429203067">[外部サイト]</a> <span style="color:cornflowerblue;">â—†Ã_span>片平 洌彦・榎 å®æœ—　2019　「HPV ワクãƒãƒ³ã®æŽ¥ç¨®å‹§å¥¨ä¸­æ­¢ãŒ 「副å応疑ã„報告〠数ã«ä¸ŽãˆãŸå½±éŸ¿: 厚生労åƒçœå…¬è¡¨ã® 「副å応疑ã„報告〠ã®ç—‡ä¾‹ãƒ‡ãƒ¼ã‚¿ã‹ã‚‰ã®è€ƒå¯Ÿã€,　『社会医学研究= Bulletin of social medicine: 日本社会医学会機関誌ã€36.1:81-89.　<a href="http:å]jssm.umin.jp/reporËzno36-1.html">[外部サイト]Ã_a> <span style="color:cornflowerblue;">â—†</span>髙嶋 åš.　2018　「ヒトパピローマウイルスワクãƒãƒ³æŽ¥ç¨®å¾Œã®ç¥žçµŒç—‡çŠ¶ã¯, ãªãœå¿ƒå› æ€§ç–¾æ‚£ã¨é–“é•ã‚れるã®ã‹ã€,　『神経治療学ã€k�g�5.4:Õ0é0ó06-542.　<a href="https:å]www.jstage.jst.go.jp/article/jsnËz35/4Ô0¯0ë05_Õ0é0ó0þ^_article/-char/jæt">[外部サイト]</a> <span style="color:cornflowerblue;">â—†Ã_span>高æ©"幸利 ä»–ã€�N017　「ヒトパピローマウイルス (å­å®®é ¸ãŒã‚“) ワクãƒãƒ³æŽ¥ç¨®å¾Œã«ã¿ã‚‰ã‚Œã‚‹ä¸­æž¢ç¥žçµŒç³»é–¢é€£ç—‡çŠ¶ã€,　『神経治療学ã€106.8:15-1597.　<a href="https:å]www.jstage.jst.go.jp/article/naika/106/8/106q59þ]_article/-char/jæt">[外部サイト]</a> <span style="color:cornflowerblue;">â—†Ã_span>æ± ç”° 修一ã€�N016　「å­å®®é ¸ãŒã‚“ワクãƒãƒ³é–¢é€£ã®ç¥žçµŒç—‡å€™ã¨ãã®ç—…æ…‹ã€,　『神経治療学ã€Õ0£0ü0È0.1Ú0ó0¹02-39.　<a href="httpsa_/www.jstage.jst.go.j:yarticl0ujsntÔ0¯0ë0z^þ]Õ0£0ü0È07�¹pr^_article/-char/jæt">[外部サイト]</a> <span style="color:cornflowerblue;">â—†Ã_span>今é‡)�良 他　2015　「仮説HANSã‚’HPVワクãƒãƒ³å‰¯åå¿œã¨ã™ã‚‹åŒ»å­¦çš„根拠ã®æ¬ å¦‚　ーーワクãƒãƒ³å­¦ãƒ»ç–«å­¦çš„視点ã‹ã‚‰ã€,　『日本医事新報ã€4783:14-16.　<a href="httpa_/jssm.umin.j:yreport/n2�3�¹p6-1.html">[外部サイト]</a> <span style="color:cornflowerblue;">â—†Ã_span>片平洌彦・榎å®æœ—　2014　「海外ã«ãŠã‘ã‚‹HPVワクãƒãƒ³è¢«å®³å ±å‘Šã¨è£œå„Ÿãƒ»è¨´è¨Ÿã®å®Ÿæ…‹(第2å ±)ã€,　『新潟医療ç¦ç¥‰å­¦ä¼šèªŒã€14-1:70. <blockquote>米国:接種後ã«èµ·ããŸæœ‰å®³äº‹è±¡(AE)ã¨ã—ã¦ã€CDC・FDAç­‰ã«ã‚ˆã‚ŠVEARSReportã«é›†ç´„・公表。2014å¹´7月ç¾åœ¨ã€AEåˆè¨ˆãr�a�d�"s�2�5,692ã€ã“ã®ä¸­ã«ã¯ã€æ­»äº¡170ã€ç”Ÿå‘½ã¸ã®è„…å¨645ã€æ•‘急室入院11,4ã€å…¥é™¢3,Ú0½07ã€é‡ç¯¤4,984ã€æœªå›žå¾©7(�4l)�(�åe)�ç­‰ãŒå«ã¾ã‚Œã€ã¾ãŸã€ãƒ‘ップスメア検査異常577ã€å­å®®é šéƒ¨ç•°å½¢æˆ249ã€ãã—ã¦å­å®®é šãŒã‚“ASãŒå«ã¾ã‚Œã¦ã„る。臨床試験ã§17人ã®å°‘女ã®æ­»äº¡ãŒå ±å‘Šã•ã‚Œã¦ã„ã‚‹m]。20Ó0ë0å¹p�V�月ç¾åœ¨ã€200人ãŒæ訴ã—ã€ã†ãO人ã®æ­»äº¡ã‚’å«ã‚€49人ãŒç±³å›½ãƒ¯ã‚¯ãƒãƒ³è¢«å®³è£œå„Ÿãƒ—ログラム(VICP:政府ãŒè²¬ä»»ã‚’è² ã†)ã«ã‚ˆã‚Šè£œå„Ÿã•ã‚ŒãŸ[2]〠N014å¹´8月4æ—¥ã¾ã§ã®é›†è¨ˆã§ã¯ã€è£œå„Ÿã¯71人ã§ã€æ£„å´ãŒ80人ã¨ãªã£ã¦ã„ã‚‹3�¹p]。Ã_blockquote> <h6><span style="color:dimgrey;">â– </span>論文・医薬å“情報学（日本語）Ã_h6> <span style="color:cornflowerblue;">â—†</span>é•·å— è¬™ä¸0�他　2020　「医薬å“副作用被害救済制度ã«ãŠã‘ã‚‹HPVワクãƒãƒ³ã®å‰¯ä½œç”¨çµ¦ä»˜çŠ¶æ³ã«ã¤ã„ã¦ã€ï¼Œã€ŽåŒ»è–¬å“情報学,ã€(� g)�-1°-6.　<a href="httpsa_/www.jstage.jst.go.j:yarticl0ujjdi(�W)�r^þ](� g)�q/_articl0u-cha¾yja.".">[外部サイト]Ã_a> <h4 id="12">◆英語Ã_h4> <h2 2 2 id="(�*h)�2"><span style="color:lightgrey;">â– </span>論文（英語）Ã_h4> CASTLE, Phili0�E., et al. Impac4�of improved classification on the association of human papillomavirus with cervical precancer. American journal of epidemiology,(��N)�010, 1(�Ñ‘)�: 155-163. httpsa_/academic.oup.coÛwaj0uarticl0u17þ]r^15ô^Ó0ë0(�*h)�Õ0¡0é0Ã0É0?login=false <h4><span style="color:lightgrey;">â– Ã_span>ä»–Ã_h4> å­å®®é ¸ãŒã‚“ワクãƒãƒ³å ±é“å誉毀æ訴訟ã€å‹è€…ã¯èª°ï¼Ÿ httpsa_/www.m3.coÛwnews/opeâwiryoishiâwAS67Õ0é0ó0 <a href="../pass_âw20200809.pdf">[pdf]</a �ï¼ <a href=".Û]pass_n(�W)�(�åe)�00AS9.txt">[txt]Ã_a> HPVワクãƒãƒ³å ±é“ã®å誉毀æè£åˆ¤ã€ä¸Šå‘Šå—ç†ç”³ç«‹ã¦ã¸ https:å]www.2�1�¹p.com/newtzopen/iryoishin/708392 < HPVワクãƒãƒ³ã€ŒæŽ¨å¥¨æ´¾æ•—訴ã€ã¨æŽ¥ç¨®ã®æ˜¯éžã¯åˆ¥å•é¡Œ https:å]mainichi.j:ypremie¾yhealth/articletz20190418/med/00m/100/001000c HPVワクãƒãƒ³å ±é“ã®å誉毀æè£åˆ¤ã€æ‘中æ°ãŒæ•—訴 https:å]www.2�1�¹p.com/newtzopen/iryoishin/667875 HPVワクãƒãƒ³å誉毀æ訴訟ã€ã€Œè¨˜äº‹ã«é–“é•ã„ãªã—ã€ã€Œç ”究ã«æ造ãªã—〠httpsa_/www.m3.coÛwnews/opeâwiryoishiâw­9887 Drug Makers’ Push Leads to Cancer Vaccinesâ€n�Rise httpsa_/www.nytimes.com(�W)�00_08(�W)�ñ]health/policQ20vaccine.html 201607� ワクãƒãƒ³å®³è©•ä¾¡ã¨ç—…者除外ãƒã‚¤ã‚¢ã‚¹ https:å]www.medical-confidential.com(�W)�01þ^07/1þ]post-159 _ HPV ワクãƒãƒ³è¢«å®³ã¨ã€Œç—…者除外ãƒã‚¤ã‚¢ã‚¹ã€ åå¤å±‹å¸‚ã¯ã€é€Ÿå ±ã‚’撤回ã—ã€é©åˆ‡ãªè§£æžã®ã‚„ã‚Šç›´ã—ã‚’ httpsa_/npojip.or’uchk_ti:yNo65-file05.pdf HPV ワクãƒãƒ³æŽ¥ç¨®å¾Œã®ç—‡çŠ¶ã¨ãƒ¯ã‚¯ãƒãƒ³ã¨ã®é–¢ä¿‚ 鈴木らã®åå¤å±‹å¸‚調査論文ã¯ã‚€ã—ã‚ワクãƒãƒ³ã®å®³ã‚’示ã—ã¦ã„ã‚‹ NPO 法人医薬ビジランスセンター（薬ã®ãƒã‚§ãƒƒã‚¯ï¼9�æµt�六郎 httpsa_/www.npojip.or’usokuho/NÝ77-bessi.pdf <1�6�¹p><span style="color:dimgrey;">â– </span>ワクãƒãƒ³æ·»ä»˜æ–‡æ›¸Ã_1�6�¹p> https:å]www.fda.gos|mediæt7435ñ]download 設楽æ•; æ©‹å£æ­£è¡Œ. å­å®®é ¸ãŒã‚“ウイルスワクãƒãƒ³æŽ¥ç¨®å¾Œã®ä½“調変化â€yr1 自治ä½x�[鎌倉市・大和市・寒å·ç”ºãƒ»èŒ…ヶ崎市・藤沢市・美唄市・国立市・武蔵野市・宮å¤å³¶å¸‚・æ±æ‘山市・é™å²¡å¸‚・秦野市・浦添市・会津若æ¾å¸‚・豊見城市・那覇市・犬山市・å‰å·å¸‚・身延町・太田市・å—部町] ã®ã‚¢ãƒ³ã‚±ãƒ¼ãƒˆèª¿æŸ»çµæžœâ€•. 医薬å“医療機器レギュラトリーサイエンス,(��N)�(�åe)�2, 53.2: 1-1ª. HPVワクãƒãƒ³ã®å®‰å…¨æ€§ã«é–¢ã™ã‚‹ç ”究　httpsa_/mhlw-grants.niph.go.j:yprojecËz27(�>y)�9 厚生労åƒç§‘学研究費補助金（新興・å†èˆˆæ„ŸæŸ“ç—‡åŠã³äºˆé˜²æŽ¥ç¨®æ”¿ç­–推進研究事業） å­å®®é ¸ãŒã‚“ワクãƒãƒ³ã®æœ‰åŠ¹æ€§ã¨å®‰å…¨æ€§ã®è©•ä¾¡ã«é–¢ã™ã‚‹ç–«å­¦ç ”究https:å]mhlw-grants.niph.go.jp/systeÛwfiletz2016/1(�¡Œ)��þ]201617(�åe)�0A_uploa(u201617(�åe)�0A0004.pdf <h4><span style="color:lightgrey;">â– Ã_span>関連ã™ã‚‹è¨€åŠ</h4> <h4><span style="color:lightgrey;">â– Ã_span>未整ç†Ã_h4> HARPER, Diane M.; WILLIAMS, Karen B. Prophylactic HPV vaccines: current knowledge of impact on gynecologic premalignancies. Discovery Medicine,(��N)�010, 10.50: 7-17. Presenting factual information in ways that generate fear, such as advertising thatµ0ó0Á0ü0à00 women per da9�in the U.S. ge4�cervical cancer, serves women poorly. Factual framing that can be compared across options must be provided b9�physicians for the well being of their patients. For example, with cervical cancer screening in the U.S., _100,000 women ge4�cervical cancer ever9�year<�s�p�a�n� �c�l�a�s�s�=�"�n�a�k�e�d�_�s�i�g�n�"�>�; <�/�s�p�a�n�>�<�s�p�a�n� �c�l�a�s�s�=�"�n�a�k�e�d�_�a�u�r�a�l�"�>�(�èlŠ)�<�/�s�p�a�n�>�whereas, with HPV vaccination withou4�screening, assuming lifetime vaccine efficac9�and all women being vaccinated, 9.ô^100,000 and 14/100,000 women could get cervical cancer every year using Cervarix or Gardasil, respectively. Combining screening with vaccination does no4�significantl9�lower the number of women getting cervical cancer ever9�year, bu4�does decrease the number of women with abnormal screening tests. This ma9�no4�be information tha4�influences increased uptake of vaccination, bu4�physiciansâ€n�goals are no4�to sell vaccine product. Physicians’ goals include providing full and open discussion guiding women to make a decision for their cervical cancer protection that is in line with the woman’s own personal values. 米国ã§ã¯1æ—¥ã«30人ãŒå­å®®é ¸ãŒã‚“ã«ã‹ã‹ã‚‹ã¨ã„ã†å®£ä¼ã®ã‚ˆã†ã«ã€æ怖心を与ãˆã‚‹ã‚ˆã†ãªæ–¹æ³•ã§äº‹å®Ÿã«åŸºã¥ã情報をæ示ã™ã‚‹ã“ã¨ã¯ã€å¥³æ€§ã«ã¨ã£ã¦æœ‰ç›Šã§ã¯ãªã„。é¸æŠžè‚¢é–“ã§æ¯”較ã§ãる事実ã«åŸºã¥ãフレーミングã¯ã€æ‚£è€…ã®å¹¸ç¦ã®ãŸã‚ã«åŒ»å¸«ãŒæä¾›ã—ãªã‘ã‚Œã°ãªã‚‰ãªã„。例ãˆã°ã€ç±³å›½ã§ã¯å­å®®é ¸ãŒã‚“検診をå—ã‘ã‚‹ã¨ã€æ¯Žå¹´10万人ã‚ãŸã‚Š8人ãŒå­å®®é ¸ãŒã‚“ã«ãªã‚‹ã€‚一方ã€æ¤œè¨ºã‚’å—ã‘ãªã„HPVワクãƒãƒ³æŽ¥ç¨®ã§ã¯ã€ç”Ÿæ¶¯ã®ãƒ¯ã‚¯ãƒãƒ³åŠ¹æžœã¨ã™ã¹ã¦ã®å¥³æ€§ãŒæŽ¥ç¨®ã•ã‚Œã‚‹ã¨ä»®å®šã™ã‚‹ã¨ã€ã‚µãƒ¼ãƒãƒªãƒƒã‚¯ã‚¹ã‚’使用ã—ã¦æ¯Žå¹´10万人ã‚ãŸã‚Š9.5人ãŒã€ã‚¬ãƒ¼ãƒ€ã‚·ãƒ«ã‚’使用ã—ã¦æ¯Žå¹´10万人ã‚ãŸã‚‘4人ãŒå­å®®é ¸ãŒã‚“ã«ãªã‚‹å¯èƒ½æ€§ãŒã‚る。検診ã¨ãƒ¯ã‚¯ãƒãƒ³æŽ¥ç¨®ã®ä½µç”¨ã¯ã€æ¯Žå¹´å­å®®é ¸ãŒã‚“ã«ãªã‚‹å¥³æ€§ã®æ•°ã‚’大ãã減らã™ã‚ã‘ã§ã¯ãªã„ãŒã€æ¤œè¨ºã§ç•°å¸¸ã®ã‚る女性ã®æ•°ã‚’減らã™ã“ã¨ãŒã§ãる。ã“ã‚Œã¯ãƒ¯ã‚¯ãƒãƒ³æŽ¥ç¨®ã®æ™®åŠã«å½±éŸ¿ã‚’与ãˆã‚‹æƒ…å ±ã§ã¯ãªã„ã‹ã‚‚ã—ã‚Œãªã„ãŒã€åŒ»å¸«ã®ç›®æ¨™ã¯ãƒ¯ã‚¯ãƒãƒ³è£½å“を販売ã™ã‚‹ã“ã¨ã§ã¯ãªã„。医師ã®ç›®æ¨™ã¯ã€å¥³æ€§ãŒå­å®®é ¸ãŒã‚“予防ã®ãŸã‚ã«ã€ãã®äººè‡ªèº«ã®ä¾¡å€¤è¦³ã«æ²¿ã£ãŸæ±ºæ–­ãŒã§ãるよã†ã€å分ã‹ã¤ã‚ªãƒ¼ãƒ—ンãªè­°è«–ã‚’æä¾›ã™ã‚‹ã“ã¨ã ã€‚ www.DeepL.com/Translator（無料版）ã§ç¿»è¨³ã—ã¾ã—ãŸã€‚ Dangers of HPV Vaccination The generall9�recognized maximum amoun4�of foreign protein tha4�the human body can tolerate in one injection is 200 micrograms before severe adverse events occur in mos4�recipients. Given that Gardasil has (�*h)�0 micrograms and Cervari8�has 40 micrograms of highl9�antigenic foreign protein in the form of VLPs to different L1 genotypes, the amoun4�of VLP antigens becomes importan4�to monitor in both the current HPV vaccines as well as in second generation vaccines (http, 2010d; http,(��N)�010e). In general, a4�this time both vaccines are considered safe for most women. However, there is no medicine or vaccine tha4�is completel9�harmless. While national and international regulator9�bodies continue to monitor surveillance safety data after millions of vaccinations, independen4�scientists are publishing reports of patients who have had autoimmune demyelinating neurologic sequelae after Gardasil administration, resulting in blindness, paralysis, and death (Sutton et al., 2009<�s�p�a�n� �c�l�a�s�s�=�"�n�a�k�e�d�_�s�i�g�n�"�>�; <�/�s�p�a�n�>�<�s�p�a�n� �c�l�a�s�s�=�"�n�a�k�e�d�_�a�u�r�a�l�"�>�(�èlŠ)�<�/�s�p�a�n�>�CDC,(��N)�008; Beller and Abu-Rustum, 2009<�s�p�a�n� �c�l�a�s�s�=�"�n�a�k�e�d�_�s�i�g�n�"�>�; <�/�s�p�a�n�>�<�s�p�a�n� �c�l�a�s�s�=�"�n�a�k�e�d�_�a�u�r�a�l�"�>�(�èlŠ)�<�/�s�p�a�n�>�Marsee e4�al.,(��N)�008; Studdiford et al., 2008<�s�p�a�n� �c�l�a�s�s�=�"�n�a�k�e�d�_�s�i�g�n�"�>�; <�/�s�p�a�n�>�<�s�p�a�n� �c�l�a�s�s�=�"�n�a�k�e�d�_�a�u�r�a�l�"�>�(�èlŠ)�<�/�s�p�a�n�>�Kang e4�al.,(��N)�008; Brotherton et al., 2008<�s�p�a�n� �c�l�a�s�s�=�"�n�a�k�e�d�_�s�i�g�n�"�>�; <�/�s�p�a�n�>�<�s�p�a�n� �c�l�a�s�s�=�"�n�a�k�e�d�_�a�u�r�a�l�"�>�(�èlŠ)�<�/�s�p�a�n�>�Debeer e4�al.,(��N)�008; Das e4�al.,(��N)�008; Lower, 2008<�s�p�a�n� �c�l�a�s�s�=�"�n�a�k�e�d�_�s�i�g�n�"�>�; <�/�s�p�a�n�>�<�s�p�a�n� �c�l�a�s�s�=�"�n�a�k�e�d�_�a�u�r�a�l�"�>�(�èlŠ)�<�/�s�p�a�n�>�Lawrence e4�al.,(��N)�008; Wildemann e4�al.,(��N)�009; McCarth9�and Filiano,(��N)�009; Cohen, 2009). The current postmarketing commitmen4�between Merck and the FDA is to recognize a rate of serious adverse events tha4�exceed(��N)�/10,000 women in a cohor4�of 44,000 women who have received all three doses of Gardasil (http,(��N)�010f). Yet, although autoimmune neurologic sequelae after Gardasil administration have occurred, because the frequency of autoimmune neurologic diseases is less than r^10,000, regulatory authorities do no4�have to evaluate these reactions, such as Guillain-Barr? Syndrome, as possible serious adverse events. Nevertheless, recognizing tha4�these issues could be life-threatening to some girls, studies are registered, bu4�no4�ye4�recruiting subjects, to evaluate the effec4�of Gardasil on young girls with systemic lupus erythematosus, inflammatory bowel disease, juvenile idiopathic arthritis, juvenile dermatomyositis, solid organ transplants, HI*rAIDS, and chronic illnesses (http,(��N)�010c). Additionally, fetal malformations and death were evaluated for both vaccines over various time intervals between conception and injection. Analysis of pregnancy events withinµ0ó0Á0ü0à00 days of injection has evolved over two publications (Koutsky, 2007<�s�p�a�n� �c�l�a�s�s�=�"�n�a�k�e�d�_�s�i�g�n�"�>�; <�/�s�p�a�n�>�<�s�p�a�n� �c�l�a�s�s�=�"�n�a�k�e�d�_�a�u�r�a�l�"�>�(�èlŠ)�<�/�s�p�a�n�>�Garland et al., 2009), indicating initial significan4�fetal anomalies withinµ0ó0Á0ü0à00 days of Gardasil<�s�p�a�n� �c�l�a�s�s�=�"�n�a�k�e�d�_�s�i�g�n�"�>�; <�/�s�p�a�n�>�<�s�p�a�n� �c�l�a�s�s�=�"�n�a�k�e�d�_�a�u�r�a�l�"�>�(�èlŠ)�<�/�s�p�a�n�>�however, upon the discover9�of one additional fetal anomal9�in the placebo group, differences were no longer statistically significant. The prevalence of schizencephaly and anencephaly in the general population is 1.ô^100,000 and 1.þ]10,000, respectively, with both events happening to fetuses of women who received Gardasil (Dana e4�al.,(��N)�009). Neither Cervarix nor Gardasil has been implicated in teratogenic adverse events to date, but the9�continue to be monitored via self-report pregnancy surveillance databases (Garland e4�al.,(��N)�009; Dana et al., 2009<�s�p�a�n� �c�l�a�s�s�=�"�n�a�k�e�d�_�s�i�g�n�"�>�; <�/�s�p�a�n�>�<�s�p�a�n� �c�l�a�s�s�=�"�n�a�k�e�d�_�a�u�r�a�l�"�>�(�èlŠ)�<�/�s�p�a�n�>�McCune-Smith and Sawaya,(��N)�009; Descamps et al., 2009<�s�p�a�n� �c�l�a�s�s�=�"�n�a�k�e�d�_�s�i�g�n�"�>�; <�/�s�p�a�n�>�<�s�p�a�n� �c�l�a�s�s�=�"�n�a�k�e�d�_�a�u�r�a�l�"�>�(�èlŠ)�<�/�s�p�a�n�>�Wacholder et al., 2010). As was stated b9�an editorialist, “The curren4�findings are fragile: analyses are interim, the total number of outcomes is small (especiall9�in the placebo group), and the association [of reproductive effects] lacks clear biologic plausibility. Nevertheless, results from randomized trials suggesting harm warrant focused attention†(McCune-Smith and Sawaya, 2009). HPVワクãƒãƒ³æŽ¥ç¨®ã®å±é™ºæ€§ 一般ã«ã€L回ã®æ³¨å°„ã§äººä½“ãŒè¨±å®¹ã§ãる異種タンパク質ã®æœ€å¤§é‡ã¯ã€ã»ã¨ã‚“ã©ã®è¢«æŽ¥ç¨®è€…ã«é‡ç¯¤ãªæœ‰å®³äº‹è±¡ãŒèµ·ã“ã‚‹å‰ãf[00マイクログラムã§ã‚ã‚‹ã¨ã•ã‚Œã¦ã„ã¾ã™ã€‚ガーダシルã«ã¯120マイクログラムã€ã‚µãƒ¼ãƒãƒªãƒƒã‚¯ã‚¹ã«ã¯40マイクログラムã®ç•°ãªã‚‹éºä¼å­åž‹ã«å¯¾ã™ã‚‹VLPã®å½¢ã§æŠ—原性ã®é«˜ã„外æ¥ã‚¿ãƒ³ãƒ‘ク質ãŒå«ã¾ã‚Œã¦ã„ã‚‹ã“ã¨ã‚’考ãˆã‚‹ã¨ã€ç¾åœ¨ã®HPVワクãƒãƒ³ã¨ç¬¬2世代ワクãƒãƒ³ã®ä¸¡æ–¹ã§VLP抗原ã®é‡ã‚’監視ã™ã‚‹ã“ã¨ãŒé‡è¦ã«ãªã‚‹ï¼ˆhttp, 2010d; http,(��N)�010e）。一般ã«ã€ç¾æ™‚点ã§ã¯ã€ã©ã¡ã‚‰ã®ãƒ¯ã‚¯ãƒãƒ³ã‚‚ã»ã¨ã‚“ã©ã®å¥³æ€§ã«ã¨ã£ã¦å®‰å…¨ã§ã‚ã‚‹ã¨è€ƒãˆã‚‰ã‚Œã¦ã„る。ã—ã‹ã—ã€å®Œå…¨ã«ç„¡å®³ãªè–¬ã‚„ワクãƒãƒ³ã¯å­˜åœ¨ã—ãªã„。国内外ã®è¦åˆ¶æ©Ÿé–¢ãŒæ•°ç™¾ä¸‡å›žã®æŽ¥ç¨®å¾Œã®å®‰å…¨æ€§ãƒ‡ãƒ¼ã‚¿ã‚’監視ã—続ã‘ã¦ã„る一方ã§ã€ç‹¬ç«‹ã—ãŸç§‘学者ãŒã‚¬ãƒ¼ãƒ€ã‚·ãƒ«æŠ•ä¸Žå¾Œã«è‡ªå·±å…疫性脱髄性神経後éºç—‡ã‚’発症ã—ã€å¤±æ˜Žã€éº»ç—ºã€æ­»äº¡ã—ãŸæ‚£è€…ã®å ±å‘Šæ›¸ã‚’発表ã—ã¦ã„ã¾ã™ï¼ˆSutton e4�al, 2009<�s�p�a�n� �c�l�a�s�s�=�"�n�a�k�e�d�_�s�i�g�n�"�>�; <�/�s�p�a�n�>�<�s�p�a�n� �c�l�a�s�s�=�"�n�a�k�e�d�_�a�u�r�a�l�"�>�(�èlŠ)�<�/�s�p�a�n�>�CDC,(��N)�008; Beller and Abu-Rustum, 2009<�s�p�a�n� �c�l�a�s�s�=�"�n�a�k�e�d�_�s�i�g�n�"�>�; <�/�s�p�a�n�>�<�s�p�a�n� �c�l�a�s�s�=�"�n�a�k�e�d�_�a�u�r�a�l�"�>�(�èlŠ)�<�/�s�p�a�n�>�Marsee e4�al.,(��N)�008; Studdiford et al., 2008<�s�p�a�n� �c�l�a�s�s�=�"�n�a�k�e�d�_�s�i�g�n�"�>�; <�/�s�p�a�n�>�<�s�p�a�n� �c�l�a�s�s�=�"�n�a�k�e�d�_�a�u�r�a�l�"�>�(�èlŠ)�<�/�s�p�a�n�>�Kang e4�al.,(��N)�008; Brotherton et al., 2008<�s�p�a�n� �c�l�a�s�s�=�"�n�a�k�e�d�_�s�i�g�n�"�>�; <�/�s�p�a�n�>�<�s�p�a�n� �c�l�a�s�s�=�"�n�a�k�e�d�_�a�u�r�a�l�"�>�(�èlŠ)�<�/�s�p�a�n�>�Debeer e4�al.,(��N)�008; Das e4�al.,(��N)�008; Lower, 2008<�s�p�a�n� �c�l�a�s�s�=�"�n�a�k�e�d�_�s�i�g�n�"�>�; <�/�s�p�a�n�>�<�s�p�a�n� �c�l�a�s�s�=�"�n�a�k�e�d�_�a�u�r�a�l�"�>�(�èlŠ)�<�/�s�p�a�n�>�Lawrence e4�al.,(��N)�008; Wildemann e4�al.,(��N)�009; McCarth9�and Filiano,(��N)�009; Cohen, 2009) ãŒã‚ã‚Šã¾ã™ã€‚メルク社ã¨FDAã®ç¾åœ¨ã®å¸‚販後ã®ç´„æŸã¯ã€ã‚¬ãƒ¼ãƒ€ã‚·ãƒ«ã®3回分ã®æŠ•ä¸Žã‚’ã™ã¹ã¦å—ã‘ãŸ44,000人ã®å¥³æ€§ã®ã‚³ãƒ›ãƒ¼ãƒˆã«ãŠã„ã¦ã€é‡ç¯¤ãªæœ‰å®³äº‹è±¡ã®å‰²åˆãŒr^10,000を超ãˆã‚‹ã“ã¨ã‚’èªã‚ã‚‹ã“ã¨ã§ã™ï¼ˆhttp,(��N)�010f）。ã—ã‹ã—ã€ã‚¬ãƒ¼ãƒ€ã‚·ãƒ«æŠ•ä¸Žå¾Œã®è‡ªå·±å…疫性神経学的後éºç—‡ã¯ç™ºç”Ÿã—ã¦ã„ã‚‹ã‚‚ã®ã®ã€è‡ªå·±å…疫性神経疾患ã®é »åº¦ãTS/10,000以下ã§ã‚ã‚‹ãŸã‚ã€è¦åˆ¶å½“å±€ã¯ã‚®ãƒ©ãƒ³ãƒãƒ¬ãƒ¼ç—‡å€™ç¾¤ã®ã‚ˆã†ãªã“れらã®å応をé‡å¤§ãªæœ‰å®³äº‹è±¡ã®å¯èƒ½æ€§ã¨ã—ã¦è©•ä¾¡ã™ã‚‹å¿…è¦ã¯ãªã„ã¨ã•ã‚Œã¦ã„ã¾ã™ã€‚ã—ã‹ã—ãªãŒã‚‰ã€ã“れらã®å•é¡ŒãŒä¸€éƒ¨ã®å¥³å…ã«ã¨ã£ã¦ç”Ÿå‘½ã‚’è„…ã‹ã™å¯èƒ½æ€§ãŒã‚ã‚‹ã“ã¨ã‚’èªè­˜ã—ã€å…¨èº«æ€§ã‚¨ãƒªãƒ†ãƒžãƒˆãƒ¼ãƒ‡ã‚¹ã€ç‚Žç—‡æ€§è…¸ç–¾æ‚£ã€è‹¥å¹´æ€§ç‰¹ç™ºæ€§é–¢ç¯€ç‚Žã€è‹¥å¹´æ€§çš®è†šç­‹ç‚Žã€å›ºå½¢è‡“器移æ¤ã€HIVï¼ã‚¨ã‚¤ã‚ºã€æ…¢æ€§ç–¾æ‚£ã‚’有ã™ã‚‹å°‘女ã«å¯¾ã™ã‚‹ã‚¬ãƒ¼ãƒ€ã‚·ãƒ«ã®å½±éŸ¿ã‚’評価ã™ã‚‹è©¦é¨“ãŒã€ç™»éŒ²ã•ã‚Œã¦ã„ã‚‹ãŒã¾ã è¢«é¨“者ã¯å‹Ÿé›†ã—ã¦ã„ãªã4�(http,(��N)�010c)。 ã•ã‚‰ã«ã€å—胎ã‹ã‚‰æ³¨å°„ã¾ã§ã®ã•ã¾ã–ã¾ãªæ™‚é–“é–“éš”ã«ãŠã‘る胎å…ã®å¥‡å½¢ã¨æ­»äº¡ã‚’ã€ä¸¡æ–¹ã®ãƒ¯ã‚¯ãƒãƒ³ã«ã¤ã„ã¦è©•ä¾¡ã—ãŸã€‚注射徼F�0日以内ã®å¦Šå¨ ã‚¤ãƒ™ãƒ³ãƒˆã®åˆ†æžã¯ã€2ã¤ã®å‡ºç‰ˆç‰©ï¼ˆKoutsky, 2007<�s�p�a�n� �c�l�a�s�s�=�"�n�a�k�e�d�_�s�i�g�n�"�>�; <�/�s�p�a�n�>�<�s�p�a�n� �c�l�a�s�s�=�"�n�a�k�e�d�_�a�u�r�a�l�"�>�(�èlŠ)�<�/�s�p�a�n�>�Garland et al.「N009）ã«ãŠã„ã¦ç™ºå±•ã—ã€ã‚¬ãƒ¼ãƒ€ã‚·ãƒ«ã®30日以内ã®åˆæœŸæœ‰æ„胎å…異常を示ã—ãŸã€‚ã—ã‹ã—ã€ãƒ—ラセボ群ã«ãŠã‘ã‚‹1ã¤ã®è¿½åŠ èƒŽå…異常ã®ç™ºè¦‹ã«ã‚ˆã‚Šã€é•ã„ã¯ã‚‚ã¯ã‚„統計的ã«æœ‰æ„ã§ã¯ãªããªã£ãŸã€‚一般集団ã«ãŠã‘ã‚‹çµ±åˆå¤±èª¿ç—‡ã¨ç„¡è„³ç—‡ã®æœ‰ç—…率ã¯ã€ãã‚Œãžã‚”0万分ã®1.5ã¨1万分ã®1ã§ã‚ã‚Šã€ã‚¬ãƒ¼ãƒ€ã‚·ãƒ«ã‚’å—ã‘ãŸå¥³æ€§ã®èƒŽå…ã«ä¸¡æ–¹ã®äº‹è±¡ãŒèµ·ã“ã£ã¦ã„る（Danaら「N009）。サーãƒãƒªãƒƒã‚¯ã‚¹ã¨ã‚¬ãƒ¼ãƒ€ã‚·ãƒ«ã®ã„ãšã‚Œã‚‚ã€ç¾åœ¨ã¾ã§ã«å‚¬å¥‡å½¢æ€§ã®æœ‰å®³äº‹è±¡ã«é–¢ä¸Žã—ã¦ã„ãªã„ã¨ã•ã‚Œã¦ã„ã¾ã™ãŒã€è‡ªå·±ç”³å‘Šã«ã‚ˆã‚‹å¦Šå¨ ç›£è¦–データベースを通ã˜ã¦ã€å¼•ã続ã監視ã•ã‚Œã¦ã„ã¾ã™ï¼ˆGarland et al., 2009<�s�p�a�n� �c�l�a�s�s�=�"�n�a�k�e�d�_�s�i�g�n�"�>�; <�/�s�p�a�n�>�<�s�p�a�n� �c�l�a�s�s�=�"�n�a�k�e�d�_�a�u�r�a�l�"�>�(�èlŠ)�<�/�s�p�a�n�>�Dana e4�al.,(��N)�009; McCune-Smith and Sawaya, 2009<�s�p�a�n� �c�l�a�s�s�=�"�n�a�k�e�d�_�s�i�g�n�"�>�; <�/�s�p�a�n�>�<�s�p�a�n� �c�l�a�s�s�=�"�n�a�k�e�d�_�a�u�r�a�l�"�>�(�èlŠ)�<�/�s�p�a�n�>�Descamps e4�al.,(��N)�009; Wacholder e4�al.,(��N)�010）。論説委員ãŒè¿°ã¹ãŸã‚ˆã†ã«ã€ã€Œç¾åœ¨ã®çŸ¥è¦‹ã¯è„†å¼±ã§ã‚る：解æžãŒæš«å®šçš„ã§ã‚ã‚Šã€ã‚¢ã‚¦ãƒˆã‚«ãƒ ã®ç·æ•°ãŒå°‘ãªã（特ã«ãƒ—ラセボ群）ã€ï¼ˆç”Ÿæ®–ã¸ã®å½±éŸ¿ã®ï¼‰é–¢é€£ã¯æ˜Žç¢ºãªç”Ÿç‰©å­¦çš„妥当性を欠ã„ã¦ã„る。ã¨ã¯ã„ãˆã€æœ‰å®³æ€§ã‚’示唆ã™ã‚‹ãƒ©ãƒ³ãƒ€ãƒ åŒ–試験ã®çµæžœã¯ã€æ³¨ç›®ã™ã¹ãã‚‚ã®ã§ã‚ã‚‹ã€ï¼ˆMcCune-Smith and Sawaya,(��N)�009）。 www.DeepL.com/Translator（無料版）ã§ç¿»è¨³ã—ã¾ã—ãŸã€‚ 石和久. HPV 検査ã¨ã“ã‚Œã‹ã‚‰ã®å­å®®é ¸ç™Œæ¤œè¨º. 順天堂醫事雑誌, 20Ó0ë0, 59Ô0¢0¹0È0ë0: Õ0¡0é0Ã0É06-240. 横山和正<�s�p�a�n� �c�l�a�s�s�=�"�n�a�k�e�d�_�s�i�g�n�"�>�; <�/�s�p�a�n�>�<�s�p�a�n� �c�l�a�s�s�=�"�n�a�k�e�d�_�a�u�r�a�l�"�>�(�èlŠ)�<�/�s�p�a�n�>�æœéƒ¨ä¿¡å­. 神経疾患ã«ãŠã‘るワクãƒãƒ³ã®åŠŸç½ª. 順天堂醫事雑誌, 2014, 0.Suppl. 2: sÕ0é0ó0-s59. 生労åƒçœã®ãƒ›ãƒ¼ãƒ ãƒšãƒ¼ã‚¸ã«ã¯Q and Aã®å½¢ã§æ‚£è€…㸠ã®èª¬æ˜ŽãŒãªã•ã‚Œã¦ã„ã‚‹ãŒï¼Œãã®å†…容ã¯neutralã«ãƒ¯ クãƒãƒ³ã®æœ‰åŠ¹æ€§ã¨ãƒªã‚¹ã‚¯ã‚’å分ã«ç†è§£ã—ãŸã†ãˆã§ï¼Œ å—ã‘ã‚‹ã‹ã©ã†ã‹åˆ¤æ–­ã™ã‚‹ã‚ˆã†ã«è¨˜è¼‰ã•ã‚Œã¦ã„る（表 -1）． 薬剤メーカーã®ã‚µã‚¤ãƒˆãªã©ã¨ã¯ç•°ãªã‚Šï¼Œèª‡å¼µã‚„宣 ä¼ã‚‚ãªã事実をãã®ã¾ã¾è¨˜è¼‰ã—ã¦ã„ã‚‹ãŒï¼Œæ²»ç™‚ã«ã¯ 常ã«ãƒªã‚¹ã‚¯ã¨ãƒ™ãƒãƒ•ã‚£ãƒƒãƒˆãŒã‚ã‚‹ã“ã¨ã‚’最åˆã‹ã‚‰èª¬ 明ã¨åŒæ„ã®ã†ãˆã§å¥‘約・署åã‚’ã¨ã‚‹ã¨ã„ã†æ¬§ç±³ã®ã‚¹ タイルãŒã¾ã æ—¥æœ¬ã«ãŠã„ã¦æ›¸é¡žã®ã¿ã§ã®ã‚„ã‚Šã¨ã‚Šã§ ã‚り，署åã®ã‚‚ã¤æ„味や責任ãŒç¤¾ä¼šã«æµ¸é€ã—ã¦ã„㪠ã„ã“ã¨ãŒå¤§ããªå•é¡Œã§ã‚り，HPVワクãƒãƒ³æŽ¥ç¨®å† é–‹ã®ãŸã‚ã«ã¯å…ˆé€²æ¬§ç±³è«¸å›½ã®ä¸€éƒ¨ã®å›½ã®ã‚ˆã†ã«æŽ¥ç¨® 後ã®ç–¼ç—›ãƒ»é‹å‹•éšœå®³ã«å¯¾ã™ã‚‹åŒ»ç™‚サーベイランスシ ステムã®æ§‹ç¯‰ï¼Œãƒ¯ã‚¯ãƒãƒ³æŽ¥ç¨®ã§å¾—られãŸæƒ…報やã㮠副作用ã«é–¢ã™ã‚‹å分ãªèª¬æ˜Žã‚’ã—ã¦ï¼Œè¢«æŽ¥ç¨®è€…ãŒç´å¾— ã§ãるよã†ãªç’°å¢ƒã¨æ™‚é–“ã‚’ã‹ã‘ã¦æä¾›ã™ã‚‹ã“ã¨ãŒå¿… è¦ã§ã‚る． <span style="color:dimgrey;">â– Ã_span>論文（英語） <hr> <h2 2 id="2">■引用Ã_1�6�¹p> <span style="color:cornflowerblue;">â—†Ã_span>種田 åšä¹‹ã€€ã€Œã€Žå­å®®é ¸ãŒã‚“ワクãƒãƒ³ã€æŽ¥ç¨®å¾Œã®æœ‰å®³äº‹è±¡ãªã„ã—å¥åº·è¢«å®³ã€ï¼Œæœ¬éƒ· 正武・ä½è—¤ 哲彦 編著　「薬害ã¨ã¯ãªã«ã‹â”€â”€â”€æ–°ã—ã„薬害ã®ç¤¾ä¼šå­¦ã€ï¼ŒãƒŸãƒãƒ«ãƒ´ã‚¡æ›¸æˆ¿. <blockquote>ãã†ã—ãŸãªã‹ï¼Œ2014å¹´9月ã«,「HPVワクãƒãƒ³é–¢é€£ç¥žçµŒå…疫異常症候群ã€èª¬ãŒæ—¥æœ¬ç·šç¶­ç­‹ç—›ç—‡å­¦ä¼šã«ã‚ˆã£ã¦ä¸»å¼µã•ã‚ŒãŸã€‚ HPVワクãƒãƒ³é–¢é€£ç¥žçµŒå…疫異常症候群説ã¨ã¯ã€HPVワクãƒãƒ³æŽ¥ç¨®ã«ã‚ˆã£ã¦éŽå‰°ãªå…ç–«åå¿œãŒèµ·ã“り，ãã‚ŒãŒä¸Šã§æŒ™ç¤ºã—ãŸç—‡çŠ¶ã‚’引ãã“ã—ã¦ã„ã‚‹ã¨ã™ã‚‹è€ƒãˆæ–¹ã§ã‚る。ã™ãªã‚ã¡ï¼ŒHPVワクãƒãƒ³æŽ¥ç¨®å¾Œã®æœ‰å®³äº‹è±¡ã‚’副åå¿œã«ã‚ˆã‚‹ã€Œå¥åº·è¢«å®³ã€ ã¨æ‰ãˆãŸã®ã§ã‚る。ã“ã‚Œã«ã‚ˆã£ã¦ï¼Œã€Œå·»ãè¾¼ã¾ã‚ŒãŸå¥³æ€§ã€ã¯ã€Œè¢«å®³è€…ã€ã¨æ‰±ã‚れるよã†ã«ãªã£ãŸã€‚ã¾ãŸï¼Œè‡ªèªã§ãるよã†ã«ã‚‚ãªã£ãŸã€‚ 　医薬å“ã®å¥åº·è¢«å®³ã«å¯¾ã—ã¦ã¯ï¼Œæ•‘済制度ãŒè¨­ã‘られã¦ã„る。 ã—ã‹ã—，ãã®æ•‘済制度ã«ã‚ˆã£ã¦ã‚‚ã€å†ã³ã€Œå·»ãè¾¼ã¾ã‚ŒãŸå¥³æ€§ã€ã¯å‚·ã¤ã‘られãŸã€ N013å¹´4月以é™ã«1回ã§ã‚‚接種をå—ã‘ã¦ã„ã‚Œã°ï¼Œäºˆé˜²æŽ¥ç¨®æ³•ã®ã‚‚ã¨ã§ã®æŽ¥ç¨®ã¨ã—ã¦æ‰±ã‚ã‚Œã€äºˆé˜²æŽ¥ç¨®æ³•ã§ã®æ•‘済対象ã¨ãªã‚‹ã€ N013å¹´3月末ã¾ã§ã«å…m�"s�2�回ã®æŽ¥ç¨®ã‚’終ãˆã¦ã„ã‚Œã°,，å­å®®é ¸ãŒã‚“等ワクãƒãƒ³æŽ¥ç¨®ç·Šæ€¥ä¿ƒé€²äº‹æ¥­ã«ã‚ˆã‚‹æŽ¥ç¨®ã¨ãªã‚‹ãŸã‚，医薬å“副作用被害救済制度ã§ã®æ•‘済対象ã¨ãªã‚‹ã€‚  　ã“れらã®æ•‘済制度を使ã†ã«ã¯ç”³è«‹ã‚’å¿…è¦ã¨ã™ã‚‹ã€‚ã—ã‹ã—，当åˆç”³è«‹è‡ªä½“ãŒã§ããªã‹ã£ãŸã€‚ 医師ãŒã€Œå·»ãè¾¼ã¾ã‚ŒãŸå¥³æ€§ã€ã®è¨´ãˆã‚’è©ç—…ã¨è¦‹ã¦ã„ãŸãŸã‚，申請書ã®ä½œæˆã«éžå”力的ã ã£ãŸã‹ã‚‰ã§ã‚ã‚‹(全国薬害被害者団体連絡å”議会(��N)�018)。HPVワクãƒãƒ³é–¢é€£ç¥žçµŒå…疫異常症候群説ãŒç¾ã‚ŒãŸã“ã¨ã§ã€ç”³è«‹ã¯ã—ã‚„ã™ããªã£ãŸã§ã‚ã‚ã†ã€‚ã—ã‹ã—，予防接種法ã«ãŠã‘る救済制度ã¨åŒ»è–¬å“副作用被害救済制度ã¨ã§ã¯ï¼Œãã®ä»•çµ„ã¿ã«å¤§ããªé•ã„ãŒã‚ã£ãŸã€‚å‰è€…ã¯ã€ŒæŽ¥ç¨®å¾Œã®ç—‡çŠ¶ãŒäºˆé˜²æŽ¥ç¨®ã«ã‚ˆã£ã¦èµ·ã“ã‚‹ã“ã¨ã‚’å¦å®šã§ã㪠ã„å ´åˆã‚‚対象ã¨ã•ã‚Œã€ã®å¯¾ã—，後者ã¯ã€Œé€šé™¢ã«ä¿‚る医療費・医療手当ã®æ”¯çµ¦å¯¾è±¡ãŒå…¥é™¢ç›¸å½“ã®åŒ»ç™‚ã«å¯¾ã™ã‚‹ã‚‚ã®ã«é™ã‚‰ã‚Œã¦ã„ã€ãŸ(厚生労åƒçœ(��N)�015b)。ã™ãªã‚ã¡ï¼ŒåŒ»è–¬å“副作用被害救済制度ã®å¯¾è±¡è€…ã¯ç”³è«‹ã§ããŸã‚‚ã®ã®ï¼Œã€Œå…¥é™¢ç›¸å½“ã§ã¯ãªã„ã€ãªã©ã®ç†ç”±ã§ä¸æ”¯çµ¦æ±ºå®šãŒä¸‹ã•ã‚ŒãŸã€‚ ã“ã®ä¸æ”¯çµ¦æ±ºå®šã¯ï¼Œã€Œå·»ãè¾¼ã¾ã‚ŒãŸå¥³æ€§ã€ã«ã¨ã£ã¦ï¼Œè‡ªã‚‰ã«ç¾ã‚Œã¦ã„る症状 (å¥åº·è¢«å®³)ã®å¦å®šã§ã‚ã£ãŸã€‚ã“ã†ã—ã¦ï¼Œæ•‘済を求ã‚㦠「薬害〠ã¨ã—ã¦ä¿‚争化ã—ãŸã€‚ï¼…77-178）</blockquote> <span style="color:cornflowerblue;">â—†</span>平岡 厚ã€�N(�åe)�0　「HPV ワクãƒãƒ³è«–争をå†è€ƒã™ã‚‹ã€€ãƒ¼ãƒ¼æŽ¨é€²æ´¾ã®ä¸»å¼µã®å•é¡Œç‚¹ã‚’中心ã«ã€ï¼Œã€€ã€Žç¤¾ä¼šè‡¨åºŠé›‘誌ã€28Ð0ü0ì0ë0°05-1Ó0ë0.　<a href="httpsa_/www.jstage.jst.go.j:yarticl0ujajltz(� g)�(�W)�(�W)�2_46/_articl0u-cha¾yja.".">[外部サイト]Ã_a> <blockquote>　HPVワクãƒãƒ³æŽ¥ç¨®å¾Œã®æœ‰å®³äº‹è±¡ã‚’ã€â‘ å¤§éƒ¨åˆ†ã¯å‰¯åå¿œã§ã¯ãªã他疾患（後述）ã®ç´›ã‚Œè¾¼ã¿ã§ã‚ã‚‹ã€ã‚ã‚‹ã„ã¯â‘¡å‰¯åå¿œã§ã¯ã‚ã‚‹ãŒå™¨è³ªçš„ãªå‚·å®³ã¯èµ·ãã¦ãŠã‚‰ãšé‡å¤§ãªå•é¡Œã§ã¯ãªã„ã€ã¨ã™ã‚‹ç«‹å ´ã‹ã‚‰ã¯ã€æŽ¥ç¨®äº‹æ¥­ã®æŽ¨é€²ãƒ»å®šæœŸæŽ¥ç¨®ã®æŽ¨å¥¨å†é–‹ã«è³›æˆã€â‘¢CNSã«å™¨è³ªæ€§å‚·å®³ã‚’ã‚‚ãŸã‚‰ã™è–¬å®³ãŒèµ·ãã¦ã„ã‚‹ã€ã¨ã„ã†è¦‹è§£ã‹ã‚‰ã¯ã€ãã‚Œã«æ…Žé‡ãªã„ã—å対ã®æ„見ãŒã€å„々導ã‹ã‚Œã¦ã„る。推進派ã®æ€¥å…ˆé‹’ã§ã‚ã‚‹æ‘中璃å­æ°ï¼ˆåŒ»å¸«ã€ã‚¸ãƒ£ï¼ãƒŠãƒªã‚¹ãƒˆã€äº¬éƒ½å¤§å­¦å¤§å­¦é™¢éžå¸¸å‹¤è¬›å¸«ï¼‰ã¯â‘ ã€åŽšç”ŸåŠ´åƒçœå‰¯å応検討部会ã®å¤šæ•°æ´¾ã¯â‘¡ã€HANS仮説ã®æ唱者ãªã©ãŒâ‘¢ã®ç«‹å ´ã§ã‚るよã†ã«è¦‹ãˆã‚‹ã€‚ 　副å応（ã®ç–‘ã„）ã®ç—‡çŠ¶ã‚’呈ã—ã¦ã„る女性・少女ã®æ²»ç™‚ã«ã¤ã„ã¦ã¯ã€å‰è¿°ã®â‘¡ã®ç«‹å ´ã‹ã‚‰ã¯èªçŸ¥è¡Œå‹•ç™‚法ãŒæŽ¨å¥¨ã•ã‚Œã€æ„›çŸ¥åŒ»ç§‘大学・牛田享å®æ•™æŽˆã‚‰ã®è«–æ–‡ãŒç™ºè¡¨ã•ã‚Œã¦ã„る（Ushida et al., 2016）。当該論文ã«ãŠã„ã¦è‘—者らã¯ã€ã€ŒHPVワクãƒãƒ³æŽ¥ç¨®å¾Œã®ä½“調ä¸è‰¯ã‚’訴ãˆã‚‹å—診者ã®ã†ã¡ã‚¤ãƒ³ãƒ•ã‚©ï¼ãƒ ãƒ‰ãƒ»ã‚³ãƒ³ã‚»ãƒ³ãƒˆã‚’å¾—ãŸè€…ã«èªçŸ¥è¡Œå‹•ç™‚法をé©ç”¨ã—ãŸã¨ã“ã‚ã€çµæžœã®è¿½è·¡ãŒå¯èƒ½ã§ã‚ã£ãŸæ‚£è€…ã®ç´„7割ã§ç—›ã¿ã®ç¨‹åº¦ãŒã‚る程度ã¯ä½Žæ¸›ã—ãŸã€ã¨å ±å‘Šã—ã¦ã„ã‚‹ãŒã€ç—›ã¿ä»¥å¤–ã®ç—‡çŠ¶ï¼ˆè¨˜æ†¶éšœå®³ã€ä¸éšæ„é‹å‹•ã€å…‰éŽæ•ã€ä»–）ã«ã¤ã„ã¦ã¯æ²»ç™‚対象ã§ã¯ãªãã€ã¾ãŸå…¨å—診者ã«ãŠã‘ã‚‹ç—›ã¿ä½Žæ¸›ã®æœ‰åŠ¹çŽ‡ã¯4割弱ã«éŽãŽãªã„。 　公平ã«è¦‹ã¦ã€é‡ç¯¤ãªç—‡çŠ¶ã‚’呈ã™ã‚‹æ‚£è€…ã«å¯¾ã™ã‚‹æ²»ç™‚ã§æœ€ã‚‚効果を挙ã’ã¦ã„ã‚‹ã®ã¯â‘¢ã®ç«‹å ´ã®åŒ»å¸«ã‚‰ã«ã‚ˆã‚‹ã‚¹ãƒ†ãƒ­ã‚¤ãƒ‰ï¼ˆæŠ—炎症剤）ã®æŠ•ä¸Žã‚„å…ç–«å¸ç€ç™‚法ã§ã‚る（Yonee e4�al.,20Ó0ë0ã€è’ç”°ã€é«˜å¶‹, 2018）ã€ã¨åˆ¤æ–­ã§ãる。ã¾ãŸã€ä»–疾患ã®ç´›ã‚Œè¾¼ã¿ã¨ã™ã‚‹èª¬ï¼ˆâ‘ ï¼‰ã«ã¤ã„ã¦ã¯ã€å®šæœŸæŽ¥ç¨®ã®é–‹å§‹ä»¥å‰ã‚„被接種者ã®æ¿€æ¸›ã®å¾Œã¯ãã®ã‚ˆã†ãªæ‚£è€…ãŒæ®†ã©ç™ºç”Ÿã—ã¦ã„ãªã„ã¨ã®é‡å¤§ãªçŸ¥è¦‹ï¼ˆOzawaetal., 2017ã€è’ç”°, 高嶋,(��N)�018）ã‹ã‚‰ã€æ£„å´ã•ã‚Œã‚‹ã¹ãã§ã‚ã‚‹ã¨æ€ã‚れる。　％07）</blockquote> <span style="color:cornflowerblue;">â—†</span>隈本 邦彦　2020　「"åå¤å±‹ã‚¹ã‚¿ãƒ†?ã‚£"ã¨ã„ã†ç–«å­¦ç ”究ã¯å­˜åœ¨ã—ãªã„　ーー自由記載欄ã«ã“ãã‚る真実ã«ç›®ã‚’å‘ã‘ã‚‹ã¸?ãã¦?ã‚ã‚‹ã€,　『社会臨床雑誌ã€28Ð0ü0ì0ë0:80-87.　<a href="httpsa_/www.jstage.jst.go.j:yarticl0ushakairinsho(�W)�_z^28_9/_articl0u-cha¾yja">[外部サイト]</a> <blockquote>HPVワクãƒãƒ³æŽ¨é€²ã®åŒ»å¸«ã‚„製薬ä¼æ¥­ã‚‰ã¯ã€Œã“ã®ãƒ¯ã‚¯ãƒãƒ³ã®å®‰å…¨æ€§ã¯æŸ»èª­ä»˜ãã®è«–æ–‡ã§è¨¼æ˜Žã•ã‚Œã¦ã„ã‚‹ã€ã¨ä¸»å¼µã—ã€åå¤å±‹å¸‚立大学・鈴木貞夫教授ã®â€œåå¤å±‹ã‚¹ã‚¿ãƒ‡ã‚£â€ã‚’æŒã¡å‡ºã—ã¦ãã‚‹ã“ã¨ãŒå¤šã„。当該論文ã®ã‚¿ã‚¤ãƒˆãƒ«ã¯â€™No association between HPV vaccine and reported post-vaccination symptomsin Japanese young women: Results of the Nagoya study’ã§ã‚ã‚Šã€ç›´è¨³ã™ã‚‹ã¨ã€Œï¼¨ï¼°ï¼¶ãƒ¯ã‚¯ãƒãƒ³ã¨ãƒ¯ã‚¯ãƒãƒ³æŽ¥ç¨®å¾Œã®æ—¥æœ¬ã®è‹¥ã„女性ãŸã¡ã®ç—‡çŠ¶ã¨ã®é–“ã«ã¯é–¢ä¿‚ãŒãªã„：åå¤å±‹ã‚¹ã‚¿ãƒ‡ã‚£ã®çµæžœã€ã¨ãªã‚‹ã€‚（下線ã¯ç­†è€…ã«ã‚ˆã‚‹ï¼‰ã“ã®æ¥µã‚ã¦æ–­å®šçš„ãªã‚¿ã‚¤ãƒˆãƒ«ã‚’ä¿¡ã˜ã¦ã€ãã‚ŒãŒçµè«–ã ã¨è€ƒãˆã¦ã„る人も多ã„ã‹ã‚‚ã—ã‚Œãªã„ãŒã€æŠ„録ã«ã¯ã€â€˜The results sugges4�no causal association between the HPV vaccines and reported symptoms.’ã¨ã€ã‚ãã¾ã§ã€Œç¤ºå”†ã•ã‚Œã‚‹ã€ã¨ã—ã‹æ›¸ã‹ã‚Œã¦ã„ãªã„。（下線ã¯ç­†è€…ã«ã‚ˆã‚‹ï¼‰ã‚¿ã‚¤ãƒˆãƒ«ã¨æŠ„録ã«ã¯ã€æ˜Žã‚‰ã‹ãªé½Ÿé½¬ãŒã‚る。ãã‚Œã©ã“ã‚ã‹ã€æœ¬ç¨¿ã§è©³è¿°ã™ã‚‹ã‚ˆã†ã«ã€æœ¬æ–‡ã«è¨˜ã•ã‚Œã¦ã„る研究çµæžœã‚‚ã€ã€Œãƒ¯ã‚¯ãƒãƒ³ã¨ç—‡çŠ¶ã«ã¯é–¢ä¿‚ãŒãªã„ã€ã¨æ–­å®šã§ãるよã†ãªä¸­èº«ã§ã¯æ±ºã—ã¦ãªã„ã®ã§ã‚る。ãã‚‚ãも“åå¤å±‹ã‚¹ã‚¿ãƒ‡ã‚£â€ãªã‚‹ç–«å­¦ç ”究ã¯å­˜åœ¨ã—ãªã„。疫学ã®ä¸–ç•Œã§ã¯ã€Œãƒ•ãƒ©ãƒŸãƒ³ã‚¬ãƒ ãƒ»ã‚¹ã‚¿ãƒ‡ã‚£ã€ãªã©ã€æ­´å²çš„ã«æœ‰åãªå¤§è¦æ¨¡ã‚³ãƒ›ãƒ¼ãƒˆç ”究ãŒã‚ã‚Šã€æ—¥æœ¬ã§ã‚‚「久山町スタディã€ãªã©ãŒç ”究æˆæžœã‚’ã‚ã’ã¦ããŸã€‚ãã‚“ãªæµã‚Œã§â€œåå¤å±‹ã‚¹ã‚¿ãƒ‡ã‚£â€ã¨èžã‘ã°ã€ã—ã£ã‹ã‚Šã¨ãƒ‡ã‚¶ã‚¤ãƒ³ã•ã‚ŒãŸå¤§è¦æ¨¡ã‚³ãƒ›ãƒ¼ãƒˆç ”究ãªã®ã‹ãªï¼Ÿã¨å‹˜é•ã„ã™ã‚‹äººã‚‚ã„ã‚‹ã‹ã‚‚ã—ã‚Œãªã„。ã—ã‹ã—ãã†ã§ã¯ãªãã€å­˜åœ¨ã™ã‚‹ã®ã¯â€œåå¤å±‹ã‚¹ã‚¿ãƒ‡ã‚£â€ã§ã¯ãªã「åå¤å±‹å¸‚調査ã€ã ã‘ãªã®ã§ã‚る。　（35） 調査ã¯ã€åå¤å±‹å¸‚ã®15ï½pS1æ­³ã®å¥³æ€§ï¼ˆç´„7万人）ã«èª¿æŸ»ç¥¨ã‚’é€ã‚Šã€å›žç­”を郵é€ã—ã¦ã‚‚らã†ã¨ã„ã†æ–¹æ³•ã§è¡Œã‚ã‚Œã€ç´„３万人ãŒå›žç­”ã—ãŸã€‚接種者ã«ã¯ã€æŽ¥ç¨®ã—ãŸæ™‚期ã¨ã€å°å­¦æ ¡6年生頃ã‹ã‚‰ç¾åœ¨ã¾ã§ã«ã€Œé–¢ç¯€ã‚„ã‹ã‚‰ã ãŒç—›ã‚€ã€ã€Œç‰©è¦šãˆãŒã‚ã‚‹ããªã£ãŸã€ãªã©HPVワクãƒãƒ³æŽ¥ç¨®å¾Œã«ã‚ˆã報告ã•ã‚Œã¦ã„ã‚‹24ã®ç—‡çŠ¶ãŒã‚ã£ãŸã‹ã©ã†ã‹ã‚’èžã„ãŸã€‚ãã‚Œã«ã†ã¾ã当ã¦ã¯ã¾ã‚‰ãªã„複åˆçš„ãªç—‡çŠ¶ã«ã¤ã„ã¦ã¯ã€Œãã®ä»–ã€ã¨ã—ã¦è‡ªç”±è¨˜è¼‰æ¬„ã«æ›¸ã„ã¦ã‚‚らã£ãŸã€‚éžæŽ¥ç¨®è€…ã«ã‚‚åŒã˜èª¿æŸ»ç¥¨ã‚’é€ã‚Šã€åŒã˜ã‚ˆã†ã«å°å­¦æ ¡6年生頃ã‹ã‚‰ç¾åœ¨ã¾ã§ã«çµŒé¨“ã—ãŸç—‡çŠ¶ã‚’書ã„ã¦ã‚‚らã£ãŸã€‚調査ã®ç›®çš„ã¯ã€æŽ¥ç¨®å¾Œã®å®Ÿæ…‹ã‚’調ã¹ã‚‹ã“ã¨ã ã£ãŸã®ã ã‹ã‚‰ã€ä»–ã®è‡ªæ²»ä½“ã®ã‚ˆã†ã«ã‚¢ãƒ³ã‚±ãƒ¼ãƒˆçµæžœã‚’集計ã—ã¦å…¬è¡¨ã™ã‚‹ã ã‘ã§ã‚ˆã‹ã£ãŸãŒåå¤å±‹å¸‚ã¯ä½™è¨ˆãªã“ã¨ã‚’ã—ãŸã€‚éžæŽ¥ç¨®è€…ã«ã‚‚åŒã˜è³ªå•ã‚’ã—ã¦ã„ã‚‹ãŸã‚ã«è§£é‡ˆãŒé›£ã—ã„ã¨è€ƒãˆãŸã®ã ã‚ã†ã‹ã€ãƒ‡ãƒ¼ã‚¿ã®è§£æžã‚’ã€ç–«å­¦ãŒå°‚é–€ã®åå¤å±‹å¸‚立大学ã®éˆ´æœ¨æ•™æŽˆã«ä¾é ¼ã—ãŸã®ã§ã‚る。ã›ã‚ã¦ä¸­ç«‹çš„ãªäººæã«è§£æžã‚’é ¼ã‚ã°ã‚ˆã‹ã£ãŸã®ã ãŒã€éˆ´æœ¨æ°ã¯SNS上ã§ã®ä¸»å¼µã‚„ã€è«–文発表後ã®è¨€å‹•ãƒ»è¡Œå‹•ã‹ã‚‰ã¯ã£ãã‚Šã‚ã‹ã‚‹ã‚ˆã†ã«ã€ŒHPVワクãƒãƒ³ã¯å®‰å…¨ã§ã‚ã‚Šã€æŽ¥ç¨®ã‚’推進ã™ã¹ãã€ã¨ã„ã†ç«‹å ´ã®äººç‰©ã ã£ãŸã€‚ãã†ã„ã†äººç‰©ã«è§£æžã‚’ä¾é ¼ã—ãŸçµæžœã€ã€Œãƒ¯ã‚¯ãƒãƒ³ã¨æŽ¥ç¨®å¾Œã®ç—‡çŠ¶ã«ã¯é–¢ä¿‚ãŒãªã„ã€ã¨æ–­å®šã™ã‚‹ã‚ˆã†ãªã‚¿ã‚¤ãƒˆãƒ«ã®â€œåå¤å±‹ã‚¹ã‚¿ãƒ‡ã‚£â€è«–æ–‡ãŒç”Ÿã¾ã‚ŒãŸã€‚　ï¼c�a�l�5-36）</blockquote> <h4><span style="color:lightgrey;">â– Ã_span>神経学Ã_h4> <span style="color:cornflowerblue;">â—†Ã_span>å¹³äºh�利明・黒岩 義之ã€�N019 「ヒトパピローマウイルスワクãƒãƒ³æŽ¥ç¨®å¾Œã«ç”Ÿã˜ã‚‹å‰¯åå¿œã®ç§‘学的解明　ーー自然å²ï¼Œä»–覚的検査所見，ワクãƒãƒ³ã®è«¸å•é¡Œãƒ¼ãƒ¼ã€,　『自律神経ã€56Ð0ü0ì0ë0:93-108.　<a href="https:å]www.jstage.jst.go.jp/article/ans/5þ^z^56_9z^_article/-char/jæt">[外部サイト]</a> <blockquote>ヒトパピローマウイルス（HPV）ワクãƒãƒ³é–¢é€£ç¥žçµŒå…疫異常症候群ã¯æ¦‚日リズム・エãƒãƒ«ã‚®ãƒ¼ä»£è¬éšœå®³ï¼Œ4 大症候（自律神経，情動，感覚，é‹å‹•ï¼‰ï¼ŒæŽ¥ç¨®ã‹ã‚‰3.5?4å¹´ã§ADLãŒæœ€æ‚ªã¨ãªã‚‹è‡ªç„¶å²ã‚’特徴ã¨ã™ã‚‹ï¼Ž […] 人工的ウイルス様粒å­ãŒç•°ç‰©ãƒ»å…ç–«å応，血管内皮障害ã®ãƒˆãƒªã‚¬ãƒ¼ã¨ãªã‚Šï¼Œè¦–床下部症候群を引ãèµ·ã“ã™ã¨è€ƒãˆãŸï¼Žã€€ï¼ˆ93）Ã_blockquote> <blockquote>　ヒトパピローマウイルス（human papilloma virus：HPV）ã®ãƒ¯ã‚¯ãƒãƒ³ï¼ˆhuman papilloma virus vaccine：HPVV）ã¯æœ¬é‚¦ã¸2009年導入，350万人ã®10歳代少女ã«æŽ¥ç¨®ã•ã‚ŒãŸãŒï¼Œ20Ó0ë0å¹´ã«å…¨å›½çš„勧奨åœæ­¢ãŒç™ºè¡¨ã•ã‚ŒãŸï¼Ž2014年，西岡らã¯å‰¯å応をHPVワクãƒãƒ³é–¢é€£ç¥žçµŒå…疫異常症候群（human papilloma virus vaccination associated neura-immunopathic syndrome：HANS）ã¨å‘¼ã³ï¼Œäºˆå‚™è¨ºæ–­åŸºæº–を作ã£ãŸï¼Žæœ¨ä¸‹ã‚‰ã¯å‰¯å応を起立性低血圧（orthostatic hypotension：OH）・体ä½æ€§é »è„ˆç—‡å€™ç¾¤ï¼ˆpostural tachycardia syndrome：POTS）ãªã©æœ«æ¢¢æ€§è‡ªå¾‹ç¥žçµŒéšœå®³ã¨è€ƒãˆãŸï¼Žå¹³äº•ã‚‰ã¯è¦–床下部・辺ç¸ç³»ã®ç¥žçµŒå†…分泌障害ã¨è€ƒãˆï¼Œé«˜æ©‹ã‚‰ã¯é«„液サイトカイン異常ã‹ã‚‰è‡ªå·±å…疫性機åºã‚’考ãˆãŸï¼Žã€€ï¼ˆ93）Ã_blockquote> <blockquote> […] åˆå›žæŽ¥ç¨®ã‹ã‚k�c�a�l�.5～4å¹´ã§ADLãŒæœ€ã‚‚悪化，以é™ã¯æ”¹å–„ã«è»¢ã˜ã‚‹è‡ªç„¶å²ã®å…¨ä½“åƒãŒåˆã‚ã¦æ‰ãˆã‚‰ã‚ŒãŸï¼Žç—™æ”£ã‚„ä¸éšæ„é‹å‹•ãªã©ã§24時間，目ãŒé›¢ã›ãªã„HANSé‡ç—‡ä¾‹ãTS017å¹´(�*h)�月ã®æ™‚点ã§8/44例％8%），2018å¹´10月ã®æ™‚点ã§þ^44例（14%）ã§ã‚ã£ãŸï¼Žã€€ï¼ˆ94）Ã_blockquote> <blockquote>HANS10例以上ã§æ–½è¡Œã•ã‚ŒãŸä»–覚的検査ã®ç•°å¸¸çŽ‡ã‚’血液，内分泌，生ç†æ©Ÿèƒ½ï¼Œç”»åƒã®å„検査ã”ã¨ã«ï¼Œé »åº¦é †ã«å›³ç¤ºã—ãŸï¼ŽHANSã®ç—…æ…‹ã¯è¦–床下部を首座ã¨ã—ãŸå…疫介在性ã®ç¥žçµŒãƒ»å†…分泌・代è¬éšœå®³ã§ã‚り，視床ã‹ã‚‰è¾ºç¸ç³»ï¼Œã•ã‚‰ã«ã¯æœ«æ¢¢è‡ªå¾‹ç¥žçµŒç³»ã¾ã§ã®åºƒãŒã‚Šã‚’ã‚‚ã¤ï¼Žã€€ï¼ˆ101）Ã_blockquote> <blockquote>HPVVã¯ã‚¢ãƒ«ãƒŸãƒ‹ã‚¦ãƒ å¡©ã‚’多ãå«ã‚€ãŒï¼ŒHANe1例ã®ã‚¢ãƒ«ãƒŸãƒ‹ã‚¦ãƒ è¡€ä¸­æ¿ƒåº¦ã¯å…¨ä¾‹æ­£å¸¸ã§åŒä¸­æ¯’ã¯å¦å®šã•ã‚ŒãŸï¼Žã‚¢ãƒ«ãƒ–ミン値ã¯98ï¼…ã§æ­£å¸¸ï¼Œã‚¢ãƒ«ãƒ–ミン/グロブリン比ã¯(� T)�ï¼…ã§é«˜å€¤ã§ã‚ã£ãŸã“ã¨ã‹ã‚‰ä½Žã‚°ãƒ­ãƒ–リン血症ãŒã‚り，HANSã¯ä¸€ç¨®ã®å…疫抑制状態ã«ã‚る．19ï¼…ã§LDH低値をèªã‚ãŸã“ã¨ã‹ã‚‰ï¼Œã“ã®ç‚¹ã‹ã‚‰ã‚‚HANSã¯ä¸€ç¨®ã®å…疫抑制状態ã«ã‚ã‚‹ã¨è§£é‡ˆã§ãる．　（103）Ã_blockquote> <blockquote>動脈血液ガスã®çµæžœã‹ã‚‰ã¯ï¼Œå‘¼å¸åœæ­¢ã«è‡³ã‚‹çŠ¶æ³ã§ä¹³é…¸ã‚¢ã‚·ãƒ‰ãƒ¼ã‚·ã‚¹ã‚’示ã—ã¦ã„ãŸï¼Žé‡åº¦ã®ç¡¬ç›´ç™ºä½œã¯å«Œæ°—的解糖å応を伴ã†ã“ã¨ãŒç¤ºã•ã‚Œï¼Œç™ºä½œãŒå¿ƒå› æ€§ã§ãªã„ã“ã¨ã‚’証拠付ã‘ãŸï¼Žã€€ï¼…04）</blockquote> <blockquote>HANSã§ã¯é«„液産生需è¦ã«å¯¾ã™ã‚‹ä»£å„Ÿä¸å…¨ãŒã‚り（髄液動態ホメオスタシスã®åˆ¶å¾¡ç ´ç¶»ï¼‰ï¼Œè„³è„Šé«„液減少症類似ã®è‡¨åºŠç—‡çŠ¶ã‚’示ã—ãŸã¨æŽ¨æ¸¬ã•ã‚Œã‚‹ï¼Žã€€ï¼ˆ104）Ã_blockquote> <blockquote>　HANSã®ï¼…ã«ç©ºè…¹æ™‚低血糖を，55ï¼…ã«å応性低血糖をèªã‚，血糖ã4l3m’udlã¾ã§ä½Žä¸‹ã™ã‚‹é‡ç—‡ä¾‹ã‚‚ã‚ã£ãŸï¼ŽHANSã§ã¯ï¼Œã†ã¤ç—…ã§ã¿ã‚‰ã‚Œã‚‹è¡€æ¸…コルãƒã‚¾ãƒ¼ãƒ«åŸºç¤Žå€¤ã®ä¸Šæ˜‡ã‚’èªã‚ãšï¼Œ48ï¼…ã§ã‚³ãƒ«ãƒã‚¾ãƒ¼ãƒ«ä½Žå€¤ã‚’èªã‚ãŸï¼Žè¡€æ¼¿ACTHã¯HANSãÇŒ1ï¼…ã§ä½Žå€¤ï¼ŒIGF-1ã¯Ó0ë0ï¼…ã§ä½Žå€¤ï¼Œè¡€æ¸…プロラクãƒãƒ³ã¯17ï¼…ã§é«˜å€¤ã¾ãŸã¯ä½Žå€¤ã‚’示ã—ãŸï¼Žã“れらã¯è¦–床下部・下垂体系機能ä¸å…¨ã‚’示唆ã™ã‚‹ï¼Žè¦–床下部障害を特異的ã«å映ã™ã‚‹ITTã®é«˜ã„異常率（DS％）ã¨ACTH・コルãƒã‚¾ãƒ¼ãƒ«ã®æ¦‚日リズム消失ã¯HANSã®è¦–床下部障害を証拠付ã‘る．　％04）</blockquote> <blockquote>CVRRや起立試験ã‹ã‚‰ã¯å‰¯äº¤æ„Ÿç¥žçµŒç³»ã‚„交感神経系ã®ç•°å¸¸ãŒç¤ºå”†ã•ã‚ŒãŸï¼Žé‡ç—‡ä¾‹ã®è¡€åœ§ãƒ»å¿ƒæ‹å¤‰å‹•è§£æžï¼ˆCVRRå射，CVRR起立）ã§å‰¯äº¤æ„Ÿç¥žçµŒæ©Ÿèƒ½ç•°å¸¸ãŒè‘—明ã§ã‚り，ãã®ç—™æ”£æ™‚所見ã‹ã‚‰ï¼Œç—™æ”£ã‚„ä¸éšæ„é‹å‹•ã¯å‰¯äº¤æ„Ÿç¥žçµŒç³»ã®æ©Ÿèƒ½ä½Žä¸‹ã‚„交感神経系ã®æ¥µã‚ã¦ä¸å®‰å®šãªçŠ¶æ…‹ã‚’ä¼´ã†ç—…æ…‹ã§ã‚ã‚‹ã“ã¨ãŒåˆ¤æ˜Žã—ãŸï¼Žã€€ï¼ˆ104）Ã_blockquote> <blockquote>åˆå›žæŽ¥ç¨®ã‹ã‚‰3.5～4å¹´ã§ADLãŒæœ€ã‚‚悪化，以é™ã¯ã‚ãšã‹ãªãŒã‚‰æ”¹å–„ã«å‘ã‹ã†HANS自然å²ã®å…¨ä½“åƒãŒåˆã‚ã¦æ‰ãˆã‚‰ã‚ŒãŸï¼Žé‡ç—‡ä¾‹ã®é ­éƒ¨MRIã§ã¯ï¼Œã‚ãšã’å¹´é–“ã®ã†ã¡ã«ç¬¬ä¸‰è„³å®¤æ‹¡å¤§ï¼Œã‚·ãƒ«ãƒ“ウス裂開大，大脳皮質èŽç¸®ãŒç¾ã‚Œï¼ŒHANSé‡ç—‡ä¾‹ã§ã¯å™¨è³ªçš„脳障害ãŒé€²è¡Œã™ã‚‹ã“ã¨ãŒã†ã‹ãŒã‚ã‚ŒãŸï¼ŽHANSã®ä»–覚的検査所見ã«ã¤ã„ã¦è­°è«–ã—，HANSã¯HPV-VLPワクãƒãƒ³ã«ã‚ˆã£ã¦å¼•ãèµ·ã“ã•ã‚Œã‚‹åŒ»åŽŸæ€§ã®ç—…態（黒岩ãŒæå”±ã—ãŸè¦–床下部症候群）ã§ã‚ã‚‹ã“ã¨ã‚’示ã—ãŸï¼Žã€€ï¼…06）</blockquote> <span style="color:cornflowerblue;">â—†</span>髙嶋 åšã€�N019 「自己å…疫性脳症ã®è‡¨åºŠç—‡å€™ãƒ¼ãƒ¼ãƒ’ステリーã¨ã®é‘‘別ーーã€,　『神経治療学ã€36-4Ú0ó0¹0Ð0ü0ì0ë044.　<a href="httpsa_/www.jstage.jst.go.j:yarticl0ujsntÔ0¯0ë0þ^^367�¹p/_articl0u-cha¾yja.".">[外部サイト]Ã_a> <blockquote>Medicall9�unexplained，psychogenic，hystericalãªã©ã¨ã‚れる神経症候ã¯,一般的ã«ã¯èº«ä½“表ç¾æ€§éšœå®³ãªã©ã®å¿ƒå› ã«ç”±æ¥ã™ã‚‹ç–¾æ‚£ã®ç‰¹å¾´ã¨ã—ã¦æ‰ãˆã‚‰ã‚Œã¦ã„ã‚‹.機能性麻痺，機能性疼痛ãªã©ã¨ã„ã†è¨€è‘‰ã‚‚åŒæ§˜ã®æ„味åˆã„ã‚’æŒã¤ï¼Žä¾‹ãˆã°ï¼Œè‹¥ã„女性ãŒå½¼æ°ã¨åˆ¥ã‚ŒãŸã‚ã¨ã«å–˜æ¯ç™ºä½œãŒèµ·ã“ã£ãŸã¨ã™ã‚Œã°ï¼ŒçŠ¶æ³çš„ã«ã¯å–˜æ¯ç™ºä½œã¯å¿ƒå› æ€§ã¨èªè­˜ã•ã‚ŒãŒã¡ã§ã‚ã‚‹ãŒï¼Œå®Ÿéš›ã«ã¯ç¾ä»£ã®åŒ»å­¦ã§ã¯å…疫性ã®æ°—管支炎ã§ã‚ã‚‹ã“ã¨ã¯ç–‘ã„ãŒãªã„.ã“ã®ã‚ˆã†ã«å¿ƒçš„è² è·ãŒèª˜å› ã¨ãªã£ãŸã¨ã—ã¦ã‚‚疾患ã®æœ¬è³ªãŒå¿ƒå› æ€§ã§ã‚ã‚‹ã‹ã©ã†ã‹ã¨ã¯åˆ¥ã®å•é¡Œã§ã‚ã‚‹.　（髙嶋2019Ú0ó0¹0）</blockquote> <blockquote �[…] 診断ã®é›£ã—ã„自己å…疫性脳症ã«ã¤ã„ã¦,ãã®ç¥žçµŒç—‡å€™ã®ç‰¹å¾´ã®ç¢ºç«‹ã«æŒ‘戦ã—ãŸï¼Žãã®çµè«–ã¨ã—ã¦è¨ºæ–­ã®ãƒã‚¤ãƒ³ãƒˆã¯ï¼Œè‡ªå·±å…疫性脳症ãŒå¼•ãèµ·ã“ã™ç—…変分布ã«ã‚ˆã‚‹ "ã³ã¾ã‚“性脳障害ã®æ‰€è¦‹" ã‚’ã¿ã¤ã‘ã‚‹ã“ã¨ã§ã‚ã‚‹ï¼)�[…] 　ã“ã®è€ƒãˆæ–¹ã‚’実践ã—ã¦è¨ºæ–­,治療を行ã£ãŸçµæžœ,心因性を示唆ã™ã‚‹ã¨ã—ã¦çŸ¥ã‚‰ã‚Œã¦ã„る神経症候ã®å¤šãã¯,自己å…疫性脳症ã®ä¸»ç—‡çŠ¶ã§ã‚ã‚‹ã“ã¨ãŒã‚ã‹ã£ã¦ããÍk　（髙嶋2019Ú0ó0¹0Ð0ü0ì0ë0(� T)�）</blockquote> <blockquote(�ÇŒ)�016å¹´ã«ç¥žçµŒæ²»ç™‚学㫠"自己å…疫性脳症を見ãã‚ã‚ã‚‹ãŸã‚ã®æ–°ã—ã„神経診察ã®æ案一身体表ç¾æ€§éšœå®³ã¨ã®é‘‘別ーã¨ã„ã†ã‚¿ã‚¤ãƒˆãƒ«ã§æ–°ã—ã„神経診断学ã®è€ƒãˆæ–¹ã‚’ã ã—ã¦ï¼Œãã®å¾Œ100例を越ãˆã‚‹ãƒ’ステリー症候をæŒã¤æ‚£è€…を診療ã—ã¦ããŸãŒï¼Œå¤šãã¯å…疫抑制治療ã«åå¿œã—，プライマリーã«å¿ƒå› ãŒåŽŸå› ã¨è€ƒãˆã‚‰ã‚Œã‚‹æ‚£è€…ã¯ã»ã¨ã‚“ã©ãŠã‚‰ãšï¼Œå„医師ãŒãã¡ã£ã¨è¨ºæ–­ã—ã†ã‚‹èƒ½åŠ›ãŒã‚ã‚Œã°,患者数ã¯ã‹ãªã‚Šå¤šã„ã®ã§æˆ‘々ã®æ­£ã—ã•ã¯ã™ãã«è¨¼æ˜Žã•ã‚Œã‚‹ã§ã‚ã‚ã†.　（髙å¶kp019:343）Ã_blockquote> <blockquote>実臨床ã§ã¯ï¼Œã‹ãも多ãã®æ‚£è€…ãŒèº«ä½“表ç¾æ€§éšœå®³ã«ã•ã‚Œã¦ã„ã‚‹ç¾å®ŸãŒã‚り，ãã‚ŒãŒã‚‚ã£ã¨ã‚‚明らã‹ã¨ãªã£ãŸã®ãŒï¼ŒHPVワクãƒãƒ³æŽ¥ç¨®å¾Œã®ç¥žçµŒéšœå®³æ‚£è€…ã§ã‚ã‚ã†ï¼Žãƒ’ステリー症候をæŒã¤ã ã‘ã§èº«ä½“表ç¾æ€§éšœå®³ã«ã—ã¦ã—ã¾ã†ã“ã¨ã¯ï¼Œã»ã°ç¢ºå®Ÿã«è¨ºæ–­ã‚’誤ã£ã¦ãŠã‚Šï¼Œæ‚£è€…ã¨ãã®å®¶æ—ã«å¤šå¤§ãªè¿·æƒ‘ã‚’ã‹ã‘ã¦ã„ã‚‹ã“ã¨ã‚’è‚ã«éŠ˜ã˜ã‚‹ã¹ãã§ã‚ã‚ã†. 　ヒステリーã®å¿ƒå› æ©Ÿåºã‹ã‚‰ä¸€æ­©ã‚‚引ã‹ãªã„方も多数ãŠã‚‰ã‚Œã‚‹ã¨æ€ã†ãŒï¼Œãƒ’ステリーã®ç—‡å€™ãŒãªãœã“ã‚Œã»ã©ã¾ã§ã«ä¼¼ã¦ã„ã‚‹ã®ã‹ï¼Œãªãœæ˜Žã‚‰ã‹ãªå¿ƒå› ãŒã¿ã‚ãŸã‚‰ãªã„ã®ã‹ï¼Œãªãœé‹å‹•ã®ã¿ãªã‚‰ãšæ„Ÿè¦šï¼Œæ€è€ƒï¼Œè¦–覚，自律神経，ä¸éšæ„é‹å‹•ãªã©ã«å¤šå²ã«ã‚ãŸã‚‹ã®ã‹ï¼ŒãªãœæŠ—gAChR抗体や抗TPO抗体ãªã©ãŒé«˜çŽ‡ã«å‡ºã‚‹ã®ã‹ï¼Œãªãœè‡ªå·±å…疫性脳炎ã¨ã»ã¨ã‚“ã©åŒºåˆ¥ã§ããªã„症候をæŒã¤ã®ã‹ï¼Œãªãœå¿ƒå› æ€§ã§ã‚ã‚Œã°ã©ã‚“ãªç—‡çŠ¶ã§ã‚‚èµ·ã“ã‚Šãˆã‚‹ã®ã‹ï¼Œæ©Ÿåºçš„ãªèª¬æ˜ŽãŒä¸è¦ã‹ãªã©ã®ã“ã¨ã‚’ä¸æ€è­°ã«æ„Ÿã˜ãªã„ã ã‚ã†ã‹ï¼Žã©ã†ã—ã¦åŒã˜ã‚ˆã†ãªç—‡å€™ã§ã‚ã‚ŠãªãŒã‚‰ï¼ŒæŠ—体ãŒå‡ºã‚Œã°è‡ªå·±å…疫性ã§æŠ—体ãŒå‡ºãªã‘ã‚Œã°å¿ƒå› æ€§ã«ãªã£ã¦ã—ã¾ã†ã®ã‹ï¼ŽãŸã¨ãˆã°ï¼Œé‡ç—‡ç­‹ç„¡åŠ›ç—‡ã®ç—‡å€™ã‚’æŒã£æŠ—体陽性患者ã¨é™°æ€§æ‚£è€…ãŒã„ãŸã¨ã—ã¦ï¼Œé™°æ€§æ‚£è€…もセロãƒã‚¬ãƒ†ã‚¤ãƒ—ãªé‡ç—‡ç­‹ç„¡åŠ›ç—‡ã¨ã—ã¦æŠ—体ã¯å‡ºãªã„ãŒé‡ç—‡ç­‹ç„¡åŠ›ç—‡ã¨ã—ã¦æ‰±ã†ã®ã§ã¯ãªã„ã ã‚ã†ã‹ï¼Žãã®ã‚ãŸã‚Šã‚’å«ã‚ã¦ã‚‚ã†ä¸€åº¦ã‚ˆã考ãˆã¦ã»ã—ã„.　（髙å¶kp019:343-344）Ã_blockquote> <span style="color:cornflowerblue;">â—†Ã_span>æ± ç”° 修一ã€�N018 「å­å®®é ¸ãŒã‚“ワクãƒãƒ³æŽ¥ç¨®å¾Œã®å‰¯åå¿œ: ã‚ãŒå›½ã®ç¾çŠ¶ã€,　『昭和学士会雑誌ã€78-4:µ0ó0Á0ü0à0Ô0³0Ð0ü0ì0ë014.　<a href="httpsa_/www.jstage.jst.go.j:yarticl0ujshowaunivsou78/4/78_30z^_article/-char/jæt">[外部サイト]</a> <blockquote>ç§ã¯å½“時ã€åŽšç”ŸåŠ´åƒç§‘学研究費補助金ã«ã‚ˆã‚‹æ…¢æ€§ã®ç—›ã¿å¯¾ç­–研究事業「難治性神経因性疼痛ã®åŸºç¤Žç–¾æ‚£ã®è§£æ˜Žã¨è¨ºæ–­ãƒ»æ²»ç™‚精度をå‘上ã•ã›ã‚‹ãŸã‚ã®ç ”「究ç­ã€ã®ä¸»ä»»ç ”究者を務ã‚ã¦ãŠã‚Šãã®é–¢é€£ã§åŽšç”ŸåŠ´åƒçœã‹ã‚‰å­å®®é ¸ãŒã‚“ワクãƒãƒ³æŽ¥ç¨®å¾Œã®ç—…æ…‹ã«é–¢ã™ã‚‹ä¸€ã¤ã®ç ”究ç­ã®çµ±æ‹¬è²¬ä»»è€…ã‚’ä¾é ¼ã•ã‚ŒãŸä»¥å¾Œç­†è€…ã¯æœ¬ä»¶ã«é–¢ã‚るよã†ã«ãªã£ãŸï¼Žã€€ï¼c�a�l�Ô0³0）</blockquote> <blockquote>å­å®®é ¸ãŒã‚“ワクãƒãƒ³ã§ã¯ï¼ŒæŽ¥ç¨®ã‚’å—ã‘ãŸå¥³å­å­¦ç”Ÿã®è¡€æ¸…中ã«ãŠã„ã¦HPVã«å¯¾ã™ã‚‹æŠ—体価ãŒä¸Šæ˜‡ã™ã‚‹ã“ã¨ã¯ãªãã€æœ¬ãƒ¯ã‚¯ãƒãƒ³ã®ä½“内ã«ãŠã‘る生物学的作用を追跡ã™ã‚‹æ–¹æ³•ãŒä¹ã—ã„．ãã“ã§ã‚ã‚Œã‚ã‚ŒãTS013å¹´6月ã‹ã‚‰2017å¹´12月迄ã“ã®æœŸé–“ã«å½“方をå—診ã—ã€å­å®®é ­ãŒã‚“ワクãƒãƒ³æŽ¥ç¨®å¾Œã“ã®å‰¯åå¿œã¨è¨ºæ–­ã•ã‚ŒãŸ84åã®å¥³å­å­¦ç”Ÿã‚’対象ã«ï¼Œæœ¬ãƒ¯ã‚¯ãƒãƒ³æŽ¥ç¨®æ™‚期ã¨æœ¬ãƒ¯ã‚¯ãƒãƒ³æŽ¥ç¨®å¾Œã®ç‰¹ç•°ãªç—‡çŠ¶ã®ç™ºç¾æ™‚期ã®æ™‚間的経緯を調査ã—ãŸï¼Žæœ¬ãƒ¯ã‚¯ãƒãƒ³ã®æŽ¥ç¨®é–‹å§‹ãTS010å¹´5月ã§ã‚ã‚Šã€20Ó0ë0å¹´4月ã«çµ‚了ã—ã¦ãŠã‚Šã€ãƒ”ーク時期ãTS011å¹´6月ãkp012å¹´9月ã§ã‚る．本ワクãƒãƒ³æŽ¥ç¨®ã‚’å—ã‘ãŸå¥³å­å­¦ç”ŸãŒæœ€åˆã«ç—‡çŠ¶ã‚’呈ã—ãŸã®ã4l010å¹´10月ã§ã‚り最後ã®å¥³å­å­¦ç”Ÿã®ç™ºç—…時期ãTS015å¹´10月ã§ã‚ãã®ãƒ”ーク時期ãTS011å¹´9月ã‹ã‚‰20Ó0ë0å¹´8月ã§ã‚る．図4ã®Aã¨Bを対比ã™ã‚‹ã¨ï¼Œ1)å­å®®ãŒã‚“ワクãƒãƒ³ã®æŽ¥ç¨®æ™‚期ã¨æœ¬ãƒ¯ã‚¯ãƒãƒ³ã®æŽ¥ç¨®å¾Œå‰¯åå¿œã¨æ€ã‚れる症状ãŒç™ºç¾ã—ã¦ã„る時期ãŒç›¸å½“é‡è¤‡ã—ã¦ã„る．2)本ワクãƒãƒ³ã®å‹§å¥¨ã‚’中止ã—ã Nå¹´4ã‹æœˆå¾Œã®2015å¹´10月以é™ä»Šæ—¥ã«åˆ°ã‚‹ã¾ã§ã®2å¹´5ã‹æœˆé–“．å­å®®é ¸ãŒã‚“ワクãƒãƒ³æŽ¥ç¨®å¾Œã®å‰¯å応を疑ã‚ã›ã‚‹æ–°ãŸãªå¥³å­å­¦ç”ŸãŒå‡ºã¦ã„ãªã„．ãnj点ãŒã‚ã‹ã‚‹ã“ãã®çµæžœã¯å­å®®é ¸ãŒã‚“ワクãƒãƒ³ã®æŽ¥ç¨®ã¨æœ¬ãƒ¯ã‚¯ãƒãƒ³æŽ¥ç¨®å¾Œã®å¥³å­å­¦ç”Ÿã«å‡ºç¾ã—ãŸç‰¹ç•°ãªç—‡çŠ¶ã¨ã®é–“ã«ã¯å› æžœé–¢ä¿‚ãŒç¤ºå”†ã•ã‚Œã‚‹ã¨ã®çµè«–ã«ãªã‚‹ï¼Žã€€ï¼ˆª0）Ã_blockquote> <blockquote>…… 今回ã®ä¸€é€£ã®äº‹è±¡ã‚’経験ã—ã¦æ”¹ã‚ã¦æ„Ÿã˜ã‚‹ã“ã¨ã¯ã€å­å®®é ¸ãŒã‚“ワクãƒãƒ³æŽ¥ç¨®å¾Œã®ä¸Šè¨˜ã«è¿°ã¹ãŸäºˆæœŸã›ã¬å‰¯åå¿œã«å¯¾ã—ã¦ã®è¡Œæ”¿å´ã€åŒ»ç™‚者å´ã®å¯¾å¿œãŒé©åˆ‡ã§ã‚ã£ãŸã‹ã©ã†ã‹ã§ã‚る．厚生労åƒçœã¯é€¸æ—©ãåŒãƒ¯ã‚¯ãƒãƒ³æŽ¥ç¨®ã®å‹§å¥¨ä¸­æ­¢ã‚’決定ã—ã€ãã®åŽŸå› ã‚’“心身ã®åå¿œâ€ã¨çµè«–付ã‘ãŸï¼Žå‰è€…ã¯é«˜ã評価ã•ã‚Œã‚‹ã¹ãã§ã‚ã‚‹ãŒï¼Œå¾Œè€…ã®â€œå¿ƒèº«ã®åå¿œâ€èª¬ã¯æœ¬å•é¡Œã‚’より複雑化ã•ã›ãŸã¨ç­†è€…ã¯è€ƒãˆã‚‹ï¼Žã“ã®åŽšç”ŸåŠ´åƒçœã®ç™ºè¡¨ã«ã‚ˆã‚Šå‰¯å応を訴ãˆã¦åŒ»ç™‚機関をå—診ã—ãŸå¥³å­å­¦ç”Ÿã®å¤šããŒãã¡ã‚“ã¨ã—ãŸæ¤œç´¢ã‚’å—ã‘ã‚‹ã“ã¨ãªã，心療内科・精神科å—診を勧ã‚られãŸã¨èžã„ã¦ã„る．ã¾ãŸåŒ»ç™‚者å´ã‚‚従æ¥ã®åŒ»å­¦çš„知識ã«åˆè‡´ã—ãªã„本ワクãƒãƒ³æŽ¥ç¨®å¾Œã®å‰¯å応症状をã€ã‚„ã¯ã‚Šå¥‡ç•°ãªç—…æ…‹ã¨æ‰ãˆã¦ã„ãŸå‚¾å‘ãŒã‚る．　（ª1）Ã_blockquote> <h4><span style="color:lightgrey;">â– </span>å…ç–«å­¦</h4> 原著：症状発ç¾ã«äº¤äº’作用をå«ã‚€ç–«å­¦ãƒ‡ãƒ¼ã‚¿ã®è§£æž 　　ï¼ã€Œåå¤å±‹å¸‚å­å®®é ¸ãŒã‚“予防接種調査ã€ã‹ã‚‰ï¼ httpa_/cont.o.oo7.jp/49_z^497�¹pcontents.html 論説：åå¤å±‹å¸‚HPVワクãƒãƒ³æŽ¥ç¨®å¾Œèª¿æŸ»ãƒ‡ãƒ¼ã‚¿ã‚’用ã„㟠　　2ã¤ã®è§£æžè«–æ–‡ã®æ¯”較 http:å]cont.o.oo7.j:y497�¹p/49_3contents.html <span style="color:cornflowerblue;">â—†</span>伊藤 晴康 et al　2016 「Human papillomavirus (HPV) ワクãƒãƒ³ã®æŽ¥ç¨®å¾Œã«SLEを発症ã—ãŸä¸€ä¾‹ã€,　『日本臨床å…疫学会会誌ã€k�g�9.2:145-149.　<a href="https:å]www.jstage.jst.go.jp/article/jsc}v39(�W)�Ô0¯0ë09_14ô^_article/-char/jæt">[外部サイト]</a> 症例：15 歳，女性． 主訴：発熱，関節痛，全身ã®ç­‹ç—›ï¼Œå³è€³ä¸‹è…ºè…«è„¹ ç¾ç—…歴：20XX å¹´ 8 月 19 æ—¥ ãR�s�9 æœ8�26 æ—¥ ã«(��N)� 価 Human Papillomavirus（HPV）ワクãƒãƒ³ã‚’接種ã—ãŸï¼Ž(�)� 回目ã®æŽ¥ç¨®å¾Œã‹ã‚‰å…¨èº«ã®ç–¼ç—›ã‚’自覚ã™ã‚‹ã‚ˆã†ã« ãªã£ãŸï¼Žã¾ãŸï¼Œæ—¥ç„¼ã‘ã‚’ã—ãŸéš›ï¼Œé¡”é¢ãŒç™ºèµ¤ã—ãŸã“ ã¨ãŒã‚ã£ãŸï¼¡1 月頃ã‹ã‚‰ã¯ 37 度å°ã®ç™ºç†±ãŒå‡ºç¾ã— ãŸï¼Žã•ã‚‰ã«ï¼4l0XX＋ 1 å¹´ 1 月上旬頃ã‹ã‚‰é–“歇的㪠39 度以上ã®ç™ºç†±ã¨é–¢ç¯€ç—›ãŒå‡ºç¾ã—ãŸï¼Žã“ã®ãŸã‚， 精査加療目的ã«å…¥é™¢ã¨ãªã£ãŸï¼)�145 患者ã®æ—¢å¾€æ­´ã«æ³¨ç›®ã™ã‚‹ã¨ï¼4l 例㯠SLE 以外ã®è‡ª å·±å…疫性疾患（関節リウマãƒï¼Œè‡ªå·±å…疫性血å°æ¿æ¸› 少症）ãŒã‚ã£ãŸï¼Žä»–ã® 2 例㯠SLE ã®å¯›è§£çŠ¶æ…‹ä¸­ã« HPV ワクãƒãƒ³ã‚’接種ã—å†ç‡ƒã—ãŸç—‡ä¾‹ã§ã‚ã£ãŸï¼Ž8 例 中 2 2 2 例ã¯ï¼Œä½•ã‚‰ã‹ã®è‡ªå·±å…疫性疾患ã®æ—¢å¾€æ­´ãŒã‚㣠ãŸã“ã¨ã«ãªã‚‹ï¼ˆè¡¨(��N)� ）．家æ—æ­´ã«æ³¨ç›®ã™ã‚‹ã¨ï¼Œã“ã® 2 2 2 例以外ã§ã‚2�2 例ã«ãŠã„ã¦è‡ªå·±å…疫性疾患ã®å®¶æ—æ­´ ãŒã‚ã£ãŸï¼Žã¤ã¾ã‚+�8 例中 6 例ã§ä½•ã‚‰ã‹ã®è‡ªå·±å…疫性 疾患ã®ç´ å› ãŒã‚る状態㧠HPV ワクãƒãƒ³ã‚’接種ã—㦠ã„ãŸã“ã¨ãŒåˆ†ã‹ã£ãŸï¼ˆè¡¨(��N)� ）． 接種回数ã«æ³¨ç›®ã™ã‚‹ã¨ 8 例中 5 例ã¯(��N)� 回目ã®æŽ¥ç¨® 後㫠SLE を発症ã—ã¦ã„る（è¡R�s�2 ）．ã“れらã®ç—‡ä¾‹ã® 中ã«ã¯ï¼Œ1 回目ã®æŽ¥ç¨®å¾Œï¼Œå¾®ç†±ï¼Œè»½åº¦ã®æ„Ÿå†’症状㪠ã©ã®è»½åº¦ãªæœ‰å®³äº‹è±¡ã‚’èªã‚ã¦ã„る例ãŒã‚ã£ãŸï¼Žã“ã® ã“ã¨ã‹ã‚‰ï¼Œ1 回目接種後ã«æœ‰å®³äº‹è±¡ã‚’èªã‚ãŸå ´åˆï¼Œ 2 回目ã®æŽ¥ç¨®ã¯æ…Žé‡ã«è¡Œã†å¿…è¦ãŒã‚ã‚‹ã¨è€ƒãˆã‚‰ã‚Œã‚‹ï¼Žã€€148 ワクãƒãƒ³æŽ¥ç¨®å¾Œã«ç™ºç—‡ã™ã‚‹è‡ªå·±å…疫性疾患ã®åŽŸå›  ã¨ã—ã¦ã¯ï¼Œãƒ¯ã‚¯ãƒãƒ³ã«æ·»åŠ ã•ã‚Œã¦ã„るアジュãƒãƒ³ãƒ‰ ã®é–¢ä¸ŽãŒè€ƒãˆã‚‰ã‚Œã¦ã„る．2 価，2 2 2 価 HPV ワクãƒãƒ³ ã¯ã¨ã‚‚ã«ã‚¢ã‚¸ãƒ¥ãƒãƒ³ãƒ‰ã¨ã—ã¦ã‚¢ãƒ«ãƒŸãƒ‹ã‚¦ãƒ å¡©ãŒç”¨ã„ られã¦ã„る．アルミニウム塩ã¯ï¼ŒæŽ¥ç¨®éƒ¨ä½ã«æŠ—原を 貯留ã•ã›ï¼Œå¾ã€…ã«æŠ—原を放出ã™ã‚‹ã“ã¨ã§ã‚¢ã‚¸ãƒ¥ãƒãƒ³ ドã¨ã—ã¦åƒã8） ．アルミニウム塩を使用ã—ã¦ã„ã‚"B åž‹è‚炎ウイルス（HBV）ワクãƒãƒ³æŽ¥ç¨®å¾Œã« SLE ã‚’ 発症ã—㟠10 例ãŒå ±å‘Šã•ã‚Œã¦ã„ã‚‹9）． ã•ã‚‰ã«ï¼Œæœ¬ç—‡ä¾‹ã§ä½¿ç”¨ã•ã‚ŒãŸ 2 価 HPV ワクムンã§ã¯ï¼Œã‚¢ãƒ«ãƒŸãƒ‹ã‚¦ãƒ å¡©ã« monophosphoryl lipid A （MPL）を加ãˆãŸè¤‡åˆåž‹ã‚¢ã‚¸ãƒ¥ãƒãƒ³ãƒˆï¼ˆAS02 2 2 アジュ ãƒãƒ³ãƒˆï¼‰ãŒç”¨ã„られã¦ã„る．MPL ã¯ã‚¢ã‚¸ãƒ¥ãƒãƒ³ãƒˆ 活性ãŒã‚ã‚‹ lipopolysaccharide（LPS）を無毒化㗠ãŸã‚‚ã®ã§ã‚る．MPL ã¯ï¼ŒæŠ—原æ示細胞㮠Toll-like receptor4（TLR4）ã«ç›´æŽ¥çš„ã«çµåˆã—10） ，IL-6, TNF-α, IL-1β, INF-β, IL-(�*h)� を誘導ã—，çµæžœ T 細胞，B 細胞 ã®åˆ†åŒ–を促進ã™ã‚‹8） ．SLE ã®ç™ºç—‡éŽç¨‹ã§ã‚‚，自己å 応性 T 細胞ãR�s�B 細胞ã®æ´»æ€§åŒ–ã«ã‚ˆã‚Šè‡ªå·±æŠ—体ãŒéŽ 剰ã«ç”£ç”Ÿã•ã‚Œã‚‹ï¼Žã“ã®ã‚ˆã†ãªè‡ªå·±æŠ—体産生ã®æ©Ÿåºã¨ ã—㦠Toll-like receptor（TLR）を介ã—ãŸè‡ªå·±æŠ—体産生 ãŒé–¢ä¸Žã—ã¦ã„ã‚‹ã“ã¨ãŒè¿‘年報告ã•ã‚Œã¦ã„ã‚‹4） ．MPL ãªã©ã® Toll-like receptor ã«ä½œç”¨ã™ã‚‹ã‚¢ã‚¸ãƒ¥ãƒãƒ³ãƒˆã‚’ 用ã„ãŸãƒ¯ã‚¯ãƒãƒ³ãŒï¼ŒSLE ã‚’å«ã‚ãŸè‡ªå·±å…疫性疾患㮠発症ã«é–¢ä¸Žã—ã¦ã„ã‚‹å¯èƒ½æ€§ãŒæŒ‡æ‘˜ã•ã‚Œã¦ã„ã‚‹3） 148 ． HPV ワクãƒãƒ³æŽ¥ç¨®å¾Œã«è¤‡åˆæ€§å±€æ‰€ç–¼ç—›ç—‡å€™ç¾¤ complex regional pain syndrome（CRPS）ãŒç™ºç—‡ã—㟠症例ãŒå ±å‘Šã•ã‚Œã¦ã„ã‚’3） ．ã“ã®å ±å‘Šã®ä¸­ã«ï¼Œå¤§è…¿éƒ¨ MR!�?�ã«ãŠã„ã¦ç­‹è†œç‚Žã®æ‰€è¦‹ã‚’èªã‚，ステロイド治 療後㫠MRI ã®æ‰€è¦‹ãŒæ”¹å–„ã—ãŸä¸€ä¾‹ãŒç¤ºã•ã‚Œã¦ã„る． 本症例ã¨ã“ã®ç—‡ä¾‹ã®é¡žä¼¼æ€§ã¯èˆˆå‘³æ·±ã„． 著者ら㯠HPV ワクãƒãƒ³æŽ¥ç¨®å¾Œã« SLE を発症ã—㟠一例を経験ã—ãŸï¼Žè‡ªå·±å…疫性疾患ã®æ—¢å¾€æ­´ã‚„家æ—æ­´ ãŒã‚る患者ã§ã¯ HPV ワクãƒãƒ³æ‘‚å–ã«é–¢ã—ã¦ï¼Œæ…Žé‡ ã«ã™ã‚‹å¿…è¦ãŒã‚る．HPV ワクãƒãƒ³æŽ¥ç¨®å¾Œã® SLE ã¯(�)� 回目ã®æŽ¥ç¨®å¾Œã« SLE 症状ãŒå‡ºç¾ã™ã‚‹ã“ã¨ãŒå¤šã„． １回目ã®æŽ¥ç¨®å¾Œã«è»½åº¦ã§ã‚ã£ã¦ã‚‚何ã‹ã—らã®ãƒˆãƒ©ãƒ– ルãŒã‚ã£ãŸå ´åˆã¯ï¼Œã•ã‚‰ã«æ…Žé‡ã«æŽ¥ç¨®ã™ã¹ãã§ã‚ã‚‹ï¼)�149 伊藤晴康, e4�al. Human papillomavirus (HPV) ワクãƒãƒ³ã®æŽ¥ç¨®å¾Œã« SLE を発症ã—ãŸä¸€ä¾‹. 日本臨床å…疫学会会誌, 2016, 39(�Ñ‘)�: 145-149. <h4><span style="color:lightgrey;">â– Ã_span>分å­ç”Ÿç‰©å­¦Ã_h4> <span style="color:cornflowerblue;">â—†Ã_span>G, Giannotta・N, Giannottaã€�N018　"<b><u>vaccines and neuroinflammation</u></b>",　<i>Int J Pub Health SafeÃ_i>ã€p�A�-1Ø0¯0¿0ü0ë0(�|T)�　<a href="https:å]www.hilarispublisher.com/open-access/vaccines-and-neuroinflammation.pdf">[外部サイト]Ã_a> Giannotta, G., & Giannotta, N. (2018). Vaccines and neuroinflammation. Int J Pub Health Safe, 3(163), 2. ※HTMLã‹ã‚‰å¼•ç”¨ã®ãŸã‚ページ数記載ãªã— <blockquote><b>Abstract</b> <b>Background:Ã_b> Post-vaccination adverse reactions (AEs) are a reason of strong debate among scientists.Unfortunately, we often make the mistake of discussing just the epidemiolog9�bu4�no4�the molecular biology. The action mechanism of the vaccines is still not fully known despite the fac4�that aluminum adjuvants have been used for about 100 years. 　<b>Hypothesis:Ã_b> We hypothesized a link between vaccinations and neuroinflammation. The peripheral proinflammatory cytokines (IL-1β, IL-6, and TNF-α), expressed after the injection of the vaccines can reach the brain and can cause neuroinflammation after microglia activation. Elevated pra-inflammatory cytokines, particularly TNF-α, have been described in studies regarding the cytokines profile in autistic children. IL-1β represents a cytokine tha4�controls the local pro-inflammator9�cascade and thereb9�affects the balance between protective immunit9�and destructive inflammation. A subgroup of children with ASD (Autism Spectrum Disorder) has developed neuroinflammation. Several postmortem studies have confirmed the activation of microglia and neuroinflammation. A recen4�stud9�has shown the presence of aluminum in the brain of individuals with autism and this aluminum was also found in microglia cells. Aluminum from vaccines is redistributed to numerous organs, including brain, where i4�accumulates. Each vaccine adds to this tissue differen4�level of aluminum. Aluminum, like mercury, activates microglia leading to chronic brain inflammation and neurotoxicity. 　<b>Conclusion: </b>The molecular mechanisms presented here demonstrate how peripheral cytokines, expressed after vaccination, can cause neuroinflammation in some subjects, after microglia activation, depending on the mmunogenetic background and the innate immune memory.　（1） 以下機械翻訳（DeepL）： <b>è¦æ—¨Ã_b> 　<b>背景：Ã_b>ワクãƒãƒ³æŽ¥ç¨®å¾Œã®å‰¯å応（AE）ã¯ã€ç§‘学者ã®é–“ã§å¼·ã„è­°è«–ã®å¯¾è±¡ã¨ãªã£ã¦ã„る。残念ãªãŒã‚‰ã€æˆ‘々ã¯ã—ã°ã—ã°ç–«å­¦ã ã‘ã‚’è­°è«–ã—ã€åˆ†å­ç”Ÿç‰©å­¦ã‚’è­°è«–ã—ãªã„ã¨ã„ã†é–“é•ã„を犯ã™ã€‚ワクãƒãƒ³ã®ä½œç”¨æ©Ÿåºã¯ã€ã‚¢ãƒ«ãƒŸãƒ‹ã‚¦ãƒ ã‚¢ã‚¸ãƒ¥ãƒãƒ³ãƒˆãŒç´W00年間使用ã•ã‚Œã¦ã„ã‚‹ã«ã‚‚ã‹ã‹ã‚らãšã€ã¾ã å分ã«è§£æ˜Žã•ã‚Œã¦ã„ãªã„。 　<b>仮説：Ã_b>ç§ãŸã¡ã¯ã€ãƒ¯ã‚¯ãƒãƒ³æŽ¥ç¨®ã¨ç¥žçµŒç‚Žç—‡ã®é–¢é€£æ€§ã‚’仮定ã—ãŸã€‚ワクãƒãƒ³æ³¨å°„後ã«ç™ºç¾ã™ã‚‹æœ«æ¢¢æ€§ã®ç‚Žç—‡æ€§ã‚µã‚¤ãƒˆã‚«ã‚¤ãƒ³ï¼ˆIL-1βã€IL-6ã€TNF-α）ã¯è„³ã«åˆ°é”ã—ã€ãƒŸã‚¯ãƒ­ã‚°ãƒªã‚¢æ´»æ€§åŒ–後ã«ç¥žçµŒç‚Žç—‡ã‚’引ãèµ·ã“ã™å¯èƒ½æ€§ãŒã‚る。炎症性サイトカインã€ç‰¹ã«TNF-αã®ä¸Šæ˜‡ã¯ã€è‡ªé–‰ç—‡å…ã®ã‚µã‚¤ãƒˆã‚«ã‚¤ãƒ³ãƒ—ロファイルã«é–¢ã™ã‚‹ç ”究ã§å ±å‘Šã•ã‚Œã¦ã„る。IL-1βã¯ã€å±€æ‰€çš„ãªç‚Žç—‡ã‚«ã‚¹ã‚±ãƒ¼ãƒ‰ã‚’制御ã™ã‚‹ã‚µã‚¤ãƒˆã‚«ã‚¤ãƒ³ã§ã‚ã‚Šã€ãã‚Œã«ã‚ˆã£ã¦é˜²å¾¡çš„å…ç–«ã¨ç ´å£Šçš„ç‚Žç—‡ã®é–“ã®ãƒãƒ©ãƒ³ã‚¹ã«å½±éŸ¿ã‚’åŠã¼ã™ã¨ã•ã‚Œã¦ã„る。ASD（自閉症スペクトラム）å…ã®ã‚µãƒ–グループã¯ã€ç¥žçµŒç‚Žç—‡ã‚’発症ã—ã¦ã„る。ã„ãã¤ã‹ã®æ­»å¾Œèª¿æŸ»ã«ã‚ˆã‚Šã€ãƒŸã‚¯ãƒ­ã‚°ãƒªã‚¢ã®æ´»æ€§åŒ–ã¨ç¥žçµŒç‚Žç—‡ãŒç¢ºèªã•ã‚Œã¦ã„る。最近ã®ç ”究ã§ã¯ã€è‡ªé–‰ç—‡æ‚£è€…ã®è„³å†…ã«ã‚¢ãƒ«ãƒŸãƒ‹ã‚¦ãƒ ãŒå­˜åœ¨ã—ã€ã“ã®ã‚¢ãƒ«ãƒŸãƒ‹ã‚¦ãƒ ã¯ãƒŸã‚¯ãƒ­ã‚°ãƒªã‚¢ç´°èƒžã«ã‚‚見出ã•ã‚ŒãŸã€‚ワクãƒãƒ³ã‹ã‚‰ã®ã‚¢ãƒ«ãƒŸãƒ‹ã‚¦ãƒ ã¯ã€è„³ã‚’å«ã‚€å¤šãã®è‡“器ã«å†åˆ†é…ã•ã‚Œã€ãã“ã§è“„ç©ã•ã‚Œã‚‹ã€‚å„ワクãƒãƒ³ã¯ã€ã“ã®çµ„ç¹”ã«ç•°ãªã‚‹ãƒ¬ãƒ™ãƒ«ã®ã‚¢ãƒ«ãƒŸãƒ‹ã‚¦ãƒ ã‚’追加ã™ã‚‹ã€‚アルミニウムã¯ã€æ°´éŠ€ã¨åŒæ§˜ã«ãƒŸã‚¯ãƒ­ã‚°ãƒªã‚¢ã‚’活性化ã—ã€æ…¢æ€§çš„ãªè„³ã®ç‚Žç—‡ã¨ç¥žçµŒæ¯’性を引ãèµ·ã“ã™ã€‚ 　<b>çµè«–Ã_b>：ã“ã“ã«ç¤ºã—ãŸåˆ†å­ãƒ¡ã‚«ãƒ‹ã‚ºãƒ ã¯ã€ãƒ¯ã‚¯ãƒãƒ³æŽ¥ç¨®å¾Œã«ç™ºç¾ã™ã‚‹æœ«æ¢¢æ€§ã‚µã‚¤ãƒˆã‚«ã‚¤ãƒ³ãŒã€å…疫原性背景や自然å…疫記憶ã«ä¾å­˜ã—ã¦ã€ãƒŸã‚¯ãƒ­ã‚°ãƒªã‚¢æ´»æ€§åŒ–後ã«ä¸€éƒ¨ã®è¢«é¨“者ã§ç¥žçµŒç‚Žç—‡ã‚’引ãèµ·ã“ã™å¯èƒ½æ€§ãŒã‚ã‚‹ã“ã¨ã‚’示ã™ã‚‚ã®ã§ã‚ã£ãŸã€‚Ã_blockquote> <blockquote>Regarding the possible relationships between HPV vaccines and CRPS type I, at the molecular level, the cytokines typical of CRPS type I environment, with high levels of IL-1β, IL-6, and TNF-α, it is faithfully reproduced by the injection of HPV vaccines. Whereas in patients with POTS, sympathetic activation and parasympathetic withdrawal were associated with increased serum IL-6. IL-1β, IL-6 and TNF-α are strongly expressed after the injection of HPV vaccines, and in patients with CFS/ME, the same proinflammator9�cytokines are elevated. 　Suzuki and Hosono did no4�find an association between HPV vaccine and reported post-vaccination symptoms in Japanese young women. The survey tool was an anonymous postal questionnaire. 　As is evident, epidemiology uses differen4�investigative tools than molecular biology. In the case of HPV vaccine AEs, molecular biolog9�demonstrates wha4�epidemiology does no4�detect.（8） 以下機械翻訳（DeepL）： 　HPVワクãƒãƒ³ã¨CRPSâ… åž‹ã®é–¢ä¿‚ã®å¯èƒ½æ€§ã«ã¤ã„ã¦ã€åˆ†å­ãƒ¬ãƒ™ãƒ«ã§ã¯ã€IL-1βã€IL-6ã€TNF-αãŒé«˜å€¤ã§ã€CRPSⅠ型環境ã«å…¸åž‹çš„ãªã‚µã‚¤ãƒˆã‚«ã‚¤ãƒ³ã§ã‚ã‚Šã€ãã‚Œã¯HPVワクãƒãƒ³æ³¨å°„ã«ã‚ˆã£ã¦å¿ å®Ÿã«å†ç¾ã•ã‚Œã‚‹ã€‚一方ã€ä½“ä½æ€§é »è„ˆç—‡å€™ç¾¤æ‚£è€…ã§ã¯ã€äº¤æ„Ÿç¥žçµŒã®æ´»æ€§åŒ–ã¨å‰¯äº¤æ„Ÿç¥žçµŒã®é›¢è„±ãŒã€è¡€æ¸…IL-6ã®ä¸Šæ˜‡ã¨é–¢é€£ã—ã¦ã„ã‚‹ã“ã¨ãŒã‚ã‹ã£ãŸã€‚IL-1βã€IL-6ã€TNF-αã¯ã€HPVワクãƒãƒ³æ³¨å°„後ã«å¼·ã発ç¾ã—ã€CFS/ME患者ã§ã¯ã€åŒã˜ç‚Žç—‡æ€§ã‚µã‚¤ãƒˆã‚«ã‚¤ãƒ³ãŒä¸Šæ˜‡ã™ã‚‹ã€‚ 　Suzukiã¨Hosonoã¯ã€æ—¥æœ¬ã®è‹¥ã„女性ã«ãŠã„ã¦ã€HPVワクãƒãƒ³ã¨å ±å‘Šã•ã‚ŒãŸãƒ¯ã‚¯ãƒãƒ³æŽ¥ç¨®å¾Œã®ç—‡çŠ¶ã¨ã®é–“ã«é–¢é€£æ€§ã‚’見ã„ã ã›ãªã‹ã£ãŸã€‚調査ツールã¯ã€åŒ¿åã®éƒµä¾¿ã‚¢ãƒ³ã‚±ãƒ¼ãƒˆã§ã‚る。 　明らã‹ãªã‚ˆã†ã«ã€ç–«å­¦ã¯åˆ†å­ç”Ÿç‰©å­¦ã¨ã¯ç•°ãªã‚‹èª¿æŸ»æ‰‹æ®µã‚’用ã„る。HPV ワクãƒãƒ³ã®æœ‰å®³äº‹è±¡ã®å ´åˆã€åˆ†å­ç”Ÿç‰©å­¦ã¯ç–«å­¦ã§ã¯æ¤œå‡ºã§ããªã„ã“ã¨ã‚’明らã‹ã«ã™ã‚‹ã€‚Ã_blockquote> <h4><span style="color:lightgrey;">â– </span>リウマãƒå­¦</h4> <span style="color:cornflowerblue;">â—†Ã_span>Hineno, A e4�al.　2019　"<b><u>Autoantibodies against autonomic nerve receptors in adolescent Japanese girls after immunization with human papillomavirus vaccineÃ_u>Ã_b>",　<i>Ann Arthritis Clin RheumatolÃ_i>ã€�N(�(g)�°014　<a href="http:å]www.remedypublications.com/annals-of-arthritis-and-clinical-rheumatology-abstract.php?aid=¬47">[外部サイト]</a> ※HTMLã‹ã‚‰å¼•ç”¨ã®ãŸã‚ページ数記載ãªã— <blockquote>The exact pathogenesis of various symptoms after HPV vaccination remains unclear and therefore, affected individuals are diagnosed to have psychiatric illness. The symptoms developed after HPV vaccination cannot be clearl9�categorized into anytraditional well-defined conditions. This migh4�be because tha4�a vulnerable subse4�of the population is a4�a risk of developing postHPV vaccination symptoms. To clarif9�the associated molecular backgrounds, a wide range of approaches are required. The present preliminary study provides that some of the symptoms after HPV vaccination can be attributed to the abnormal autoimmune response after HPV vaccination. Therefore, immune modulator9�therapies, which remove these pathologic autoantibodies an(uor suppress their production in serum, can be used for the patients with post-HPV vaccination symptoms. 以下機械翻訳（DeepL）： HPVワクãƒãƒ³æŽ¥ç¨®å¾Œã«ç”Ÿã˜ã‚‹æ§˜ã€…ãªç—‡çŠ¶ã®æ­£ç¢ºãªåŽŸå› ã¯ä¸æ˜Žã§ã‚ã‚Šã€ãã®ãŸã‚罹患者ã¯ç²¾ç¥žç–¾æ‚£ã¨è¨ºæ–­ã•ã‚Œã¦ã„る。HPVワクãƒãƒ³æŽ¥ç¨®å¾Œã«ç™ºç—‡ã™ã‚‹ç—‡çŠ¶ã¯ã€å¾“æ¥ã®å®šç¾©ã•ã‚ŒãŸç—…æ…‹ã«æ˜Žç¢ºã«åˆ†é¡žã™ã‚‹ã“ã¨ã¯ã§ããªã„。ã“ã‚Œã¯ã€HPV ワクãƒãƒ³æŽ¥ç¨®å¾Œã®ç—‡çŠ¶ã‚’発症ã™ã‚‹ãƒªã‚¹ã‚¯ãŒã‚る脆弱ãªé›†å›£ãŒå­˜åœ¨ã™ã‚‹ãŸã‚ã¨è€ƒãˆã‚‰ã‚Œã‚‹ã€‚ã“ã®ã‚ˆã†ãªåˆ†å­çš„背景を明らã‹ã«ã™ã‚‹ãŸã‚ã«ã¯ã€æ§˜ã€…ãªã‚¢ãƒ—ローãƒãŒå¿…è¦ã§ã‚る。今回ã®äºˆå‚™çš„研究ã«ã‚ˆã‚Šã€HPVワクãƒãƒ³æŽ¥ç¨®å¾Œã®ç—‡çŠ¶ã®ä¸€éƒ¨ã¯ã€HPVワクãƒãƒ³æŽ¥ç¨®å¾Œã®è‡ªå·±å…ç–«åå¿œã®ç•°å¸¸ã«èµ·å› ã—ã¦ã„ã‚‹å¯èƒ½æ€§ãŒã‚ã‚‹ã“ã¨ãŒç¤ºã•ã‚ŒãŸã€‚ã—ãŸãŒã£ã¦ï¼ŒHPV ワクãƒãƒ³æŽ¥ç¨®å¾Œã®ç—‡çŠ¶ã‚’有ã™ã‚‹æ‚£è€…ã«å¯¾ã—ã¦ã¯ï¼Œã“れらã®ç—…的自己抗体ã®é™¤åŽ»ã‚„血清中ã®ç”£ç”Ÿã‚’抑制ã™ã‚‹å…疫調節療法ãŒæœ‰åŠ¹ã§ã‚る．Ã_blockquote> <h4><span style="color:lightgrey;">â– </span>リウマãƒå­¦</h4> <span style="color:cornflowerblue;">â—†Ã_span>Manuel, MART?NEZ-LAV?N・Luis, AMEZCUA-GUERRA.　2017　"<b><u>Serious adverse events after HPV vaccination: a critical revie7�of randomized trials and post-marketing case series.Ã_u>Ã_b>",　<i>Clinical rheumatology</i>　36-10:69(�(g)�178．　<a href="https:å]link.springer.coÛwarticl0u10.100 _ 0067-017Ð0ü0ì0ë0768-5">[外部サイト]Ã_a> MART?NEZ-LAV?N, Manuel<�s�p�a�n� �c�l�a�s�s�=�"�n�a�k�e�d�_�s�i�g�n�"�>�; <�/�s�p�a�n�>�<�s�p�a�n� �c�l�a�s�s�=�"�n�a�k�e�d�_�a�u�r�a�l�"�>�(�èlŠ)�<�/�s�p�a�n�>�AMEZCUA-GUERRA, Luis. Serious adverse events after HPV vaccination: a critical revie7�of randomized trials and post-marketing case series. Clinical rheumatology, 2017, 36.10:(��N)�169-78. <h4><span style="color:lightgrey;">â– </span>è…«ç˜å­¦ãƒ»ãŒã‚“研究Ã_h4> Hu, Shang-Ying, e4�al. "Performance of cervical screening a decade following HPV vaccination: The Costa Rica Vaccine Trial." Journal Of The National Cancer Institute 114.9 (20(� g)�): 1253-(�*h)�­. <span style="color:cornflowerblue;">â—†Ã_span>Shang-Ying, H5�et al.ã€�N(�åe)�2　"<b><u>Performance of cervical screening a decade following HPV vaccination: The Costa Rica Vaccine Trial.Ã_u>Ã_b>",　<i>Journal Of The National Cancer InstituteÃ_i>ã€G14-9°253-(�*h)�­.　<a href="httpsa_/academic.oup.coÛwjnci/article/114/9/125z^6596052?login=false">[外部サイト]Ã_a> ※HTMLã‹ã‚‰å¼•ç”¨ã®ãŸã‚ページ数記載ãªã— <blockquote>Abstract � <b>BackgroundÃ_b> We investigated the impac4�of human papillomavirus (HPV) vaccination on the performance of cytology-based and HPV-based screening for detection of cervical precancer among women vaccinated as young adults and reaching screening age. <b>Methods</b> A total of 4Ø0¯0¿0ü0ë02 women aged(��N)�5-36?years from the Costa Rica HPV Vaccine Trial were included (2418 HPV-vaccinated as young adults and (� g)�14 unvaccinated). We assessed the performance of cytology- and HPV-based cervical screening modalities in vaccinated and unvaccinated women to detec4�high-grade cervical precancers diagnosed over 2 2 2 years and the absolute risk of cumulative cervical precancers by screening results a4�entry. <b>ResultsÃ_b> We detected 95 cervical intraepithelial neoplasia gradeµ0ó0Á0ü0à0 or worse (52 in unvaccinated and Ö0Ã0·0§0ë0 in vaccinated women). HPV16/1_ªÔ0¯0ë0z^45 was predominant (69%) among unvaccinated participants, and HPì0ó0È0²0ó0ô^(�yr)�/5_39/5þ]56/5P_66/68 predominated (65%) among vaccinated participants. Sensitivit9�and specificit9�of cervical screening approaches were comparable between women vaccinated as young adults and unvaccinated women. Colposcopy referral rates were lower in the vaccinated group for HPV-based screening modalities, but the positive predictive value was comparable between the 2 groups. <b>Conclusions</b> Among women approaching screening ages, vaccinated as young adults, and with a history of intensive screening, the expected reduction in the positive predictive value of HPV testing, associated with dropping prevalence of HPV-associated lesions, was no4�observed. This is likely due to the presence of high-grade lesions associated with nonvaccine HPV types, which may be less likel9�to progress to cancer. 以下機械翻訳（DeepL）： アブストラクト 背景 若年æˆäººæ™‚ã«ãƒ¯ã‚¯ãƒãƒ³æŽ¥ç¨®ã‚’å—ã‘ã€æ¤œè¨ºå¹´é½¢ã«é”ã—ãŸå¥³æ€§ã«ãŠã„ã¦ã€ãƒ’トパピローマウイルス（HPV）ワクãƒãƒ³æŽ¥ç¨®ãŒã€ç´°èƒžè¨ºã«ã‚ˆã‚‹æ¤œè¨ºã¨HPVã«ã‚ˆã‚‹æ¤œè¨ºã®å­å®®é ¸éƒ¨å‰ç™Œæ¤œå‡ºã®æˆç¸¾ã«ä¸Žãˆã‚‹å½±éŸ¿ã‚’検討ã—ãŸã€‚ 調査方法 コスタリカHPVワクãƒãƒ³è©¦é¨“ã‹ã‚AS5～36æ­³ã®å¥³æ€§è¨ˆ4Ø0¯0¿0ü0ë02人（若年期ã«HPVワクãƒãƒ³ã‚’接種ã—ãèl8人ã€æœªæŽ¥ç¨®(� g)�14人）を対象ã¨ã—ãŸã€‚ワクãƒãƒ³æŽ¥ç¨®å¥³æ€§ã¨ãƒ¯ã‚¯ãƒãƒ³æœªæŽ¥ç¨®å¥³æ€§ã‚’対象ã«ã€ç´°èƒžè¨ºãŠã‚ˆã³HPVを用ã„ãŸå­å®®é ¸éƒ¨ã‚¹ã‚¯ãƒªãƒ¼ãƒ‹ãƒ³ã‚°æ³•ã«ã¤ã„ã¦ã€4å¹´é–“ã§è¨ºæ–­ã•ã‚ŒãŸé«˜æ‚ªæ€§åº¦å­å®®é ¸éƒ¨å‰ç™Œã®æ¤œå‡ºæ€§èƒ½ã¨ã€ã‚¨ãƒ³ãƒˆãƒªãƒ¼æ™‚ã®ã‚¹ã‚¯ãƒªãƒ¼ãƒ‹ãƒ³ã‚°çµæžœã«ã‚ˆã‚‹ç´¯ç©å­å®®é ¸éƒ¨å‰ç™Œã®çµ¶å¯¾ãƒªã‚¹ã‚¯ã‚’評価ã—ã¾ã—ãŸã€‚ çµæžœ グレード3以上ã®å­å®®é ¸éƒ¨ä¸Šçš®å†…新生物を95人（ワクãƒãƒ³æœªæŽ¥ç¨®è€…52人ã€ãƒ¯ã‚¯ãƒãƒ³æŽ¥ç¨®è€…Ö0Ã0·0§0ë0人）検出ã—ã¾ã—ãŸã€‚ワクãƒãƒ³æŽ¥ç¨®è€…ã§ã¯HPhþ^18Ô0¯0ë0þ]Õ0£0ü0È0/45ãŒå„ªå‹¢ï¼ˆ69％）ã§ã€ãƒ¯ã‚¯ãƒãƒ³æŽ¥ç¨®è€…ã§ã¯HPì0ó0È0²0ó0ô^(�yr)�/5_39/5þ]56/5P_66/68ãŒå„ªå‹¢ï¼ˆ65％）ã ã£ãŸã€‚å­å®®é ¸éƒ¨ã‚¹ã‚¯ãƒªãƒ¼ãƒ‹ãƒ³ã‚°ã‚¢ãƒ—ローãƒã®æ„Ÿåº¦ãŠã‚ˆã³ç‰¹ç•°æ€§ã¯ã€è‹¥å¹´æˆäººæ™‚ã«ãƒ¯ã‚¯ãƒãƒ³æŽ¥ç¨®ã‚’å—ã‘ãŸå¥³æ€§ã¨ãƒ¯ã‚¯ãƒãƒ³æŽ¥ç¨®ã‚’å—ã‘ã¦ã„ãªã„女性ã§åŒç­‰ã§ã‚ã£ãŸã€‚HPVベースã®ã‚¹ã‚¯ãƒªãƒ¼ãƒ‹ãƒ³ã‚°æ³•ã§ã¯ã€ã‚³ãƒ«ãƒã‚¹ã‚³ãƒ”ー紹介率ã¯ãƒ¯ã‚¯ãƒãƒ³æŽ¥ç¨®ç¾¤ã§ä½Žã‹ã£ãŸãŒã€é™½æ€§çš„中率ãTS群間ã§åŒç¨‹åº¦ã§ã‚ã£ãŸã€‚ çµè«– スクリーニング年齢ã«è¿‘ã¥ã„ãŸå¥³æ€§ã€è‹¥å¹´æœŸã«ãƒ¯ã‚¯ãƒãƒ³æŽ¥ç¨®ã‚’å—ã‘ãŸå¥³æ€§ã€é›†ä¸­çš„ãªã‚¹ã‚¯ãƒªãƒ¼ãƒ‹ãƒ³ã‚°ã‚’å—ã‘ãŸçµŒé¨“ã®ã‚る女性ã§ã¯ã€HPV関連病変ã®æœ‰ç—…率ã®ä½Žä¸‹ã«ä¼´ã†HPV検査ã®é™½æ€§é©ä¸­çŽ‡ã®ä½Žä¸‹ãŒæœŸå¾…ã•ã‚ŒãŸãŒã€è¦³å¯Ÿã•ã‚Œãªã‹ã£ãŸã€‚ã“ã‚Œã¯ã€ãŒã‚“ã«é€²è¡Œã—ã«ãã„ã¨è€ƒãˆã‚‰ã‚Œã¦ã„ã‚‹éžãƒ¯ã‚¯ãƒãƒ³HPVåž‹ã«é–¢é€£ã™ã‚‹é«˜æ‚ªæ€§åº¦ç—…変ãŒå­˜åœ¨ã™ã‚‹ãŸã‚ã¨è€ƒãˆã‚‰ã‚Œã‚‹ã€‚Ã_blockquote> <span style="color:cornflowerblue;">â—†Ã_span>Wen-Qiang, HE・Chenxi, LI　20　"<b><u>Recent global burden of cervical cancer incidence and mortality, predictors, and temporal trendsÃ_u>Ã_b>",　<i>Gynecologic OncologyÃ_i>ã€GØ0¯0¿0ü0ë0Ð0ü0ì0ë0:5Ú0Ë0Ò0-5(�ãN)�.　<a href="httpsa_/www.sciencedirect.com/science/article/pii/S00DS(�´R)�5801¬95?casa_token=SLCBVNqgubEAAAAA:J5SzAt4N9lbT63co0RC¬ÀpkjRd0iU1OhQNQv9szIm5GRTci1qiJCM7ecO7ESxdJHrN8XXnQHOl">[外部サイト]Ã_a> ※HTMLã‹ã‚‰å¼•ç”¨ã®ãŸã‚ページ数記載ãªã— <blockquote>Nevertheless, onlyµ0ó0Á0ü0à00 countries have started universal HPV vaccination among teenagers from 2006 to 2010, although 81 countries have implemented HPV vaccination u0�to(��N)�018. Given the average age a4�diagnosis of cervical cancer a4�Õ0é0ó0 years, the impact of HPV vaccination among general population will no4�be observed until at least another(��N)�0 years. 以下機械翻訳（DeepL）： ã—ã‹ã—ãªãŒã‚‰ã€2006å¹´ã‹ã‚AS010å¹´ã«ã‹ã‘ã¦ã€L0代ã¸ã®HPVワクãƒãƒ³æŽ¥ç¨®ã‚’開始ã—ãŸå›½ã¯30カ国ã«éŽãŽãšã€ŒN018å¹´ã¾ã§ã«81カ国ã§HPVワクãƒãƒ³æŽ¥ç¨®ãŒå®Ÿæ–½ã•ã‚Œã¦ã„る。å­å®®é ¸ãŒã‚“ã®å¹³å‡è¨ºæ–­å¹´é½¢ãŒ53æ­³ã§ã‚ã‚‹ã“ã¨ã‚’考ãˆã‚‹ã¨ã€ä¸€èˆ¬ä½æ°‘ã¸ã®HPVワクãƒãƒ³æŽ¥ç¨®ã®å½±éŸ¿ãŒç¾ã‚Œã‚‹ã®ã¯å°‘ãªãã¨ã‚‚ã‚ã¨20年後ã§ã‚ã‚‹ã¨è€ƒãˆã‚‰ã‚Œã‚‹ã€‚Ã_blockquote> <blockquote>Of fe7�countries with consisten4�increase of incidence and mortalit9�(Japan and Italy) or where onl9�incidence (China and Uganda) or mortalit9�data (Russia) were available, the increasing trend might be associated with lo7�screening uptakes, high prevalence of HPV, and increased smoking. 以下機械翻訳（DeepL）： 発生率ã¨æ­»äº¡çŽ‡ãŒä¸€è²«ã—ã¦å¢—加ã—ã¦ã„る国（日本ã€ã‚¤ã‚¿ãƒªã‚¢ï¼‰ã€ã¾ãŸã¯ç™ºç”ŸçŽ‡ï¼ˆä¸­å›½ã€ã‚¦ã‚¬ãƒ³ãƒ€ï¼‰ã‹æ­»äº¡çŽ‡ï¼ˆãƒ­ã‚·ã‚¢ï¼‰ã—ã‹ãƒ‡ãƒ¼ã‚¿ãŒãªã„国ã§ã¯ã€å¢—加傾å‘ã¯æ¤œè¨ºå—診率ã®ä½Žã•ã€HPVã®é«˜ã„有病率ã€å–«ç…™çŽ‡ã®å¢—加ã¨é–¢é€£ã—ã¦ã„ã‚‹å¯èƒ½æ€§ãŒã‚る。</blockquote> <blockquote>In our study, contrasting patterns of decreasing mortality and increasing incidence were found from Belarus, Estonia, Finland, Netherland, Sweden, and United Kingdom in the mos4�recent five years. The reduction of mortalit9�ma9�be related to increasing awareness, earl9�detection, and treatment of the cervical cancer in these countries, resulting in better oncological control. In contrast, the increasing incidence might be explained by the inadequate uptake and insufficien4�qualit9�of the cancer screening program as reported in Estonia, Belarus, or less intensive screening in more recen4�years in Netherlands. 以下機械翻訳（DeepL）： 我々ã®ç ”究ã§ã¯ã€æœ€è¿‘ã®5å¹´é–“ã§ã€ãƒ™ãƒ©ãƒ«ãƒ¼ã‚·ã€ã‚¨ã‚¹ãƒˆãƒ‹ã‚¢ã€ãƒ•ã‚£ãƒ³ãƒ©ãƒ³ãƒ‰ã€ã‚ªãƒ©ãƒ³ãƒ€ã€ã‚¹ã‚¦ã‚§ãƒ¼ãƒ‡ãƒ³ã€ã‚¤ã‚®ãƒªã‚¹ã‹ã‚‰ã€æ­»äº¡çŽ‡ã®æ¸›å°‘ã¨ç™ºç”ŸçŽ‡ã®å¢—加ã¨ã„ã†å¯¾ç…§çš„ãªãƒ‘ターンãŒè¦‹ã„ã ã•ã‚ŒãŸã€‚死亡率ã®æ¸›å°‘ã¯ã€ã“れらã®å›½ã€…ã§å­å®®é ¸ç™Œã«å¯¾ã™ã‚‹èªè­˜ã€æ—©æœŸç™ºè¦‹ã€æ²»ç™‚ãŒé€²ã¿ã€è…«ç˜å­¦çš„コントロールãŒå‘上ã—ãŸã“ã¨ã¨é–¢ä¿‚ãŒã‚ã‚‹ã¨æ€ã‚れる。一方ã€ç½¹æ‚£çŽ‡ã®å¢—加ã¯ã€ã‚¨ã‚¹ãƒˆãƒ‹ã‚¢ã€ãƒ™ãƒ©ãƒ«ãƒ¼ã‚·ã§å ±å‘Šã•ã‚ŒãŸã‚ˆã†ã«ã€ãŒã‚“検診プログラムã®ä¸å分ãªæ™®åŠã¨è³ªã®ä½Žã•ã€ã‚ã‚‹ã„ã¯ã‚ªãƒ©ãƒ³ãƒ€ã§ã¯è¿‘å¹´ã€æ¤œè¨ºãŒã‚ã¾ã‚Šå¼·åŒ–ã•ã‚Œã¦ã„ãªã„ã“ã¨ãŒåŽŸå› ã§ã‚ã‚‹å¯èƒ½æ€§ãŒã‚る。Ã_blockquote> <blockquote>Of importance, increase of incidence rate was onl9�found among younger women from Australia, Belarus, Denmark, Iceland, Netherlands, Norway, Sweden, United Kingdom, and Turkey, which was consistent with previous reports. These migh4�be associated with rises in the prevalence of high risk HPV infection following the changing aspects of sexual behavior, including earlier age a4�firs4�sexual intercourse and multiple partners in their lifetime. More importantly, a willful lack of screening was reported b9�the Finnish Mass Screening Registr9�that less than 60% of women younger than 40 years of age accepted the invitation to be screened in(��N)�002 2 and only(��N)�0% of the women 25Û0ó00 years of age participated in the screening programme. Similarl9�cervical screening coverage is falling a4�higher degree year on year among younger women than that among older women in Australia, England, Denmark and Sweden. 以下機械翻訳（DeepL）： 特ã«ã€ã‚ªãƒ¼ã‚¹ãƒˆãƒ©ãƒªã‚¢ã€ãƒ™ãƒ©ãƒ«ãƒ¼ã‚·ã€ãƒ‡ãƒ³ãƒžãƒ¼ã‚¯ã€ã‚¢ã‚¤ã‚¹ãƒ©ãƒ³ãƒ‰ã€ã‚ªãƒ©ãƒ³ãƒ€ã€ãƒŽãƒ«ã‚¦ã‚§ãƒ¼ã€ã‚¹ã‚¦ã‚§ãƒ¼ãƒ‡ãƒ³ã€è‹±å›½ã€ãƒˆãƒ«ã‚³ã®è‹¥å¹´å¥³æ€§ã«ãŠã„ã¦ã®ã¿ç½¹æ‚£çŽ‡ã®ä¸Šæ˜‡ãŒèªã‚られã€ã“ã‚Œã¯éŽåŽ»ã®å ±å‘Šã¨ä¸€è‡´ã—ã¦ã„ãŸã€‚ã“れらã¯ã€åˆå›žæ€§äº¤å¹´é½¢ã®æ—©æœŸåŒ–や生涯ã®è¤‡æ•°å›žã®ãƒ‘ートナーãªã©ã€æ€§è¡Œå‹•ã®å¤‰åŒ–ã«ä¼´ã†ãƒã‚¤ãƒªã‚¹ã‚¯HPV感染率ã®ä¸Šæ˜‡ã¨é–¢é€£ã—ã¦ã„ã‚‹å¯èƒ½æ€§ãŒã‚る。よりé‡è¦ãªã“ã¨ã¯ã€ãƒ•ã‚£ãƒ³ãƒ©ãƒ³ãƒ‰ã®é›†å›£æ¤œè¨ºç™»éŒ²ã«ã‚ˆã£ã¦ã€20Ô0³0å¹´ã«æ¤œè¨ºã®æ¡ˆå†…ã‚’å—ã‘ãŸ40歳未満ã®å¥³æ€§ã¯0％未満ã§ã‚り「N5?30æ­³ã®å¥³æ€§ã®ã†ã¡æ¤œè¨ºãƒ—ログラムã«å‚加ã—ãŸã®ãTS0ï¼…ã«éŽãŽãªã‹ã£ãŸã¨ã„ã†ã€æ¤œè¨ºã®æ•…æ„ã®æ¬ å¦‚ãŒå ±å‘Šã•ã‚Œã¦ã„ã‚‹ã“ã¨ã§ã‚る。åŒæ§˜ã«ã€ã‚ªãƒ¼ã‚¹ãƒˆãƒ©ãƒªã‚¢ã€ã‚¤ã‚®ãƒªã‚¹ã€ãƒ‡ãƒ³ãƒžãƒ¼ã‚¯ã€ã‚¹ã‚¦ã‚§ãƒ¼ãƒ‡ãƒ³ã§ã¯ã€è‹¥ã„女性ã®å­å®®é ¸éƒ¨æ¤œè¨ºã®å—診率ãŒã€é«˜é½¢ã®å¥³æ€§ã‚ˆã‚Šã‚‚年々高ã„割åˆã§ä½Žä¸‹ã—ã¦ã„る。Ã_blockquote> <span style="color:cornflowerblue;">â—†Ã_span>Jiangrong, WANG e4�al.　2020　"<b><u>Cervical cancer case?control audit: Results from routine evaluation of a nationwide cervical screening programÃ_u>Ã_b>",　<i>International journal of cancer</i>　146-5:(�*h)�30-1240.　<a href="https:å]onlinelibrary.wiley.coÛwdo}vfull/10.10(�åe)�/ijcÔ0¢0¹0È0ë02416">[外部サイト]</a> ※HTMLã‹ã‚‰å¼•ç”¨ã®ãŸã‚ページ数記載ãªã— <blockquote>Cervical cancer has been acknowledged as the firs4�cancer tha4�can be effectively prevented, for which the implementation of cervical screening is meritorious in the pas4�half-century. Established evidence shows a strong preventive effec4�from cervical screening, through detecting, managing and treating precursor lesions. An organized, population-based cervical screening program, as recommended b9�the International Agency for Research on Cancer, achieving high coverage and equality, can contribute to a substantial reduction in cervical cancer incidence and mortality. 以下機械翻訳（DeepL）： � å­å®®é ¸ãŒã‚“ã¯ã€åŠ¹æžœçš„ã«äºˆé˜²ã§ãる最åˆã®ãŒã‚“ã¨ã—ã¦èªè­˜ã•ã‚Œã¦ãŠã‚Šã€éŽåŽ»åŠä¸–ç´€ã«ãŠã‘ã‚‹å­å®®é ¸éƒ¨æ¤œè¨ºã®å®Ÿæ–½ã¯ç§°è³›ã«å€¤ã™ã‚‹ã‚‚ã®ã§ã‚る。確立ã•ã‚ŒãŸè¨¼æ‹ ã¯ã€å‰é§†ç—…変ã®ç™ºè¦‹ã€ç®¡ç†ã€æ²»ç™‚を通ã˜ã¦ã€å­å®®é ¸éƒ¨ã‚¹ã‚¯ãƒªãƒ¼ãƒ‹ãƒ³ã‚°ã«ã‚ˆã‚‹å¼·åŠ›ãªäºˆé˜²åŠ¹æžœã‚’示ã—ã¦ã„る。国際ãŒã‚“研究機関ãŒæŽ¨å¥¨ã™ã‚‹ã€çµ„織化ã•ã‚ŒãŸä½æ°‘ベースã®å­å®®é ¸éƒ¨æ¤œè¨ºãƒ—ログラムã¯ã€é«˜ã„æ™®åŠçŽ‡ã¨å¹³ç­‰æ€§ã‚’é”æˆã—ã€å­å®®é ¸ãŒã‚“ã®ç™ºç”ŸçŽ‡ã¨æ­»äº¡çŽ‡ã®å¤§å¹…ãªæ¸›å°‘ã«è²¢çŒ®ã™ã‚‹ã“ã¨ãŒã§ãる。</blockquote> <span style="color:cornflowerblue;">â—†</span>Diane M, HARPER・Leslie R, DEMARSã€�N017　"<b><u>HPV vaccines?a review of the firs4�decadeÃ_u>Ã_b>",　<i>Gynecologic oncologyÃ_i>ã€G46-1: 196-204.　<a href="https:å]www.sciencedirect.coÛwscienc0uarticl0upi}vS0090825Ú0½007746">[外部サイト]Ã_a> <blockquote>Pertinen4�to the reduction in cervical cancer incidence is quality of the screening programs available in the high income and upper middle income countries. Without continued participation in these screening programs, the incidence of cervical cancer will increase . Early studies repor4�on the effec4�of HPV vaccination campaigns on continued uptake in the cervical cancer screening programs. � 以下機械翻訳（DeepL）： å­å®®é ¸ãŒã‚“罹患率ã®ä½Žä¸‹ã«ã¯ã€é«˜æ‰€å¾—国ãŠã‚ˆã³é«˜ä¸­æ‰€å¾—国ã§å®Ÿæ–½ã•ã‚Œã¦ã„る検診プログラムã®è³ªãŒé–¢ä¿‚ã—ã¦ã„る。ã“れらã®æ¤œè¨ºãƒ—ログラムã¸ã®ç¶™ç¶šçš„ãªå‚加ãŒãªã‘ã‚Œã°ã€å­å®®é ¸ãŒã‚“ã®ç™ºç”ŸçŽ‡ã¯ä¸Šæ˜‡ã™ã‚‹ã€‚åˆæœŸã®ç ”究ã§ã¯ã€HPVワクãƒãƒ³æŽ¥ç¨®ã‚­ãƒ£ãƒ³ãƒšãƒ¼ãƒ³ãŒå­å®®é ¸ãŒã‚“検診プログラムã®ç¶™ç¶šçš„ãªå—診ã«ä¸Žãˆã‚‹å½±éŸ¿ã«ã¤ã„ã¦å ±å‘Šã•ã‚Œã¦ã„る。Ã_blockquote> � <blockquote>In the US, a stud9�of high risk, lo7�income women showed that those who received, a4�an9�age, one dose of HPV vaccine were most likel9�to participate in screening at(��N)�1 years or older, significantl9�more than those receiving two, three or no doses . Mos4�often the women participated in an initial screening within 15 days of their vaccination. Long term, though, continued screening compliance occurred significantly more often among those receiving three doses of vaccine<�s�p�a�n� �c�l�a�s�s�=�"�n�a�k�e�d�_�s�i�g�n�"�>�; <�/�s�p�a�n�>�<�s�p�a�n� �c�l�a�s�s�=�"�n�a�k�e�d�_�a�u�r�a�l�"�>�(�èlŠ)�<�/�s�p�a�n�>�these highly compliant women were significantl9�more likel9�to participate in ever9�2 2 year screening over 5 5 5 years than those receiving fewer than three or no doses. Nevertheless, participation in screening was dependen4�on the age a4�which women received vaccination. Women who were fully three dose vaccinated a4�or older than  years had a significantly higher initial screening rate than women full9�three dose vaccinated younger than(��N)�1 years: 84% vs 24%. � 以下機械翻訳（DeepL）： 米国ã§ã¯ã€é«˜ãƒªã‚¹ã‚¯ã€ä½Žæ‰€å¾—ã®å¥³æ€§ã‚’対象ã¨ã—ãŸç ”究ã§ã€å¹´é½¢ã«é–¢ä¿‚ãªãHPVワクãƒãƒ³ã‚�N回接種ã—ãŸäººã¯ã€2回ã€n�A�回ã€ã¾ãŸã¯å…¨ã接種ã—ãªã‹ã£ãŸäººã‚ˆã‚Šã‚‚「N1歳以上ã§æ¤œè¨ºã«å‚加ã™ã‚‹å¯èƒ½æ€§ãŒæœ€ã‚‚高ã„ã“ã¨ãŒç¤ºã•ã‚ŒãŸ 。ã»ã¨ã‚“ã©ã®å ´åˆã€å¥³æ€§ã¯ãƒ¯ã‚¯ãƒãƒ³æŽ¥ç¨®å¾”5日以内ã«æœ€åˆã®ã‚¹ã‚¯ãƒªãƒ¼ãƒ‹ãƒ³ã‚°ã«å‚加ã—ãŸã€‚ã—ã‹ã—ã€é•·æœŸçš„ã«ã¯ã€n�A�回ã®ãƒ¯ã‚¯ãƒãƒ³æŽ¥ç¨®ã‚’å—ã‘ãŸå¥³æ€§ã§ã¯ã€æ¤œè¨ºã®ç¶™ç¶šçš„ãªéµå®ˆãŒæœ‰æ„ã«å¤šã‹ã£ãŸã€‚ã“れらã®é«˜ã„éµå®ˆçŽ‡ã®å¥³æ€§ã¯ã€n�A�回未満ã¾ãŸã¯å…¨ã接種をå—ã‘ã¦ã„ãªã„女性よりもã€7å¹´é–“ã«ã‚ãŸã£ãk�m�3�å¹´ã”ã¨ã®æ¤œè¨ºã«å‚加ã™ã‚‹ç¢ºçŽ‡ãŒæœ‰æ„ã«é«˜ã‹ã£ãŸã€‚ãã‚Œã§ã‚‚ã€ã‚¹ã‚¯ãƒªãƒ¼ãƒ‹ãƒ³ã‚°ã¸ã®å‚加ã¯ã€å¥³æ€§ãŒãƒ¯ã‚¯ãƒãƒ³æŽ¥ç¨®ã‚’å—ã‘ãŸå¹´é½¢ã«ä¾å­˜ã—ã¦ã„ãŸã€ N1歳以上ãm�"s�回接種を完全ã«å—ã‘ãŸå¥³æ€§ã¯ã€歳未満ã§3回接種を完全ã«å—ã‘ãŸå¥³æ€§ã‚ˆã‚Šã‚‚åˆå›žæ¤œè¨ºçŽ‡ãŒæœ‰æ„ã«é«˜ã‹ã£ãŸã€‚84％対24ï¼…ã§ã‚ã£ãŸã€‚Ã_blockquote> � <blockquote>In Australia, the reverse happened. […] Their participation in cervical cancer screening was significantl9�lower among vaccinated women in both the(��N)�0?24 and(��N)�5?29 year old age groups compared to same aged unvaccinated women. In addition, among women 30Û0ó02 2 2 years old who electively received HPV vaccination, onl9�28.�.�participated in screening, whereas 61% of unvaccinatedµ0ó0Á0ü0à00?34 year olds participated in screening. � 以下機械翻訳（DeepL）： オーストラリアã§ã¯ã€ãã®é€†ãŒèµ·ã“ã£ãŸã€2�[…] å­å®®é ¸ãŒã‚“検診ã¸ã®å‚加率ã¯ã€20(�(g)�4歳「N5-29æ­³ã®ä¸¡å¹´é½¢å±¤ã§ã€ãƒ¯ã‚¯ãƒãƒ³æœªæŽ¥ç¨®ã®åŒå¹´é½¢å¥³æ€§ã¨æ¯”較ã—ã¦ã€ãƒ¯ã‚¯ãƒãƒ³æŽ¥ç¨®å¥³æ€§ã§ã¯è‘—ã—ã低ã„。ã¾ãŸã€HPVワクãƒãƒ³æŽ¥ç¨®ã‚’é¸æŠžçš„ã«å—ã‘ãm�m�2�0-34æ­³ã®å¥³æ€§ã§ã¯ã€æ¤œè¨ºã¸ã®å‚加ã¯28ï¼…ã«ã¨ã©ã¾ã£ãŸãŒã€ãƒ¯ã‚¯ãƒãƒ³æœªæŽ¥ç¨®ãr�a�d�"s�0-34æ­³ã®å¥³æ€§ã§ã¯­ï¼…ãŒæ¤œè¨ºã«å‚加ã—ãŸã€‚Ã_blockquote> � <blockquote>In the United Kingdom, the Scottish Cervical Call and Recall system showed a general downward trend for screening participation b9�women born between 1988 and 19Ø0ë0Ä0. […] The screening rates among the most deprived Scottish women were 44.�.�if the9�were not vaccinated or had one dose, 48% if two doses were received and Õ0é0ó0.�.�if three doses were received. Overall, the uptake of screening after the HPV vaccine introduction regardless of vaccine uptake has been lower than necessary to reduce population incidence of cervical cancer. This should be concerning to public health. � 以下機械翻訳（DeepL）： 英国ã§ã¯ã€ã‚¹ã‚³ãƒƒãƒˆãƒ©ãƒ³ãƒ‰ã®å­å®®é ¸éƒ¨ã‚³ãƒ¼ãƒ«ï¼†ãƒªã‚³ãƒ¼ãƒ«ã‚·ã‚¹ãƒ†ãƒ ã«ã‚ˆã‚Šã€L988å¹´ã‹ã‚‰19Ø0ë0Ä0å¹´ã®é–“ã«ç”Ÿã¾ã‚ŒãŸå¥³æ€§ã®æ¤œè¨ºå‚加率ãŒå…¨èˆ¬çš„ã«ä½Žä¸‹ã™ã‚‹å‚¾å‘ãŒè¦‹ã‚‰ã‚ŒãŸã€2�[…] スコットランドã®æœ€ã‚‚æµã¾ã‚Œãªã„女性ã®æ¤œè¨ºçŽ‡ã¯ã€ãƒ¯ã‚¯ãƒãƒ³æœªæŽ¥ç¨®ã¾ãŸã¯1回接種ã®å ´åˆã¯44％「N回接種ã®å ´åˆã¯48ï¼…ã€n�A�回接種ã®å ´åˆã¯53ï¼…ã§ã‚ã£ãŸã€‚全体ã¨ã—ã¦ã€ãƒ¯ã‚¯ãƒãƒ³ã®æŽ¥ç¨®çŽ‡ã«ã‹ã‹ã‚らãšã€HPVワクãƒãƒ³å°Žå…¥å¾Œã®æ¤œè¨ºã®å—診率ã¯ã€å­å®®é ¸ãŒã‚“ã®é›†å›£ç™ºç”Ÿã‚’減らã™ãŸã‚ã«å¿…è¦ãªå€¤ã‚ˆã‚Šã‚‚低ããªã£ã¦ã„る。ã“ã®ã“ã¨ã¯å…¬è¡†è¡›ç”Ÿã«ã¨ã£ã¦æ‡¸å¿µã™ã¹ãã“ã¨ã§ã‚る。</blockquote> <blockquote>Women in the Swedish population based health register were followed for participation in both screening and opportunistic HPV vaccination offered to those 19 years and older. The cervical cancer screening rates were similar to those seen in the US, a4�86%, in full9�vaccinated women, which is significantly higher than in unvaccinated women (75%). � 以下機械翻訳（DeepL）： 英国ã§ã¯ã€ã‚¹ã‚³ãƒƒãƒˆãƒ©ãƒ³ãƒ‰ã®å­å®®é ¸éƒ¨ã‚³ãƒ¼ãƒ«ï¼†ãƒªã‚³ãƒ¼ãƒ«ã‚·ã‚¹ãƒ†ãƒ ã«ã‚ˆã‚Šã€L988å¹´ã‹ã‚‰19Ø0ë0Ä0å¹´ã®é–“ã«ç”Ÿã¾ã‚ŒãŸå¥³æ€§ã®æ¤œè¨ºå‚加率ãŒå…¨èˆ¬çš„ã«ä½Žä¸‹ã™ã‚‹å‚¾å‘ãŒè¦‹ã‚‰ã‚ŒãŸã€2�[…] スコットランドã®æœ€ã‚‚æµã¾ã‚Œãªã„女性ã®æ¤œè¨ºçŽ‡ã¯ã€ãƒ¯ã‚¯ãƒãƒ³æœªæŽ¥ç¨®ã¾ãŸã¯1回接種ã®å ´åˆã¯44％「N回接種ã®å ´åˆã¯48ï¼…ã€n�A�回接種ã®å ´åˆã¯53ï¼…ã§ã‚ã£ãŸã€‚全体ã¨ã—ã¦ã€ãƒ¯ã‚¯ãƒãƒ³ã®æŽ¥ç¨®çŽ‡ã«ã‹ã‹ã‚らãšã€HPVワクãƒãƒ³å°Žå…¥å¾Œã®æ¤œè¨ºã®å—診率ã¯ã€å­å®®é ¸ãŒã‚“ã®é›†å›£ç™ºç”Ÿã‚’減らã™ãŸã‚ã«å¿…è¦ãªå€¤ã‚ˆã‚Šã‚‚低ããªã£ã¦ã„る。ã“ã®ã“ã¨ã¯å…¬è¡†è¡›ç”Ÿã«ã¨ã£ã¦æ‡¸å¿µã™ã¹ãã“ã¨ã§ã‚る。</blockquote> <span style="color:cornflowerblue;">â—†Ã_span>Diane M, HARPER e4�al.　2010　"<b><u>Cervical cancer incidence can increase despite HPV vaccination. The Lancet Infectious DiseasesÃ_u>Ã_b>",　<i>Lancet Reg Health West PacÃ_i>ã€G0-9:594-595.　<a href="https:å]www.thelancet.coÛwjournals/lanin‹uarticl0uPIIS14Ú0½03099107018/fulltext">[外部サイト]Ã_a> ※HTMLã‹ã‚‰å¼•ç”¨ã®ãŸã‚ページ数記載ãªã— <blockquote>Previous studies have alread9�shown that a willful cessation of screening in a generation of women who had little contac4�with friends who were developing or dying from invasive cervical cancer has resulted in increases in cervical cancer rates measurable at the population level. Misunderstanding of the benefits of individual HPV vaccination is real. If even more young vaccinated adolescents mature into women who willfully refuse cervical cancer screening, the population rates of cervical cancer will increase. 以下機械翻訳（DeepL）： ã“ã‚Œã¾ã§ã®ç ”究ã§ã€æµ¸æ½¤æ€§å­å®®é ¸ãŒã‚“を発症ã—ãŸã‚Šæ­»äº¡ã—ãŸã‚Šã—ã¦ã„ã‚‹å‹äººã¨ã»ã¨ã‚“ã©æŽ¥è§¦ã™ã‚‹ã“ã¨ã®ãªã‹ã£ãŸä¸–代ã®å¥³æ€§ãŒã€æ•…æ„ã«æ¤œè¨ºã‚’中止ã—ãŸã“ã¨ãŒã€é›†å›£ãƒ¬ãƒ™ãƒ«ã§æ¸¬å®šã§ãã‚‹å­å®®é ¸ãŒã‚“率ã®ä¸Šæ˜‡ã‚’ã‚‚ãŸã‚‰ã—ãŸã“ã¨ãŒæ—¢ã«æ˜Žã‚‰ã‹ã«ãªã£ã¦ã„る。HPVワクãƒãƒ³ã®å€‹äººæŽ¥ç¨®ã®åˆ©ç‚¹ã«å¯¾ã™ã‚‹èª¤è§£ã¯ç¾å®Ÿã®ã‚‚ã®ã¨ãªã£ã¦ã„る。ワクãƒãƒ³æŽ¥ç¨®ã‚’å—ã‘ãŸè‹¥ã„é’å¹´ãŒã•ã‚‰ã«æˆç†Ÿã—ã¦ã€å­å®®é ¸ãŒã‚“検診を故æ„ã«æ‹’å¦ã™ã‚‹å¥³æ€§ã«ãªã‚Œã°ã€å­å®®é ¸ãŒã‚“ã®äººå£æ¯”率ã¯ä¸Šæ˜‡ã™ã‚‹ã ã‚ã†ã€‚Ã_blockquote> <h4><span style="color:lightgrey;">â– </span>ウイルス学</h4> <span style="color:cornflowerblue;">â—†</span>Julia ML, BROTHERTONã€�N019　"<b><u>Impac4�of HPV vaccination: Achievements and future challengesÃ_u>Ã_b>",　<i>Papillomavirus research</i>　7:Ó0ë08.　<a href="https:å]www.ncbi.nlm.nih.gov/pmc/articletzPMC64655.".">[外部サイト]Ã_a> ※HTMLã‹ã‚‰å¼•ç”¨ã®ãŸã‚ページ数記載ãªã— <blockquote>As cervical cancers arising from HPV infection typically take decades to develop, this is the same time horizon in which we should expec4�to confirm vaccine impac4�agains4�cancer. Whilst one follow-up study of vaccine trial participants is suggestive of a lower cervical cancer risk, it has limitations in the questionable comparability of the post-hoc control group used. Women underµ0ó0Á0ü0à00 are at a low absolute risk of cervical cancer so i4�is onl9�in large populations with high effective coverage that a decline is likely to be statistically detectable at this time. US data sugges4�falling cervical cancer rates in young women, bu4�these promising data are somewha4�difficul4�to interpret with recent changes in screening recommendations for young women. In ever9�countr9�where vaccinated women are now in screening age groups, management of ‘vaccine failures’ (i.e. women with cancer or pre-cancer diagnosed despite vaccination) will be importan4�public health and communication challenges. Because the vaccines do no4�cover all HPV types, and because man9�alread9�sexually active women have been vaccinated, these scenarios will be, and are, common. An additional complexity is the move to HPV based screening programs underwa9�in man9�countries, which can be expected to result in a transien4�increase in cervical cancer diagnosis as prevalent cases are found b9�the more sensitive test. 以下機械翻訳（DeepL）： HPV感染ã«èµ·å› ã™ã‚‹å­å®®é ¸ç™Œã®ç™ºç—‡ã«ã¯é€šå¸¸æ•°åå¹´ã‹ã‹ã‚‹ãŸã‚ã€ã“ã‚Œã¯ã€ç™Œã«å¯¾ã™ã‚‹ãƒ¯ã‚¯ãƒãƒ³ã®å½±éŸ¿ã‚’確èªã™ã‚‹ãŸã‚ã«æœŸå¾…ã•ã‚Œã‚‹ã®ã¨åŒã˜æ™‚間軸ã§ã‚る。ワクãƒãƒ³è©¦é¨“å‚加者ã®ã‚るフォローアップ研究ã¯ã€å­å®®é ¸ãŒã‚“リスクã®ä½Žä¸‹ã‚’示唆ã—ã¦ã„ã‚‹ãŒã€ä½¿ç”¨ã—ãŸãƒã‚¹ãƒˆãƒ›ãƒƒã‚¯ã‚³ãƒ³ãƒˆãƒ­ãƒ¼ãƒ«ã‚°ãƒ«ãƒ¼ãƒ—ã®æ¯”較å¯èƒ½æ€§ã«ç–‘å•ãŒã‚ã‚‹ãŸã‚ã€é™ç•ŒãŒã‚る〼A�0歳未満ã®å¥³æ€§ã¯å­å®®é ¸ãŒã‚“ã®çµ¶å¯¾ãƒªã‚¹ã‚¯ãŒä½Žã„ãŸã‚ã€ç¾æ™‚点ã§çµ±è¨ˆçš„ã«æ¤œå‡ºå¯èƒ½ãªæ¸›å°‘ãŒè¦‹ã‚‰ã‚Œã‚‹ã®ã¯ã€æœ‰åŠ¹æŽ¥ç¨®çŽ‡ãŒé«˜ã„大è¦æ¨¡é›†å›£ã«ãŠã„ã¦ã®ã¿ã§ã‚る。米国ã®ãƒ‡ãƒ¼ã‚¿ã¯ã€è‹¥ã„女性ã«ãŠã‘ã‚‹å­å®®é ¸ç™ŒçŽ‡ã®ä½Žä¸‹ã‚’示唆ã—ã¦ã„ã‚‹ãŒã€è‹¥ã„女性ã«å¯¾ã™ã‚‹ã‚¹ã‚¯ãƒªãƒ¼ãƒ‹ãƒ³ã‚°ã®æŽ¨å¥¨ãŒæœ€è¿‘変更ã•ã‚ŒãŸãŸã‚ã€ã“ã®æœ‰æœ›ãªãƒ‡ãƒ¼ã‚¿ã®è§£é‡ˆã¯ã‚„や困難ã§ã‚る。ワクãƒãƒ³æŽ¥ç¨®ã‚’å—ã‘ãŸå¥³æ€§ãŒç¾åœ¨æ¤œè¨ºå¹´é½¢å±¤ã«ã‚ã‚‹ã™ã¹ã¦ã®å›½ã§ã€ã€Œãƒ¯ã‚¯ãƒãƒ³ã®å¤±æ•—ã€ï¼ˆã™ãªã‚ã¡ã€ãƒ¯ã‚¯ãƒãƒ³æŽ¥ç¨®ã«ã‚‚ã‹ã‹ã‚らãšç™Œã¾ãŸã¯å‰ç™Œã¨è¨ºæ–­ã•ã‚ŒãŸå¥³æ€§ï¼‰ã®ç®¡ç†ã¯ã€å…¬è¡†è¡›ç”Ÿã¨ã‚³ãƒŸãƒ¥ãƒ‹ã‚±ãƒ¼ã‚·ãƒ§ãƒ³ã®é‡è¦ãªèª²é¡Œã§ã‚ã‚‹ã ã‚ã†ã€‚ワクãƒãƒ³ã¯ã™ã¹ã¦ã®HPVåž‹ã‚’ã‚«ãƒãƒ¼ã—ã¦ã„ã‚‹ã‚ã‘ã§ã¯ãªã„ã®ã§ã€ã¾ãŸã€ã™ã§ã«æ€§çš„ã«æ´»ç™ºãªå¥³æ€§ã®å¤šããŒãƒ¯ã‚¯ãƒãƒ³ã‚’接種ã—ã¦ã„ã‚‹ã®ã§ã€ã“ã®ã‚ˆã†ãªã‚·ãƒŠãƒªã‚ªã¯ã‚ˆãã‚ã‚‹ã“ã¨ã§ã‚ã‚Šã€ç¾åœ¨ã‚‚ãã†ãªã£ã¦ã„る。ã•ã‚‰ã«è¤‡é›‘ãªã®ã¯ã€å¤šãã®å›½ã§é€²è¡Œä¸­ã®HPVã«åŸºã¥ãスクリーニングプログラムã¸ã®ç§»è¡Œã§ã€ã‚ˆã‚Šæ„Ÿåº¦ã®é«˜ã„検査ã§æœ‰ç—…例ãŒç™ºè¦‹ã•ã‚Œã‚‹ãŸã‚ã€å­å®®é ¸ãŒã‚“ã®è¨ºæ–­ãŒä¸€éŽæ€§ã«å¢—加ã™ã‚‹ã“ã¨ãŒäºˆæƒ³ã•ã‚Œã‚‹ã®ã§ã‚る。Ã_blockquote> <h4><span style="color:lightgrey;">â– </span>ワクãƒãƒ³å­¦</h4> Issanov, Alpamys, et al. "Does Vaccination Protect against Human Papillomavirus-Related Cancers? Preliminary Findings from the United States National Health and Nutrition Examination Surve9�(�]N)�011?2018)." Vaccines 10.(�*h)� (20(� g)�):(��N)��3. <span style="color:cornflowerblue;">â—†</span>Alpamys, Issanov e4�al.　20(� g)�　"<b><u>Does Vaccination Protect against Human Papillomavirus-Related Cancers? Preliminary Findings from the United States National Health and Nutrition Examination Surve9�(�]N)�011?2018)</u></b>",　<i>Vaccines</i>　10-12:Ó0ë0.　<a href="httpsa_/www.mdpi.coÛw2076Ð0ü0ì0ë0Ø0ë0Ä0;r10/1r^Ó0ë0">[外部サイト]</a> ※HTMLã‹ã‚‰å¼•ç”¨ã®ãŸã‚ページ数記載ãªã— <blockquote> Most oropharyngeal and anogenital cancers are caused b9�human papillomavirus (HPV). Although HPV vaccines showed high efficacy against oropharyngeal and anogenital HPV infections, and cancer precursors in randomized clinical trials, there are limited data on the effectiveness of HPV vaccination agains4�HPV-related cancers. 以下機械翻訳（DeepL）： å£è…”咽頭ãŒã‚“や肛門性器ãŒã‚“ã®å¤šãã¯ã€ãƒ’トパピローマウイルス（HPV）ã«èµ·å› ã—ã¦ã„ã¾ã™ã€‚HPVワクãƒãƒ³ã¯ã€ãƒ©ãƒ³ãƒ€ãƒ åŒ–臨床試験ã«ãŠã„ã¦ã€ä¸­å’½é ­ãƒ»æ€§å™¨HPV感染症ã€ãŠã‚ˆã³ãŒã‚“å‰é§†ä½“ã«å¯¾ã—ã¦é«˜ã„有効性を示ã—ãŸãŒã€HPV関連ãŒã‚“ã«å¯¾ã™ã‚‹HPVワクãƒãƒ³æŽ¥ç¨®ã®æœ‰åŠ¹æ€§ã«é–¢ã™ã‚‹ãƒ‡ãƒ¼ã‚¿ã¯é™ã‚‰ã‚Œã¦ã„る。</blockquote> <h4><span style="color:lightgrey;">â– Ã_span>婦人科学</h4> <span style="color:cornflowerblue;">â—†</span>å·å　敬ã€�N(�åe)�2 「HPVワクãƒãƒ³ã®æŽ¥ç¨®ã‚’ã™ã™ã‚ã‚‹ãŸã‚ã«ã€€ãƒ¼ãƒ¼ç”£å©¦äººç§‘医ã®ç«‹å ´ã‹ã‚‰ã€,　『モダンメディアã€68Ð0ü0ì0ë0:90-95.　<a href="httpsa_/jglobal.jst.go.jp/detail?JGLOBAL_ID(�O)�(�åe)�20(� g)�2684(�yr)�205">[外部サイト]Ã_a> <blockquote>　HPVワクãƒãƒ³æŽ¥ç¨®ãŒãƒ•ã‚£ãƒ³ãƒ©ãƒ³ãƒ‰ã§é–‹å§‹ã•ã‚ŒãŸ2007年当時ã«14-19æ­³ã®å‡ºç”Ÿã‚³ãƒ›ãƒ¼ãƒˆã‚’7年間追跡ã—ãŸã¨ã“ã‚ã€HPVã«é–¢é€£ã™ã‚‹å­å®®é ¸ç™Œã€å¤–é™°ç—›ã€é ­ç—›ã®ç™ºç”ŸãŒã€HPVワクãƒãƒ³æŽ¥ç¨®ç¾¤ã§ã¯1例もã„ãªã‹ã£ãŸã€‚éžæŽ¥ç¨®ç¾¤ã§ã¯ä¸€å®šæ•°èªã‚られãŸã€‚スウェーデンã§ã¯ã€2006(�(g)�017å¹´ã®é–“ã«10-30æ­³ã ã£ãŸå¥³æ€§ã®å­å®®é ¸ãŒã‚“ã®ç™ºç”ŸçŽ‡ã‚’検討ã—ãŸã€‚16æ­³ã¾ã§ã«HPVワクãƒãƒ³ã‚’接種ã—ãŸå¥³æ€§ã§ã¯ã€å­å®®é ¸ãŒã‚“ã®ç™ºç”ŸçŽ‡ã¯ã€æœªæŽ¥ç¨®è€…ã®ç™ºç”ŸçŽ‡ã¨æ¯”ã¹ã¦ã€HR-0.(�*h)�000034)ã¨ãªã‚Šç™ºç”Ÿãƒªã‚¹ã‚¯ãŒ88%減少ã—ãŸã€‚ã¾ã¾ãŸã€17Ð0ü0ì0ë00æ­³ã§æŽ¥ç¨®ã—ãŸå¥³æ€§ã«ãŠã„ã¦ã‚‚ã€HR-0.47(0(�Ñ‘)�7-0.75)53%減少ã—ãŸã€‚ã•ã‚‰ã«ã€ã“ã®ãƒ‡ãƒ¼ã‚¿ã§ã¯ã€HPVワクãƒãƒ³ã®å®šæœŸæŽ¥ç¨®ã‚’学童女å…ã®ã†ã¡ã«å—ã‘ã¦ã„ã‚Œã°ã€L0万人ã‚ãŸã‚Š1å¹´é–“ã§ã®å­å®®é ¸ãŒã‚“発生数ã¯ã€0.1人ã§ã‚ã‚‹ã“ã¨ã‚’示ã—ã¦ã„ã‚‹(未接種ã®å ´åˆã¯5.27)。デンマークã§ã¯ã€HPVワクãƒãƒ³éžæŽ¥ç¨®è€…ã‚’1ã¨ã—ãŸå ´åˆã€L6æ­³ã¾ã§ã«æŽ¥ç¨®ã—ãŸå¥³æ€§ã§ã¯å­å®®é ¸ç™Œã®ç™ºç”Ÿãƒªã‚¹ã‚¯ãŒ0.Ó0ë0(87%減少)ã§ã‚ã£ãŸã€‚ã¾ãŸ17-19æ­³ã§æŽ¥ç¨®ã—ãŸå ´åˆã§ã‚‚0(�Ñ‘)�9ã§ã‚ã‚Šã€ã‚­ãƒ£ãƒƒãƒã‚¢ãƒƒãƒ—接種ã®æœ‰åŠ¹æ€§ã‚’å­å®®é ¸ç™Œæ¸›å°‘効果ã§è¨¼æ˜Žã—ãŸã“ã¨ã«ãªã‚‹ã€‚ãŸã ã—ã€20Ð0ü0ì0ë00æ­³ã§ã®æŽ¥ç¨®è€…ã§ã¯1.15ã§æ¸›å°‘効果ã¯è¦‹ã‚‰ã‚Œãªã‹ã£ãŸ(表2)。考察ã¨ã—ã¦ã¯ã€ã“ã®å¹´é½¢ã§ã‚­ãƒ£ãƒƒãƒã‚¢ãƒƒãƒ—接種を希望ã—ãŸå¥³æ€§ã§ã¯æ€§æ´»å‹•æ€§ãŒé«˜ãã€ãƒã‚¤ãƒªã‚¹ã‚¯HPVã®æ—¢æ„ŸæŸ“者ãŒå¤šãå«ã¾ã‚Œã¦ã„ãŸå¯èƒ½æ€§ãŒæŒ‡æ‘˜ã•ã‚Œã¦ã„る。やã¯ã‚Šã€æ€§äº¤çµŒé¨“å‰ã®ä¸–代ã«æŽ¥ç¨®ã™ã‚‹ã“ã¨ãŒç¢ºå®Ÿãªå­å®®é ¸ç™Œäºˆé˜²ã«ãªã‚‹ã€‚ ?HPVワクãƒãƒ³ã®æ„ŸæŸ“予防効果ã®æŒç¶šæœŸé–“ã¯ã©ã†ã§ã‚ã‚ã†ã‹?HPVワクãƒãƒ³æŽ¥ç¨®ã‹ã‚ˆ4å¹´(追跡期間中央値�.9å¹´)経ã£ã¦ã‚‚ã€HPV16,18åž‹ã«èµ·å› ã™ã‚‹é«˜åº¦å­å®®é ¸éƒ¨ä¸Šçš®å†…è…«ç˜(CIN2以上)ã¯ç™ºç—‡ã—ã¦ã„ãªã„ã“ã¨ãŒç¤ºã•ã‚ŒãºN4。臨床試験ã«å‚加ã—ãŸå¥³æ€§ã¯ã€ŒN(�åe)�0å¹´ç¾åœ¨30f»l7æ­³ã«ãªã£ã¦ã„ã‚‹ã“ã¨ã‹ã‚‰ã€å­å®®é ¸ãŒã‚“ã®å‰ãŒã‚“病変ã®ç½¹æ‚£å¹´é½¢ãƒ”ークã¯æ—¢ã«è¶Šãˆã¦ã„る。　ï¼]N5-27）</blockquote> <blockquote>……20Ð0ü0ì0ë00歳女性ã§ã¯ã™ã§ã«HPV16,18åž‹ã«æ„ŸæŸ“ã—ã¦ã„る女性ãŒå¤šãå«ã¾ã‚Œã€HPVワクãƒãƒ³ã‚’接種ã—ã¦ã‚‚“時ã™ã§ã«é…ã—â€ã§å­å®®é ¸ç™Œã«ãªã£ã¦ã—ã¾ã£ãŸã€ã¨ã„ã†æ„味ã§ã‚る。ç¾æ™‚点ã§ã®ã‚¨ãƒ“デンスã‹ã‚‰ã¯ã€HPVワクãƒãƒ³ã¯ã‚„ã¯ã‚‘0代ã«æŽ¥ç¨®ã™ã‚‹ã¹ããªã®ã‹ã‚‚ã—ã‚Œãªã„。　（27）</blockquote> <blockquote>　HPVワクãƒãƒ³æŽ¥ç¨®å¾Œã«å ±å‘Šã•ã‚ŒãŸæœ‰å®³äº‹è±¡ã«é–¢ã—ã¦ã€å›½å†…外ã§å†èª¿æŸ»ã«ã‚ˆã£ã¦ã‚ã‹ã£ã¦ããŸæŽ¥ç¨®å¾Œå‰¯åå¿œã®è»¢å¸°ã«ã¤ã„ã¦ã¾ã¨ã‚られãŸã€‚é‡ç¯¤ãªå‰¯å応疑ã„ã¨å ±å‘Šã•ã‚ŒãŸã‚±ãƒ¼ã‚¹ã®ã†ã¡ã€ç´„90%ãŒå›žå¾©ã¾ãŸã¯è»½å¿«ã—通院ä¸è¦ã¨ãªã£ãŸã€‚未回復ã®æ–¹ã¯186人(ã®ã¹æŽ¥ç¨®å›žæ•°ã®ç´„0.0(�åe)�%)ã§ã‚ã£ãŸã€‚ã—ã‹ã‚‚ã€ã“れらã®æœªå›žå¾©è€…ã®åŽŸå› ãŒHPVワクãƒãƒ³ã§ã‚ã‚‹ã¨ã„ã†è¨¼æ˜Žã¯ãªã„。åå¤å±‹å¸‚ã®èª¿æŸ»ã§ã¯ã€HPVワクãƒãƒ³æŽ¥ç¨®è€…ã¨éžæŽ¥ç¨®è€…ã®å¥³å­ã«ã¤ã„ã¦ã€å¤šæ–¹é¢ã®ç—‡çŠ¶ã®æœ‰ç„¡ã‚„病院å—診歴を調査ã—公表ã—ãŸ18。少ãªãã¨ã‚‚ワクãƒãƒ³æŽ¥ç¨®ã«ã‚ˆã£ã¦æ§˜ã€…ãªç—‡çŠ¶ãŒç™ºç—‡ã™ã‚‹ã“ã¨ã¯ãªã„ã“ã¨ãŒå›½å†…ã§è¨¼æ˜Žã•ã‚ŒãŸã€‚　ï¼]N7）Ã_blockquote> <blockquote>厚労çœã¯ã€ä¸€èˆ¬å¸‚æ°‘å‘ã‘ã«ãƒªãƒ¼ãƒ•ãƒ¬ãƒƒãƒˆã‚’2020å¹´10月ã«ç™ºè¡Œã—ãŸã€‚ã“ã®ãƒªãƒ¼ãƒ•ãƒ¬ãƒƒãƒˆã‚�N2-16歳女å­ãŒå±…ã‚‹ã™ã¹ã¦ã®å®¶åº­ã«å€‹åˆ¥é€šçŸ¥ã™ã‚‹ã“ã¨ã«ãªã£ã¦ã„る。多ãã®è‡ªæ²»ä½“ã§å€‹åˆ¥é€šçŸ¥ã•ã‚Œã€æœ€è¿‘ã§ã¯HPVワクãƒãƒ³æŽ¥ç¨®çŽ‡ãŒå°‘ã—ãšã¤ä¸Šæ˜‡ã—ã¯ã˜ã‚ã¦ã‚‹ã€‚ã•ã‚‰ã«ã€20å¹p�V�月ã«ã¯ã€æ–‡éƒ¨ç§‘å­¦çœãŒã€ŒãŒã‚“教育推進ã®ãŸã‚ã®æ•™æã€ã‚’改訂ã—ã€ãã“ã«HPVワクãƒãƒ³ã®è¨˜è¼‰ãŒç››ã‚Šè¾¼ã¾ã‚ŒãŸã€‚全国ã®å°ä¸­é«˜æ ¡ã«ãŠã„ã¦HPVワクãƒãƒ³ã®ã“ã¨ãŒæŽˆæ¥­ã§æ•™ãˆã‚‰ã‚Œã‚‹ã“ã¨ã«ãªã‚‹ã€‚ 　20å¹´10月ã‹ã‚‰åŽšåŠ´çœå†…ã®å¯©è­°ä¼š(ワクãƒãƒ³åˆ†ç§‘会副å応検討部会)ã«ã¦ã€HPVワクãƒãƒ³æŽ¥ç¨®å‹§å¥¨å†é–‹ã«ã¤ã„ã¦è­°è«–ãŒå§‹ã¾ã‚Šã€æŽ¥ç¨®å‹§å¥¨ã‚’8å¹´ã¶ã‚Šã«å†é–‹ã™ã‚‹æ–¹å‘ã§æº–å‚™ãŒã¯ã˜ã¾ã£ãŸ。ã„よã„よ厚労çœã‹ã‚‰ã®æŽ¥ç¨®å‹§å¥¨ã®ãŠå¢¨ä»˜ããŒå‡ºã‚‹æ—¥ãŒè¿‘ã„。ã‚ã¨ã¯HPVワクãƒãƒ³æŽ¥ç¨®ã®å¿…è¦æ€§ã‚„接種後ã«èµ·ã“ã‚Šã†ã‚‹ç—‡çŠ¶ãªã©ã‚’é©åˆ‡ã«èª¬æ˜Žã—ã¦ã€ã‚ˆãç†è§£ã—ã¦ã‚‚らã„ãªãŒã‚‰ã€ç€å®Ÿã«æŽ¥ç¨®è€…を増やã™ã“ã¨ãŒé‡è¦ã§ã‚ã‚ã†ã€‚　（27(�(g)�8）Ã_blockquote> <span style="color:cornflowerblue;">â—†Ã_span>Juan, DU et al.ã€�N(�åe)�1　"<b><u>Human papilloma virus (HPV) prevalence upon HPV vaccination in Swedish youth: A revie7�based on our findings</u></b>",　<i>Archives of gynecolog9�and obstetricsÃ_i>ã€p�A�Ô0³0(�(g)�Ú0ó0¹029Ð0ü0ì0ë035.　<a href="httpsa_/link.springer.com/article/10.1007/s00404-(�åe)�0-05879-7">[外部サイト]Ã_a> ※HTMLã‹ã‚‰å¼•ç”¨ã®ãŸã‚ページ数記載ãªã— <blockquote>In Sweden, from 20(�*h)�, Gardasil was offered to 10µ2 year old girls through the school-based vaccination program, and as catchu0�vaccination for women up to 26 years. 以下機械翻訳（DeepL）： スウェーデンã§ã¯ã€ŒN012å¹´ã‹ã‚‰ã€L0～(�*h)�æ­³ã®å¥³å­ã‚’対象ã«å­¦æ ¡ã§ã®äºˆé˜²æŽ¥ç¨®ãƒ—ログラムを通ã˜ã¦ã‚¬ãƒ¼ãƒ€ã‚·ãƒ«ã‚’æä¾›ã—「N6æ­³ã¾ã§ã®å¥³æ€§ã«ã¯ã‚­ãƒ£ãƒƒãƒã‚¢ãƒƒãƒ—接種ã¨ã—ã¦æä¾›ã—ã¦ã„る。Ã_blockquote> <blockquote>Mos4�common cervical HR-HPV types were HPì0ó0È0²0ó09, 51, 52, 56, and 59 together accounting for?~?10.�.�of cervical cancer, and where only HPV(�yr)� is included in Gardasil-9. 以下機械翻訳（DeepL）： å­å®®é ¸éƒ¨ãƒã‚¤ãƒªã‚¹ã‚¯HPVã®æœ€ã‚‚多ã„åž‹ã¯HPì0ó0È0²0ó09〬ã€52ã€56ã€59ã§ã€åˆã‚ã›ã¦å­å®®é ¸ãŒã‚“ã®ç´„10ï¼…ã‚’å ã‚ã¦ãŠã‚Šã€HPV52ã®ã¿ãŒã‚¬ãƒ¼ãƒ€ã‚·ãƒ«-9ã«å«ã¾ã‚Œã¦ã„る。</blockquote> <blockquote>To conclude, Gardasil HPV types have decreased, bu4�it is still importan4�to follo7�remaining HR-HPV types and cancer development, since there is an ongoing increase in the incidence of HPV-associated tonsillar and base of tongue cancer, and cervical cancer in Sweden. 以下機械翻訳（DeepL）： çµè«–ã¨ã—ã¦ã€ã‚¬ãƒ¼ãƒ€ã‚·ãƒ«HPVåž‹ã¯æ¸›å°‘ã—ãŸãŒã€ã‚¹ã‚¦ã‚§ãƒ¼ãƒ‡ãƒ³ã§ã¯HPVã«é–¢é€£ã™ã‚‹æ‰æ¡ƒè…ºãŒã‚“ã€èˆŒæ ¹éƒ¨ãŒã‚“ã€å­å®®é ¸ãŒã‚“ã®ç™ºç”ŸçŽ‡ãŒå¢—加ã—続ã‘ã¦ã„ã‚‹ãŸã‚ã€æ®‹å­˜ã™ã‚‹ãƒã‚¤ãƒªã‚¹ã‚¯HPVåž‹ã¨ãŒã‚“ã®ç™ºç”Ÿã‚’追跡ã™ã‚‹ã“ã¨ã¯ä¾ç„¶ã¨ã—ã¦é‡è¦ã§ã‚る。Ã_blockquote> <h4><span style="color:lightgrey;">â– </span>看護学</h4> <span style="color:cornflowerblue;">â—†</span>今井 美å’=�他　2019　「å­å®®é ¸ãŒã‚“ã¨ãã®äºˆé˜²ã«é–¢ã™ã‚‹å¥³å­å¤§å­¦ç”Ÿã®çŸ¥è­˜ã¨æ…‹åº¦ã®çŠ¶æ³ã«ã¤ã„ã¦ã€,　『石å·çœ‹è­·é›‘誌ã€16:Ó0ë0(�(g)�4.　<a href="https:å]ipnu.repo.nii.ac.j:y?action=pages_view_main&active_action=repository_view_main_item_detail&item_id(�O)�75&item_no³&page_id³3&block_id(�O)�1">[外部サイト]Ã_a> <blockquote> 質å•èª¿æŸ»é …ç›® […] ワクãƒãƒ³ã®åŠ¹ç”¨ HPV ワクãƒãƒ³ã¯ï¼Œç´„7割ã®å­å®®é ¸ãŒã‚“を予防ã§ãる．　％6）Ã_blockquote> <span style="color:cornflowerblue;">â—†Ã_span>YAJU, Yukari・TSUBAKI, Hiroeã€�N019　"<b><u>Safet9�concerns with human papilloma virus immunization in Japan: Analysis and evaluation of Nagoya City's surveillance data for adverse eventsÃ_u>Ã_b>",　<i>Japan Journal of Nursing ScienceÃ_i>ã€G6.4:Ö0Ã0·0§0ë03-449　<a href="httpsa_/onlinelibrary.wiley.com/doi/fulîv10.1�þ]jjns.1(� g)�(�yr)�">[外部サイト]</a> ※HTMLã‹ã‚‰å¼•ç”¨ã®ãŸã‚ページ数記載ãªã— YAJU, Yukari・TSUBAKI, Hiroe. Safety concerns with human papilloma virus immunization in Japan: Analysis and evaluation of Nagoya City's surveillance data for adverse events. Japan Journal of Nursing Science,(��N)�019, 16.4: 4Õ0£0ü0È0-449. <blockquote><b>AbstractÃ_b> <b>Aim</b> To assess the safety of human papilloma virus (HPV) vaccines b9�using data from the “Nagoya City Cervical Cancer Immunization Program Surveyâ€. <b>MethodsÃ_b> Unadjusted odds ratios (OR) were calculated between HPV-vaccinated cases and un-vaccinated controls. Age-stratified analyses were performed to evaluate the interaction between age and events. Adjusted ORs were also estimated with multiple logistic regression models. <b>Results</b> In the 15?16-year-old group, the unadjusted ORs were significantly higher for symptoms of memory impairment, dyscalculia, and involuntar9�movement. The age-adjusted multivariate analyses demonstrated that the vaccinated cases were less likely than the unvaccinated controls to have experienced symptoms in almost all symptoms, excep4�for two symptoms such as involuntary movemen4�and weakness. However, study period-adjusted multivariate analyses demonstrated that the vaccinated cases were significantly more likely than un-vaccinated controls to have experienced symptoms of memor9�impairment and involuntary movement. <b>ConclusionsÃ_b> Based on our analysis using data from the Nagoya City surveillance survey, a possible association between HPV vaccination and distinc4�symptoms such as cognitive impairmen4�or movemen4�disorders exists. A consistent causal relationship between HPV vaccination and these symptoms remains uncertain. However, given the seriousness of symptoms, we believe that a more comprehensive and large-scale stud9�is essential to confirm the safety of HPV vaccination. 以下機械翻訳（DeepL）： <b>目的Ã_b> 「åå¤å±‹å¸‚å­å®®é ¸ãŒã‚“予防接種事業調査ã€ã®ãƒ‡ãƒ¼ã‚¿ã‚’用ã„ã¦ã€ãƒ’ト乳頭腫ウイルス（HPV）ワクãƒãƒ³ã®å®‰å…¨æ€§ã‚’評価ã™ã‚‹ã“ã¨ã€‚ <b>方法Ã_b> HPVワクãƒãƒ³æŽ¥ç¨®ä¾‹ã¨éžæŽ¥ç¨®ä¾‹ã¨ã®é–“ã®æœªèª¿æ•´ã‚ªãƒƒã‚ºæ¯”（OR）を算出ã—ãŸã€‚å¹´é½¢ã¨ã‚¤ãƒ™ãƒ³ãƒˆã®ç›¸äº’作用を評価ã™ã‚‹ãŸã‚ã«ã€å¹´é½¢å±¤åˆ¥åˆ†æžã‚’è¡Œã£ãŸã€‚ã¾ãŸã€å¤šé‡ãƒ­ã‚¸ã‚¹ãƒ†ã‚£ãƒƒã‚¯å›žå¸°ãƒ¢ãƒ‡ãƒ«ã‚’用ã„ã¦èª¿æ•´å¾Œã®ORを推定ã—ãŸã€‚ <b>çµæžœ</b> 15-16歳群ã§ã¯ã€è¨˜æ†¶éšœå®³ã€è¨ˆç®—障害ã€ä¸éšæ„é‹å‹•ã®ç—‡çŠ¶ã«ã¤ã„ã¦ã€æœªèª¿æ•´ã®ORãŒæœ‰æ„ã«é«˜å€¤ã§ã‚ã£ãŸã€‚年齢調整ã—ãŸå¤šå¤‰é‡è§£æžã§ã¯ã€ä¸éšæ„é‹å‹•ã‚„脱力感ã¨ã„ã£ãèlã¤ã®ç—‡çŠ¶ã‚’除ãã»ã¼ã™ã¹ã¦ã®ç—‡çŠ¶ã«ãŠã„ã¦ã€ãƒ¯ã‚¯ãƒãƒ³æŽ¥ç¨®ä¾‹ã¯ãƒ¯ã‚¯ãƒãƒ³éžæŽ¥ç¨®å¯¾ç…§ä¾‹ã‚ˆã‚Šã‚‚症状を経験ã™ã‚‹ç¢ºçŽ‡ãŒä½Žã„ã“ã¨ãŒç¤ºã•ã‚ŒãŸã€‚ã—ã‹ã—，研究期間調整後ã®å¤šå¤‰é‡è§£æžã§ã¯ï¼Œãƒ¯ã‚¯ãƒãƒ³æŽ¥ç¨®ä¾‹ã¯ãƒ¯ã‚¯ãƒãƒ³éžæŽ¥ç¨®ä¾‹ã«æ¯”ã¹ï¼Œè¨˜æ†¶éšœå®³ã¨ä¸éšæ„é‹å‹•ã®ç—‡çŠ¶ã‚’経験ã™ã‚‹å¯èƒ½æ€§ãŒæœ‰æ„ã«é«˜ã„ã“ã¨ãŒç¤ºã•ã‚ŒãŸï¼Ž <b>çµè«–</b> åå¤å±‹å¸‚ã®ã‚µãƒ¼ãƒ™ã‚¤ãƒ©ãƒ³ã‚¹èª¿æŸ»ã®ãƒ‡ãƒ¼ã‚¿ã‚’用ã„ãŸè§£æžã‹ã‚‰ï¼ŒHPVワクãƒãƒ³æŽ¥ç¨®ã¨èªçŸ¥éšœå®³ã‚„é‹å‹•éšœå®³ãªã©ã®æ˜Žç¢ºãªç—‡çŠ¶ã¨ã®é–“ã«é–¢é€£æ€§ãŒå­˜åœ¨ã™ã‚‹å¯èƒ½æ€§ãŒã‚ã‚‹ã“ã¨ãŒç¤ºã•ã‚ŒãŸï¼ŽHPVワクãƒãƒ³æŽ¥ç¨®ã¨ã“れらã®ç—‡çŠ¶ã¨ã®é–“ã«ä¸€è²«ã—ãŸå› æžœé–¢ä¿‚ãŒã‚ã‚‹ã‹ã©ã†ã‹ã¯ä¸æ˜Žã§ã‚る。ã—ã‹ã—，症状ã®é‡ç¯¤æ€§ã‹ã‚‰ï¼ŒHPVワクãƒãƒ³æŽ¥ç¨®ã®å®‰å…¨æ€§ã‚’確èªã™ã‚‹ãŸã‚ã«ã¯ï¼Œã‚ˆã‚ŠåŒ…括的ã§å¤§è¦æ¨¡ãªèª¿æŸ»ãŒä¸å¯æ¬ ã§ã‚ã‚‹ã¨è€ƒãˆã‚‹ï¼Ž </blockquote> <h4><span style="color:lightgrey;">â– Ã_span>ä¿å¥ãƒ»è¡›ç”ŸÃ_h4> <span style="color:cornflowerblue;">â—†Ã_span>Yagi, A e4�al.　20　"<b><u>The looming health hazard: A wave of HPV-related cancers in Japan is becoming a realit9�due to the continued suspension of the governmental recommendation of HPV vaccine</u></b>",　<i>Lance4�Reg Health Wes4�Pac</i>　DOI: 10.1016/j.lanwpc.20.100(�>y)�7..　<a href="httpsa_/www.ncbi.nlm.nih.gos|pmuarticles/PMC8669(�>y)�ñ]">[外部サイト]</a> ※HTMLã‹ã‚‰å¼•ç”¨ã®ãŸã‚ページ数記載ãªã— <blockquote>We should continue to pressure our government to resume its vaccine recommendation, but a4�the same time we mus4�recommend that women of the ‘vaccine-suspension generationâ€n�receive ‘catch-u0�HPV vaccinations’, although its effectiveness was unfortunatel9�shown to be limited for females older than(��N)�0 in Japan.7 Those females should be strongl9�encouraged to undergo regular cervical cancer screening and receive appropriate treatments for cervical lesions. 以下機械翻訳（DeepL）： ç§ãŸã¡ã¯ã€æ”¿åºœã«å¯¾ã—ã¦ãƒ¯ã‚¯ãƒãƒ³æŽ¨å¥¨ã®å†é–‹ã‚’引ã続ãå¼·ãåƒãã‹ã‘ã‚‹ã¨åŒæ™‚ã«ã€æ—¥æœ¬ã§ã¯æ®‹å¿µãªãŒã‚AS0歳以上ã®å¥³æ€§ã«ã¯åŠ¹æžœãŒé™å®šçš„ã§ã‚ã‚‹ã“ã¨ãŒç¤ºã•ã‚ŒãŸã‚‚ã®ã®ã€ã€Œãƒ¯ã‚¯ãƒãƒ³ä¸­æ–­ä¸–代ã€ã®å¥³æ€§ã«ã¯ã€Œã‚­ãƒ£ãƒƒãƒã‚¢ãƒƒãƒ—HPVワクãƒãƒ³ã€ã®æŽ¥ç¨®ã‚’推奨ã—ãªã‘ã‚Œã°ãªã‚‰ãªã„。ã“れらã®å¥³æ€§ã«ã¯ã€å®šæœŸçš„ã«å­å®®ãŒã‚“検診をå—ã‘ã€å­å®®é ¸éƒ¨ç—…変ã®é©åˆ‡ãªæ²»ç™‚ã‚’å—ã‘るよã†å¼·ã奨励ã—ãªã‘ã‚Œã°ãªã‚‰ãªã„。 Ã_blockquote> <span style="color:cornflowerblue;">â—†Ã_span>æ¡åŽŸ ã‚ãšã¿ 他　2019　「ヒトパピローマウイルスワクãƒãƒ³æŽ¨å¥¨ä¸–代ã®æŽ¥ç¨®å¾Œã®ç¶™ç¶šçš„ãªæ¤œè¨ºã®å¿…è¦æ€§ã«ã¤ã„ã¦ã®çŸ¥è­˜ã«é–¢ã™ã‚‹ç ”究ã€,　『日本ä¿å¥åŒ»ç™‚行動科学会雑誌ã€k�g�4-2:�8-(�*h)�5.　<a href="httpa_/www.jahbs.infówjournaîvjourna2�0�¹p4_2.html">[外部サイト]</a> <blockquote(�ÇŒ)�009å¹´ï½ps013å¹´ã®æ—¥æœ¬ã®ç©æ¥µçš„ãªå­å®®é ¸ãŒã‚“ワクãƒãƒ³æŽ¥ç¨®ãƒ—ログラムã§ã¯ï¼Œãƒ¯ã‚¯ãƒãƒ³æŽ¥ç¨®ã‚’促ã™ãƒ—ロモーションãŒå…ˆè¡Œã—å­å®®é ¸ãŒã‚“ã‚„ãã®äºˆé˜²ã«é–¢ã™ã‚‹æ•™è‚²ãŒè¿½ã„付ã‹ãšï¼Œãƒ¯ã‚¯ãƒãƒ³æŽ¥ç¨®å¾Œã‚‚継続ã—ã¦æ¤œè¨ºã‚’å—ã‘ã‚‹å¿…è¦æ€§ãŒèªçŸ¥ã•ã‚Œã¦ã„ãªã„å¯èƒ½æ€§ãŒã‚ã‚‹ã€2�[…] ワクãƒãƒ³æŽ¥ç¨®å¾Œã‚‚継続的ãªæ¤œè¨ºã®å¿…è¦æ€§ã‚’知ã£ã¦ã„ãŸç¾¤ãr�a�d�"s�2�9ï¼…ã§ã‚り，知らãªã‹ã£ãŸç¾¤ã¯­ï¼…ã§ã‚ã£ãŸã€‚ […] ワクãƒãƒ³ã‚’接種ã—ã¦ã‚‚検診頻度ã«ã¤ã„ã¦å­¦ã¶æ©Ÿä¼šãŒãªã‘ã‚Œã°ï¼Œãƒ¯ã‚¯ãƒãƒ³æŽ¥ç¨®å¾Œã®ç¶™ç¶šçš„ãªæ¤œè¨ºã®å¿…è¦æ€§ã‚’誤ã£ã¦èªè­˜ã—ã¦ã—ã¾ã†å¯èƒ½æ€§ãŒã‚る。　（�8）Ã_blockquote> <h4><span style="color:lightgrey;">â– </span>ç–«å­¦Ã_h4> <span style="color:cornflowerblue;">â—†Ã_span>FUKUSHIMA, Wakaba e4�al.　20(� g)�　"<b><u>A nationwide epidemiological surve9�of adolescen4�patients with diverse symptoms similar to those following human papillomavirus vaccination: background prevalence and incidence for considering vaccine safety in Japan</u></b>",　<i>Journal of epidemiologyÃ_i>ã€p�A�2.1:34-43　<a href="httpsa_/www.ncbi.nlm.nih.gos|pmuarticles/PMC8666ªþ]">[外部サイト]</a> ※HTMLã‹ã‚‰å¼•ç”¨ã®ãŸã‚ページ数記載ãªã— <blockquote>Reports similar to ours have no4�ye4�been published in terms of severit9�of diverse symptoms. The previous stud9�in Nagoya, Japan, which targeted diverse symptoms among Japanese adolescen4�girls, differed from our surve9�no4�only because i4�compared the odds of various symptoms in vaccinated and non-vaccinated girls, bu4�also because i4�evaluated milder symptoms, with cumulative incidences in unvaccinated girls of 0(�Ñ‘)�.�.�to(��N)�5.6%. While that study showed no association between HPV vaccination and(��N)�2 2 2 symptoms b9�comparing vaccinated and unvaccinated girls, another study re-analyzed the data and showed possible associations for several symptoms, such as cognitive impairmen4�and movement disorders. That study used the same dataset but applied different methodology, in terms of stud9�period, interaction term, age adjustment, and selection of unvaccinated controls. Such discrepancies may indicate the difficulty of controlling confounding and reducing selection bias in the dataset. However, since our study targeted differen4�levels of symptoms, which were more severe and less frequent, findings from that previous stud9�are no4�directly relevan4�to our findings. 以下機械翻訳（DeepL）： 多様ãªç—‡çŠ¶ã®é‡ç—‡åº¦ã¨ã„ã†ç‚¹ã§ã¯ã€ç§ãŸã¡ã¨åŒæ§˜ã®å ±å‘Šã¯ã¾ã ç™ºè¡¨ã•ã‚Œã¦ã„ãªã„。日本ã®æ€æ˜¥æœŸå¥³å­ã®å¤šæ§˜ãªç—‡çŠ¶ã‚’対象ã¨ã—ãŸåå¤å±‹ã®å…ˆè¡Œç ”究ã¯ã€ãƒ¯ã‚¯ãƒãƒ³æŽ¥ç¨®å¥³å­ã¨éžæŽ¥ç¨®å¥³å­ã§å¤šæ§˜ãªç—‡çŠ¶ã®ç™ºç”Ÿç¢ºçŽ‡ã‚’比較ã—ã¦ã„ã‚‹ã ã‘ã§ãªãã€éžæŽ¥ç¨®å¥³å­ã§ã®ç´¯ç©ç™ºç”ŸçŽ‡ãŒ0(�Ñ‘)�％～25.6ï¼…ã¨è»½åº¦ã®ç—‡çŠ¶ã‚’評価ã—ã¦ã„る点ãŒæˆ‘々ã®èª¿æŸ»ã¨ã¯ç•°ãªã£ã¦ã„る。ãã®ç ”究ã§ã¯ã€ãƒ¯ã‚¯ãƒãƒ³æŽ¥ç¨®è€…ã¨éžæŽ¥ç¨®è€…ã®å¥³å…を比較ã—ã¦ã€HPVワクãƒãƒ³æŽ¥ç¨®ã¨24ã®ç—‡çŠ¶ã¨ã®é–“ã«é–¢é€£æ€§ãŒãªã„ã“ã¨ã‚’示ã—ãŸãŒã€åˆ¥ã®ç ”究ã§ã¯ã€ãƒ‡ãƒ¼ã‚¿ã‚’å†è§£æžã—ã€èªçŸ¥éšœå®³ã‚„é‹å‹•éšœå®³ãªã©ã„ãã¤ã‹ã®ç—‡çŠ¶ã«ã¤ã„ã¦é–¢é€£æ€§ã®å¯èƒ½æ€§ãŒã‚ã‚‹ã“ã¨ãŒç¤ºã•ã‚ŒãŸã€‚ã“ã®ç ”究ã§ã¯ã€åŒã˜ãƒ‡ãƒ¼ã‚¿ã‚»ãƒƒãƒˆã‚’用ã„ãŸãŒã€ç ”究期間ã€äº¤äº’作用項ã€å¹´é½¢èª¿æ•´ã€ãƒ¯ã‚¯ãƒãƒ³æœªæŽ¥ç¨®å¯¾ç…§ã®é¸æŠžã®ç‚¹ã§ç•°ãªã‚‹æ–¹æ³•ã‚’é©ç”¨ã—ã¦ã„る。ã“ã®ã‚ˆã†ãªä¸ä¸€è‡´ã¯ã€ãƒ‡ãƒ¼ã‚¿ã‚»ãƒƒãƒˆã«ãŠã‘る交絡ã®åˆ¶å¾¡ã¨é¸æŠžãƒã‚¤ã‚¢ã‚¹ã®ä½Žæ¸›ãŒå›°é›£ã§ã‚ã‚‹ã“ã¨ã‚’示ã—ã¦ã„ã‚‹ã®ã‹ã‚‚ã—ã‚Œãªã„。ã—ã‹ã—ã€æˆ‘々ã®ç ”究ã¯ã€ã‚ˆã‚Šé‡ãã€ã‚ˆã‚Šé »åº¦ã®ä½Žã„ã€ç•°ãªã‚‹ãƒ¬ãƒ™ãƒ«ã®ç—‡çŠ¶ã‚’対象ã¨ã—ã¦ã„ã‚‹ã®ã§ã€ãã®å…ˆè¡Œç ”究ã®çŸ¥è¦‹ã¯ã€æˆ‘々ã®çŸ¥è¦‹ã¨ç›´æŽ¥é–¢é€£ã¯ãªã„。Ã_blockquote> <blockquote>In conclusion, our nationwide epidemiological surve9�in Japan revealed that adolescen4�girls withou4�histor9�of HPV vaccination also visited hospitals with diverse symptoms similar to those following HPV vaccination. We hope our results help explain the complexit9�of HPV vaccine safet9�issues in Japan and will provide useful insigh4�into future strategies of signal assessmen4�immediatel9�after detection of AEFI. 以下機械翻訳（DeepL）： 以上よりã€æœ¬é‚¦ã«ãŠã‘る全国疫学調査ã‹ã‚‰ã€HPVワクãƒãƒ³æŽ¥ç¨®æ­´ã®ãªã„æ€æ˜¥æœŸå¥³å­ã‚‚HPVワクãƒãƒ³æŽ¥ç¨®å¾Œã«é¡žä¼¼ã—ãŸå¤šæ§˜ãªç—‡çŠ¶ã§ç—…院をå—診ã—ã¦ã„ã‚‹ã“ã¨ãŒæ˜Žã‚‰ã‹ã¨ãªã£ãŸã€‚今回ã®çµæžœãŒï¼Œæ—¥æœ¬ã«ãŠã‘ã‚‹HPVワクãƒãƒ³ã®å®‰å…¨æ€§ã®å•é¡Œã®è¤‡é›‘ã•ã‚’説明ã™ã‚‹ä¸€åŠ©ã¨ãªã‚Šï¼Œä»Šå¾Œã®AEFI検出直後ã®ã‚·ã‚°ãƒŠãƒ«è©•ä¾¡ã®æˆ¦ç•¥ã«æœ‰ç”¨ãªçŸ¥è¦‹ã‚’æä¾›ã™ã‚‹ã“ã¨ã‚’期待ã™ã‚‹ï¼Ž</blockquote> <h4><span style="color:lightgrey;">â– Ã_span>ä»–Ã_h4> <span style="color:cornflowerblue;">â—†Ã_span>æž— æ±ä½e�他　20(� g)�　「HPVワクãƒãƒ³ã‚’ã‚ãる日本ã®ãƒ„イッター上ã®è³›å¦ä¸¡è«–ã®å¯¾ç«‹ã¨å¤‰åŒ–ã€,　『人工知能学会全国大会論文集ç¬G�P�a�6回ã€WB6GS1004(�(g)�B6GS1004.　<a href="httpsa_/www.jstage.jst.go.j:yarticl0upjsa}vJSAI20(� g)�/0/JSAI2(�åe)�2_2B6Ge00^_article/-char/jæt">[外部サイト]</a> <blockquote>……ãã®å¾ŒHPVワクãƒãƒ³ã¨å‰¯ä½œç”¨ã¨ã®å› æžœé–¢ä¿‚ãŒè¨¼æ˜Žã•ã‚Œã¦ã„ãªã„ã¨ã„ã†å°‚門家ã®æŒ‡æ‘˜ã«ã‚‚ã‹ã‹ã‚らãšæŽ¥ç¨®çŽ‡ã¯å¤§ãã低下ã—[Yagi] [……] ç©æ¥µçš„勧奨ã®ä¸­æ­¢ã‹ã‚‰å†é–‹ã¾ã§ã®8å¹´é–“,HPVã«å¯¾ã™ã‚‹ä¸–è«–ã¯ã©ã†å¤‰åŒ–ã—ãŸã‹ã€‚本稿ã¯ã€æ—¥æœ¬èªžãƒ„イッターデータを分æžã—ã€HPVã‚’ã‚ãる日本国内ã®ä¸–è«–ã®æŽ¨ç§»ã¨ç‰¹æ€§ã‚’明らã‹ã«ã—ãŸã€‚　％）</blockquote> <blockquote>　賛æˆæ´¾ã¨å対派ã®11å¹´é–“ã«ã‚ãŸã‚‹å‰²åˆã®å¤‰åŒ–を調ã¹ã‚‹ãŸã‚ã€å¹´åº¦ã‚’基準ã«åˆ†ã‘ã¦åˆ†æžã—ãŸçµæžœã‚’図3ã«ç¤ºã™ã€ N015å¹´ã¾ã§ã¯å対派ã®å‰²åˆãŒé«˜ã「N016å¹´ã«ã¯ã»ã¼åŒæ§˜ã¨ãªã‚Šã€2017å¹´ã‹ã‚‰è³›æˆæ´¾ãŒå¤šæ•°æ´¾ã¨ãªã£ãŸã€‚ã—ãŸãŒã£ã¦(�4l)�015~2017å¹´ã«ç¤¾ä¼šçš„ãªåå¿œã«å¤§ããªå¤‰åŒ–ãŒã‚ã£ãŸã¨äºˆæƒ³ã•ã‚Œã‚‹ã€‚　ï¼]N）</blockquote> <blockquote>è³›æˆæ´¾ã¨å対派ã®ç‰¹å¾´ã‚’具体的ã«æŠŠæ¡ã™ã‚‹ãŸã‚ã€ãã‚Œãžã‚Œã«å±žã™ã‚‹ãƒ¦ãƒ¼ã‚¶ãƒ¼ã4l011å¹´ã‹ã‚‰20å¹´ã«ã‹ã‘ã¦ã‚ˆã引用ã—ãŸå¤–部サイトを分æžã—ãŸçµæžœãŒè¡¨1ã§ã‚る。賛æˆæ´¾ã®å ´åˆã€BuzzFeedã‚„ç¾ä»£ãƒ“ジãƒã‚¹ã€æ¯Žæ—¥æ–°èžãªã©ã‚¤ãƒ³ã‚¿ãƒ¼ãƒãƒƒãƒˆãƒ¡ãƒ‡ã‚£ã‚¢ã‚„ä¼çµ±ãƒ¡ãƒ‡ã‚£ã‚¢ã€ãã—ã¦è³›æˆæ´¾ã®ã‚µã‚¤ãƒˆã§ã‚る「ã¿ã‚“ãªã§çŸ¥ã‚ã†HPVã€ã¨ã„ã†ã‚µã‚¤ãƒˆãŒä¸Šä½ã«ãƒ©ãƒ³ã‚¯ã•ã‚ŒãŸã€‚å対派ã®å ´åˆAmebaブログやgooã¨ã„ã£ãŸãƒ–ログã€YouTubeã€ãã—ã¦HPVワクãƒãƒ³è–¬å®³è¨´è¨Ÿå¼è­·å›£ã‚µã‚¤ãƒˆãªã©ãŒ5ä½ä»¥å†…ã«ãƒ©ãƒ³ã‚¯ã—ãŸã€‚最後ã«ã€ãƒ‡ãƒ¼ã‚¿ãŒæ€¥æ¿€ã«å¢—ãˆãŸ20å¹´ã®ãƒ‡ãƒ¼ã‚¿ã®ã¿ã‚’分æžã—ãŸçµæžœãŒè¡¨2ã§ã‚る。賛æˆæ´¾ã®å ´åˆã¯å¤§ããªå¤‰åŒ–ãŒãªã„ãŒã€å対派ã®å ´åˆãƒ¦ãƒ¼ãƒãƒ¥ãƒ¼ãƒ–ã®èºé€²ãŒç›®ç«‹ã¡ã€4ä½ã«ãƒ©ãƒ³ã‚¯ã•ã‚ŒãŸã€Œrapt-plusalphaã€ã¯å¤šãã®ãƒ•ã‚§ã‚¤ã‚¯ãƒ‹ãƒ¥ãƒ¼ã‚¹ã‚’掲載ã—ãŸå®Ÿç¸¾ã‚’æŒã¤é™°è¬€è«–サイトã§ã‚る。　ï¼]N）</blockquote> <span style="color:cornflowerblue;">â—†Ã_span>Maria, HORTLUND e4�al.　2018　"<b><u>Cervical cancer screening in Sweden</u></b>",　<i>PLoS One</i>　Ó0ë0-12:e020DSÔ0³0.　<a href="httpsa_/journals.plos.org/plosone/article?id=10.137þ]journal.pone.020DSÔ0³0">[外部サイト]</a> ※HTMLã‹ã‚‰å¼•ç”¨ã®ãŸã‚ページ数記載ãªã— <blockquote><b>Methods</b> We collected individual level data on all cervical cytologies, histopathologies, human papillomavirus tests and all invitations for cervical screening in Sweden during 20Ó0ë0(�TS)�016. <b>ResultsÃ_b> There were over(��N)�(�4l)�78,000 cervical samples collected in Sweden in(��N)�014?2016. Organized samples (resulting from an invitation) constituted 69% of samples. The screening tes4�coverage of all resident women aged Õ0¡0é0Ã0É0?60 was (�´R)�%. The coverage has slowly increased for >10 years. There is large variability between counties (from .�.�to 92%) over time. There were 25,725 women with high-grade lesions in cytology during 20Ó0ë0(�TS)�015. Onl9�96.�.�of these women had a follow-up histopatholog9�within a year. Cervical cancer incidence showed an increasing trend. <b>Conclusion</b> Ke9�qualit9�indicators such as population coverage and follow-up rates were stable or improving, but there was nevertheless an unexplained cervical cancer increase. 以下機械翻訳（DeepL）： <b>方法Ã_b>(�)�013å¹´ã‹ã‚‰2016å¹´ã«ã‚¹ã‚¦ã‚§ãƒ¼ãƒ‡ãƒ³ã§è¡Œã‚ã‚ŒãŸã™ã¹ã¦ã®å­å®®é ¸éƒ¨ç´°èƒžè¨ºã€ç—…ç†çµ„織診ã€ãƒ’トパピローマウイルス検査ã€å­å®®é ¸éƒ¨ã‚¹ã‚¯ãƒªãƒ¼ãƒ‹ãƒ³ã‚°ã®ã™ã¹ã¦ã®æ¡ˆå†…ã«ã¤ã„ã¦å€‹äººãƒ¬ãƒ™ãƒ«ã®ãƒ‡ãƒ¼ã‚¿ã‚’åŽé›†ã—ãŸã€‚ <b>çµæžœ</b> 2014(�(g)�016å¹´ã«ã‚¹ã‚¦ã‚§ãƒ¼ãƒ‡ãƒ³ã§æŽ¡å–ã•ã‚ŒãŸå­å®®é ¸éƒ¨ã‚µãƒ³ãƒ—ルã¯2,278,000以上ã§ã‚ã£ãŸã€‚組織化ã•ã‚ŒãŸã‚µãƒ³ãƒ—ル（招待ã«èµ·å› ã™ã‚‹ï¼‰ãŒã‚µãƒ³ãƒ—ルã®69％を構æˆã—ã¦ã„ãŸã€‚Õ0¡0é0Ã0É0～60æ­³ã®å…¨åœ¨ä½å¥³æ€§ã®ã‚¹ã‚¯ãƒªãƒ¼ãƒ‹ãƒ³ã‚°æ¤œæŸ»ã‚«ãƒãƒ¼çŽ‡ã¯82ï¼…ã§ã‚ã£ãŸã€‚ã‚«ãƒãƒ¼çŽ‡ã¯10年以上ã«ã‚ãŸã£ã¦ã‚†ã£ãã‚Šã¨å¢—加ã—ã¦ã„る。郡ã«ã‚ˆã£ã¦å¤§ããªã°ã‚‰ã¤ããŒã‚る（ï¼…ã‹ã‚‰92％）。20Ó0ë0ï½pS015å¹´ã®é–“ã«ç´°èƒžè¨ºã§é«˜ã‚°ãƒ¬ãƒ¼ãƒ‰ã®ç—…変ãŒã‚ã£ãŸå¥³æ€§ã¯25,725人ã§ã‚ã£ãŸã€‚ã“れらã®å¥³æ€§ã®ã†ã¡ã€1年以内ã«ãƒ•ã‚©ãƒ­ãƒ¼ã‚¢ãƒƒãƒ—ã®ç—…ç†çµ„織検査をå—ã‘ãŸã®ã¯96ï¼…ã®ã¿ã§ã‚ã£ãŸã€‚å­å®®é ¸ãŒã‚“罹患率ã¯å¢—加傾å‘を示ã—ãŸã€‚ <b>çµè«–Ã_b> 人å£ã‚«ãƒãƒ¼çŽ‡ã‚„フォローアップ率ãªã©ã®ä¸»è¦ãªå“質指標ã¯å®‰å®šã—ã¦ã„ã‚‹ã‹æ”¹å–„ã—ã¦ã„ãŸãŒï¼Œãã‚Œã«ã‚‚ã‹ã‹ã‚らãšï¼ŒåŽŸå› ä¸æ˜Žã®å­å®®é ¸ãŒã‚“ã®å¢—加ãŒè¦‹ã‚‰ã‚ŒãŸã€‚</blockquote> <blockquote>The increase in cervical cancer is both unexpected (there has been no previous increases for 50 years) and unexplained (no quality indicators have suggested a deterioration of qualit9�that could explain the increase in the disease). 以下機械翻訳（DeepL）： å­å®®é ¸ãŒã‚“ã®å¢—加ã¯ã€äºˆæƒ³å¤–ã§ã‚り（éŽåŽ»50å¹´é–“ã€å¢—加ã¯ãªã‹ã£ãŸï¼‰ã€ã‹ã¤åŽŸå› ä¸æ˜Žã§ã‚る（増加を説明ã§ãるよã†ãªå“質指標ã®æ‚ªåŒ–ãŒç¤ºå”†ã•ã‚Œã¦ã„ãªã„）。</blockquote> <span style="color:cornflowerblue;">â—†</span>Suzuki, S・Hosono, A　2018　"<b><u>No association between HPV vaccine and reported post-vaccination symptoms in Japanese young women: results of the Nagoya studyÃ_u>Ã_b>",　<i>Papillomavirus Research</i>　5:96-1Ô0³0　<a href="https:å]www.sciencedirect.coÛwscienc0uarticl0upi}v2�3�4058(�yr)��Ú0½000708?via%3Dihub">[外部サイト]</a> ※HTMLã‹ã‚‰å¼•ç”¨ã®ãŸã‚ページ数記載ãªã— <blockquote>Mos4�women who develo0�cervical cancer are either under-screened or never-screened. The cervical cancer screening rate in Europe and Northern America, is roughly 80%<�s�p�a�n� �c�l�a�s�s�=�"�n�a�k�e�d�_�s�i�g�n�"�>�; <�/�s�p�a�n�>�<�s�p�a�n� �c�l�a�s�s�=�"�n�a�k�e�d�_�a�u�r�a�l�"�>�(�èlŠ)�<�/�s�p�a�n�>�however, in Japan it was onl9�37.7.�.�in(��N)�011. 以下機械翻訳（DeepL）： å­å®®é ¸ãŒã‚“を発症ã™ã‚‹å¥³æ€§ã®å¤šãã¯ã€æ¤œè¨ºã‚’å—ã‘ãªã‹ã£ãŸã‚Šã€å—ã‘ã¦ã„ãªã‹ã£ãŸã‚Šã—ã¾ã™ã€‚欧米ã§ã¯å­å®®é ¸ãŒã‚“検診ã®å—診率ã¯ç´„80ï¼…ã§ã™ãŒã€æ—¥æœ¬ã§ã¯20�å¹´ã®æ™‚点ãm�"s�7.7ï¼…ã«ã¨ã©ã¾ã£ã¦ã„ã¾ã™ã€‚ </blockquote> <blockquote>In January(��N)�014, following clinical evaluation of individual cases, the MHLW concluded tha4�the reported post-vaccination symptoms were no4�causally associated with HPV vaccination but were psychosomatic responses. Despite this statement, the MHL2 2 2 2 insisted tha4�further studies were required before once again promoting the use of HPV vaccines. I4�has been argued that this decision was not based on adequate scientific evidence because the Japanese vaccination system suffers from a failure of governance. The decision to suspend proactive recommendations for the HPV vaccines traveled globall9�through online networks and social media and was applauded b9�antivaccination groups but not b9�the global scientific community. 以下機械翻訳（DeepL）： 2014å¹´1月ã€åŽšç”ŸåŠ´åƒçœã¯ã€å€‹ã€…ã®ç—‡ä¾‹ã®è‡¨åºŠè©•ä¾¡ã‚’è¡Œã£ãŸçµæžœã€å ±å‘Šã•ã‚ŒãŸæŽ¥ç¨®å¾Œã®ç—‡çŠ¶ã¯HPVワクãƒãƒ³æŽ¥ç¨®ã¨ã®å› æžœé–¢ä¿‚ã¯ãªãã€å¿ƒèº«ç—‡åå¿œã§ã‚ã‚‹ã¨çµè«–付ã‘ã¾ã—ãŸã€‚ã“ã®å£°æ˜Žã«ã‚‚ã‹ã‹ã‚らãšã€åŽšç”ŸåŠ´åƒçœã¯ã€å†ã³HPVワクãƒãƒ³ã®ä½¿ç”¨ã‚’促進ã™ã‚‹å‰ã«ã€ã•ã‚‰ãªã‚‹ç ”究ãŒå¿…è¦ã§ã‚ã‚‹ã¨ä¸»å¼µã—ã¾ã—ãŸã€‚ã“ã®æ±ºå®šã¯ã€æ—¥æœ¬ã®äºˆé˜²æŽ¥ç¨®åˆ¶åº¦ãŒã‚¬ãƒãƒŠãƒ³ã‚¹ã®æ¬ å¦‚ã«è‹¦ã—ã‚“ã§ã„ã‚‹ãŸã‚ã€å分ãªç§‘学的証拠ã«åŸºã¥ã„ã¦ã„ãªã„ã¨ä¸»å¼µã•ã‚Œã¦ã„る。HPVワクãƒãƒ³ã®ç©æ¥µçš„ãªæŽ¨å¥¨ã‚’中止ã™ã‚‹æ±ºå®šã¯ã€ã‚ªãƒ³ãƒ©ã‚¤ãƒ³ãƒãƒƒãƒˆãƒ¯ãƒ¼ã‚¯ã‚„ソーシャルメディアを通ã˜ã¦ä¸–界中ã«ä¼ã‚ã‚Šã€åワクãƒãƒ³å›£ä½“ã‹ã‚‰ã¯ç§°è³›ã•ã‚ŒãŸãŒã€ä¸–ç•Œã®ç§‘学界ã‹ã‚‰ã¯æ­“è¿Žã•ã‚Œãªã‹ã£ãŸã€‚</blockquote> <blockquote>Other reasons include enhanced negative psychological effects in response to negative opinions about HPV vaccination and because memor9�of vaccine-associated symptoms faded as time passed. Marked changes in ORs over a shor4�interval are unlikel9�to have a biological cause and suggest the involvement of socia-psychological factors an(uor changes in the characteristics of subjects with vaccination coverage. 以下機械翻訳（DeepL）： ã¾ãŸï¼ŒHPV ワクãƒãƒ³æŽ¥ç¨®ã«å¯¾ã™ã‚‹å¦å®šçš„ãªæ„見ã«å¯¾ã—ã¦å¦å®šçš„ãªå¿ƒç†çš„影響ãŒå¼·ã¾ã£ãŸã“ã¨ã‚„，ワクãƒãƒ³æŽ¥ç¨®ã«ä¼´ã†ç—‡çŠ¶ã®è¨˜æ†¶ãŒæ™‚é–“ã®çµŒéŽã¨ã¨ã‚‚ã«è–„ã‚ŒãŸã“ã¨ãªã©ã‚‚ç†ç”±ã¨ã—ã¦æŒ™ã’られãŸï¼ŽçŸ­æœŸé–“ã§ã® OR ã®é¡•è‘—ãªå¤‰åŒ–ã¯ï¼Œç”Ÿç‰©å­¦çš„ãªåŽŸå› ã¨ã¯è€ƒãˆã«ãã，社会心ç†å­¦çš„ãªè¦å› ã®é–¢ä¸Žã‚„接種対象者ã®ç‰¹æ€§ã®å¤‰åŒ–ãŒç¤ºå”†ã•ã‚Œã‚‹</blockquote> <blockquote>In this large-scale survey in Nagoya, Japan, we found that the HPV vaccines were not significantly associated with the occurrence of(��N)�2 2 2 reported symptoms, thus suggesting no causal association between the vaccines and reported symptoms or adverse events. 以下機械翻訳（DeepL）： 今回ã®åå¤å±‹ã§ã®å¤§è¦æ¨¡ãªèª¿æŸ»ã§ã¯ã€HPVワクãƒãƒ³ã¨24ã®å ±å‘Šã•ã‚ŒãŸç—‡çŠ¶ã®ç™ºç”Ÿã¨ã®é–“ã«æœ‰æ„ãªé–¢é€£ã¯èªã‚られãšã€ãƒ¯ã‚¯ãƒãƒ³ã¨å ±å‘Šã•ã‚ŒãŸç—‡çŠ¶ã‚„有害事象ã¨ã®é–“ã«å› æžœé–¢ä¿‚ã¯ãªã„ã“ã¨ãŒç¤ºå”†ã•ã‚ŒãŸã€‚<a href="#ss1801">â˜XÃ_a>, <a href="#ss18(�åe)�">â˜mQÃ_a>Ã_blockquote> <span id="s AS1" style="color:blue;">★Ã_span><span style="color:blue;"><b><u>疫学的調査ã¨åˆ†å­ç”Ÿç‰©å­¦çš„調査</u></b></span>　cf. <span style="color:cornflowerblue;">â—†Ã_span>G, Giannotta・N, Giannottaã€�N018　"<b><u>accines and neuroinflammationÃ_u>Ã_b>",　<i>In4�J Pub Health Safe</i>　3-163:2　<a href="httpsa_/www.hilarispublisher.coÛwopen-accestzvaccines-and-neuroinflammation.pdf">[外部サイト]</a> ※HTMLã‹ã‚‰å¼•ç”¨ã®ãŸã‚ページ数記載ãªã— <blockquote>Regarding the possible relationships between HPV vaccines and CRPS type I, at the molecular level, the cytokines typical of CRPS type I environment, with high levels of IL-1β, IL-6, and TNF-α, it is faithfully reproduced by the injection of HPV vaccines. Whereas in patients with POTS, sympathetic activation and parasympathetic withdrawal were associated with increased serum IL-6. IL-1β, IL-6 and TNF-α are strongly expressed after the injection of HPV vaccines, and in patients with CFS/ME, the same proinflammator9�cytokines are elevated. 　Suzuki and Hosono did no4�find an association between HPV vaccine and reported post-vaccination symptoms in Japanese young women. The survey tool was an anonymous postal questionnaire. 　As is evident, epidemiology uses differen4�investigative tools than molecular biology. In the case of HPV vaccine AEs, molecular biolog9�demonstrates wha4�epidemiology does no4�detect.（8） 以下機械翻訳（DeepL）： 　HPVワクãƒãƒ³ã¨CRPSâ… åž‹ã®é–¢ä¿‚ã®å¯èƒ½æ€§ã«ã¤ã„ã¦ã€åˆ†å­ãƒ¬ãƒ™ãƒ«ã§ã¯ã€IL-1βã€IL-6ã€TNF-αãŒé«˜å€¤ã§ã€CRPSⅠ型環境ã«å…¸åž‹çš„ãªã‚µã‚¤ãƒˆã‚«ã‚¤ãƒ³ã§ã‚ã‚Šã€ãã‚Œã¯HPVワクãƒãƒ³æ³¨å°„ã«ã‚ˆã£ã¦å¿ å®Ÿã«å†ç¾ã•ã‚Œã‚‹ã€‚一方ã€ä½“ä½æ€§é »è„ˆç—‡å€™ç¾¤æ‚£è€…ã§ã¯ã€äº¤æ„Ÿç¥žçµŒã®æ´»æ€§åŒ–ã¨å‰¯äº¤æ„Ÿç¥žçµŒã®é›¢è„±ãŒã€è¡€æ¸…IL-6ã®ä¸Šæ˜‡ã¨é–¢é€£ã—ã¦ã„ã‚‹ã“ã¨ãŒã‚ã‹ã£ãŸã€‚IL-1βã€IL-6ã€TNF-αã¯ã€HPVワクãƒãƒ³æ³¨å°„後ã«å¼·ã発ç¾ã—ã€CFS/ME患者ã§ã¯ã€åŒã˜ç‚Žç—‡æ€§ã‚µã‚¤ãƒˆã‚«ã‚¤ãƒ³ãŒä¸Šæ˜‡ã™ã‚‹ã€‚ 　Suzukiã¨Hosonoã¯ã€æ—¥æœ¬ã®è‹¥ã„女性ã«ãŠã„ã¦ã€HPVワクãƒãƒ³ã¨å ±å‘Šã•ã‚ŒãŸãƒ¯ã‚¯ãƒãƒ³æŽ¥ç¨®å¾Œã®ç—‡çŠ¶ã¨ã®é–“ã«é–¢é€£æ€§ã‚’見ã„ã ã›ãªã‹ã£ãŸã€‚調査ツールã¯ã€åŒ¿åã®éƒµä¾¿ã‚¢ãƒ³ã‚±ãƒ¼ãƒˆã§ã‚る。 　明らã‹ãªã‚ˆã†ã«ã€ç–«å­¦ã¯åˆ†å­ç”Ÿç‰©å­¦ã¨ã¯ç•°ãªã‚‹èª¿æŸ»æ‰‹æ®µã‚’用ã„る。HPV ワクãƒãƒ³ã®æœ‰å®³äº‹è±¡ã®å ´åˆã€åˆ†å­ç”Ÿç‰©å­¦ã¯ç–«å­¦ã§ã¯æ¤œå‡ºã§ããªã„ã“ã¨ã‚’明らã‹ã«ã™ã‚‹ã€‚Ã_blockquote> <span id="s AS2" style="color:blue;">★Ã_span><span style="color:blue;"><b><u>åŒæ§˜ã®ãƒ‡ãƒ¼ã‚¿ã‚’用ã„ãŸç•°ãªã‚‹ç ”究Ã_u>Ã_b>Ã_span>　cf. <span style="color:cornflowerblue;">â—†</span>YAJU, Yukari・TSUBAKI, Hiroe　2019　"<b><u>Safety concerns with human papilloma virus immunization in Japan: Analysis and evaluation of Nagoya City's surveillance data for adverse events</u></b>",　<i>Japan Journal of Nursing Science</i>　16.4:4Õ0£0ü0È0-449　<a href="https:å]onlinelibrary.wiley.coÛwdo}vfull/10.��/jjns.(�*h)�252">[外部サイト]Ã_a> ※HTMLã‹ã‚‰å¼•ç”¨ã®ãŸã‚ページ数記載ãªã— <blockquote><b>Abstract</b> <b>AimÃ_b> To assess the safet9�of human papilloma virus (HPV) vaccines by using data from the “Nagoya Cit9�Cervical Cancer Immunization Program Surveyâ€. <b>Methods</b> Unadjusted odds ratios (OR) were calculated between HPV-vaccinated cases and un-vaccinated controls. Age-stratified analyses were performed to evaluate the interaction between age and events. Adjusted ORs were also estimated with multiple logistic regression models. <b>ResultsÃ_b> In the 15µ6-year-old group, the unadjusted ORs were significantl9�higher for symptoms of memor9�impairment, dyscalculia, and involuntary movement. The age-adjusted multivariate analyses demonstrated tha4�the vaccinated cases were less likel9�than the unvaccinated controls to have experienced symptoms in almos4�all symptoms, except for two symptoms such as involuntar9�movement and weakness. However, stud9�period-adjusted multivariate analyses demonstrated tha4�the vaccinated cases were significantl9�more likel9�than un-vaccinated controls to have experienced symptoms of memory impairmen4�and involuntar9�movement. <b>Conclusions</b> Based on our analysis using data from the Nagoya Cit9�surveillance survey, a possible association between HPV vaccination and distinct symptoms such as cognitive impairment or movement disorders exists. A consisten4�causal relationshi0�between HPV vaccination and these symptoms remains uncertain. However, given the seriousness of symptoms, we believe tha4�a more comprehensive and large-scale study is essential to confirm the safet9�of HPV vaccination. 以下機械翻訳（DeepL）： <b>目的</b> 「åå¤å±‹å¸‚å­å®®é ¸ãŒã‚“予防接種事業調査ã€ã®ãƒ‡ãƒ¼ã‚¿ã‚’用ã„ã¦ã€ãƒ’ト乳頭腫ウイルス（HPV）ワクãƒãƒ³ã®å®‰å…¨æ€§ã‚’評価ã™ã‚‹ã“ã¨ã€‚ <b>方法</b> HPVワクãƒãƒ³æŽ¥ç¨®ä¾‹ã¨éžæŽ¥ç¨®ä¾‹ã¨ã®é–“ã®æœªèª¿æ•´ã‚ªãƒƒã‚ºæ¯”（OR）を算出ã—ãŸã€‚å¹´é½¢ã¨ã‚¤ãƒ™ãƒ³ãƒˆã®ç›¸äº’作用を評価ã™ã‚‹ãŸã‚ã«ã€å¹´é½¢å±¤åˆ¥åˆ†æžã‚’è¡Œã£ãŸã€‚ã¾ãŸã€å¤šé‡ãƒ­ã‚¸ã‚¹ãƒ†ã‚£ãƒƒã‚¯å›žå¸°ãƒ¢ãƒ‡ãƒ«ã‚’用ã„ã¦èª¿æ•´å¾Œã®ORを推定ã—ãŸã€‚ <b>çµæžœÃ_b> 15-16歳群ã§ã¯ã€è¨˜æ†¶éšœå®³ã€è¨ˆç®—障害ã€ä¸éšæ„é‹å‹•ã®ç—‡çŠ¶ã«ã¤ã„ã¦ã€æœªèª¿æ•´ã®ORãŒæœ‰æ„ã«é«˜å€¤ã§ã‚ã£ãŸã€‚年齢調整ã—ãŸå¤šå¤‰é‡è§£æžã§ã¯ã€ä¸éšæ„é‹å‹•ã‚„脱力感ã¨ã„ã£ãŸ2ã¤ã®ç—‡çŠ¶ã‚’除ãã»ã¼ã™ã¹ã¦ã®ç—‡çŠ¶ã«ãŠã„ã¦ã€ãƒ¯ã‚¯ãƒãƒ³æŽ¥ç¨®ä¾‹ã¯ãƒ¯ã‚¯ãƒãƒ³éžæŽ¥ç¨®å¯¾ç…§ä¾‹ã‚ˆã‚Šã‚‚症状を経験ã™ã‚‹ç¢ºçŽ‡ãŒä½Žã„ã“ã¨ãŒç¤ºã•ã‚ŒãŸã€‚ã—ã‹ã—，研究期間調整後ã®å¤šå¤‰é‡è§£æžã§ã¯ï¼Œãƒ¯ã‚¯ãƒãƒ³æŽ¥ç¨®ä¾‹ã¯ãƒ¯ã‚¯ãƒãƒ³éžæŽ¥ç¨®ä¾‹ã«æ¯”ã¹ï¼Œè¨˜æ†¶éšœå®³ã¨ä¸éšæ„é‹å‹•ã®ç—‡çŠ¶ã‚’経験ã™ã‚‹å¯èƒ½æ€§ãŒæœ‰æ„ã«é«˜ã„ã“ã¨ãŒç¤ºã•ã‚ŒãŸï¼Ž <b>çµè«–Ã_b> åå¤å±‹å¸‚ã®ã‚µãƒ¼ãƒ™ã‚¤ãƒ©ãƒ³ã‚¹èª¿æŸ»ã®ãƒ‡ãƒ¼ã‚¿ã‚’用ã„ãŸè§£æžã‹ã‚‰ï¼ŒHPVワクãƒãƒ³æŽ¥ç¨®ã¨èªçŸ¥éšœå®³ã‚„é‹å‹•éšœå®³ãªã©ã®æ˜Žç¢ºãªç—‡çŠ¶ã¨ã®é–“ã«é–¢é€£æ€§ãŒå­˜åœ¨ã™ã‚‹å¯èƒ½æ€§ãŒã‚ã‚‹ã“ã¨ãŒç¤ºã•ã‚ŒãŸï¼ŽHPVワクãƒãƒ³æŽ¥ç¨®ã¨ã“れらã®ç—‡çŠ¶ã¨ã®é–“ã«ä¸€è²«ã—ãŸå› æžœé–¢ä¿‚ãŒã‚ã‚‹ã‹ã©ã†ã‹ã¯ä¸æ˜Žã§ã‚る。ã—ã‹ã—，症状ã®é‡ç¯¤æ€§ã‹ã‚‰ï¼ŒHPVワクãƒãƒ³æŽ¥ç¨®ã®å®‰å…¨æ€§ã‚’確èªã™ã‚‹ãŸã‚ã«ã¯ï¼Œã‚ˆã‚ŠåŒ…括的ã§å¤§è¦æ¨¡ãªèª¿æŸ»ãŒä¸å¯æ¬ ã§ã‚ã‚‹ã¨è€ƒãˆã‚‹ï¼Ž<a href="#y,9">★Ã_a> </blockquote> <span id="yy19" style="color:blue;">★</span><span style="color:blue;"><b><u>言åŠÃ_u>Ã_b>Ã_span>　cf. <span style="color:cornflowerblue;">â—†</span>FUKUSHIMA, Wakaba et al.ã€�N(�åe)�2　"<b><u>A nationwide epidemiological survey of adolescent patients with diverse symptoms similar to those following human papillomavirus vaccination: background prevalence and incidence for considering vaccine safet9�in JapanÃ_u>Ã_b>",　<i>Journal of epidemiology</i>　(�>y)�.1Ú0ó0¹04-Ö0Ã0·0§0ë0　<a href="https:å]www.ncbi.nlm.nih.gov/pmc/articletzPMC866Ø0¯0¿0ü0ë0�.".">[外部サイト]Ã_a> ※HTMLã‹ã‚‰å¼•ç”¨ã®ãŸã‚ページ数記載ãªã— <blockquote>Reports similar to ours have not yet been published in terms of severity of diverse symptoms. The previous study in Nagoya, Japan, which targeted diverse symptoms among Japanese adolescent girls, differed from our survey not onl9�because it compared the odds of various symptoms in vaccinated and non-vaccinated girls, but also because it evaluated milder symptoms, with cumulative incidences in unvaccinated girls of 0.2% to 25.6%. While tha4�stud9�showed no association between HPV vaccination and 24 symptoms by comparing vaccinated and unvaccinated girls, another stud9�re-analyzed the data and showed possible associations for several symptoms, such as cognitive impairment and movemen4�disorders. Tha4�stud9�used the same datase4�bu4�applied differen4�methodology, in terms of study period, interaction term, age adjustment, and selection of unvaccinated controls. Such discrepancies ma9�indicate the difficult9�of controlling confounding and reducing selection bias in the dataset. However, since our stud9�targeted different levels of symptoms, which were more severe and less frequent, findings from tha4�previous study are not directl9�relevant to our findings. 以下機械翻訳（DeepL）： 多様ãªç—‡çŠ¶ã®é‡ç—‡åº¦ã¨ã„ã†ç‚¹ã§ã¯ã€ç§ãŸã¡ã¨åŒæ§˜ã®å ±å‘Šã¯ã¾ã ç™ºè¡¨ã•ã‚Œã¦ã„ãªã„。日本ã®æ€æ˜¥æœŸå¥³å­ã®å¤šæ§˜ãªç—‡çŠ¶ã‚’対象ã¨ã—ãŸåå¤å±‹ã®å…ˆè¡Œç ”究ã¯ã€ãƒ¯ã‚¯ãƒãƒ³æŽ¥ç¨®å¥³å­ã¨éžæŽ¥ç¨®å¥³å­ã§å¤šæ§˜ãªç—‡çŠ¶ã®ç™ºç”Ÿç¢ºçŽ‡ã‚’比較ã—ã¦ã„ã‚‹ã ã‘ã§ãªãã€éžæŽ¥ç¨®å¥³å­ã§ã®ç´¯ç©ç™ºç”ŸçŽ‡ãŒ0.2ï¼…ï½pS5.6ï¼…ã¨è»½åº¦ã®ç—‡çŠ¶ã‚’評価ã—ã¦ã„る点ãŒæˆ‘々ã®èª¿æŸ»ã¨ã¯ç•°ãªã£ã¦ã„る。ãã®ç ”究ã§ã¯ã€ãƒ¯ã‚¯ãƒãƒ³æŽ¥ç¨®è€…ã¨éžæŽ¥ç¨®è€…ã®å¥³å…を比較ã—ã¦ã€HPVワクãƒãƒ³æŽ¥ç¨®ãóS4ã®ç—‡çŠ¶ã¨ã®é–“ã«é–¢é€£æ€§ãŒãªã„ã“ã¨ã‚’示ã—ãŸãŒã€åˆ¥ã®ç ”究ã§ã¯ã€ãƒ‡ãƒ¼ã‚¿ã‚’å†è§£æžã—ã€èªçŸ¥éšœå®³ã‚„é‹å‹•éšœå®³ãªã©ã„ãã¤ã‹ã®ç—‡çŠ¶ã«ã¤ã„ã¦é–¢é€£æ€§ã®å¯èƒ½æ€§ãŒã‚ã‚‹ã“ã¨ãŒç¤ºã•ã‚ŒãŸã€‚ã“ã®ç ”究ã§ã¯ã€åŒã˜ãƒ‡ãƒ¼ã‚¿ã‚»ãƒƒãƒˆã‚’用ã„ãŸãŒã€ç ”究期間ã€äº¤äº’作用項ã€å¹´é½¢èª¿æ•´ã€ãƒ¯ã‚¯ãƒãƒ³æœªæŽ¥ç¨®å¯¾ç…§ã®é¸æŠžã®ç‚¹ã§ç•°ãªã‚‹æ–¹æ³•ã‚’é©ç”¨ã—ã¦ã„る。ã“ã®ã‚ˆã†ãªä¸ä¸€è‡´ã¯ã€ãƒ‡ãƒ¼ã‚¿ã‚»ãƒƒãƒˆã«ãŠã‘る交絡ã®åˆ¶å¾¡ã¨é¸æŠžãƒã‚¤ã‚¢ã‚¹ã®ä½Žæ¸›ãŒå›°é›£ã§ã‚ã‚‹ã“ã¨ã‚’示ã—ã¦ã„ã‚‹ã®ã‹ã‚‚ã—ã‚Œãªã„。ã—ã‹ã—ã€æˆ‘々ã®ç ”究ã¯ã€ã‚ˆã‚Šé‡ãã€ã‚ˆã‚Šé »åº¦ã®ä½Žã„ã€ç•°ãªã‚‹ãƒ¬ãƒ™ãƒ«ã®ç—‡çŠ¶ã‚’対象ã¨ã—ã¦ã„ã‚‹ã®ã§ã€ãã®å…ˆè¡Œç ”究ã®çŸ¥è¦‹ã¯ã€æˆ‘々ã®çŸ¥è¦‹ã¨ç›´æŽ¥é–¢é€£ã¯ãªã„。</blockquote> <h4><span style="color:lightgrey;">â– Ã_span>医療倫ç†</h4> ç¦ç”°å…«å¯¿çµµ. HPV ワクãƒãƒ³ã®è‡¨åºŠåˆ©ç”¨ã‚’ã‚ãる倫ç†å•é¡Œ: 予防接種義務化ã¨ãƒ¯ã‚¯ãƒãƒ³æ”¿ç­–ã«é–¢ã™ã‚‹ä¸€è€ƒå¯Ÿ. 医学哲学 医学倫ç†,(��N)�009,(��N)�7: 52-59. <1�6�¹p><span style="color:lightgrey;">â– </span>å ±é“Ã_1�6�¹p> â—日経新èžã€Œå­å®®é ¸ãŒã‚“ワクãƒãƒ³ã€æœªæŽ¥ç¨®ã§ã‚‚「副作用ã€ã¨åŒã˜ç—‡çŠ¶ã€ httpa_/www.nikkei.coÛwarticl0uDGXLZO�0708ASW6(�O)�CR0000/ â—日経新èžã€Œå­å®®é ¸ãŒã‚“ワクãƒãƒ³å·¡ã‚ŠåŽšåŠ´çœãŒèª¿æŸ»çµæžœã€€åŽŸå‘Šå›£ã¯æ‰¹åˆ¤ã€ http:å]www.nikkei.com/article/DGXLZa��Ô0³00W6A(� g)�1C1CR800ñ] â—読売新èžã€Œå­å®®é ¸ãŒã‚“ワクãƒãƒ³éžæŽ¥ç¨®ã§ã‚‚「副作用ã€åŒç—‡çŠ¶ã€ httpa_/www.yomiuri.co.jp/nationaîv2016(�*h)�26-OYT1T50043.html <h3><span style="color:lightgrey;">â– Ã_span>ワクãƒãƒ³æ·»ä»˜æ–‡æ›¸ã‚ˆã‚Š</h3> <blockquote>Serious Adverse Reactions in the Entire Study Population 　　Across the clinical studies,(��N)�58 individuals (GARDASIL N = 128 or 0.8%<�s�p�a�n� �c�l�a�s�s�=�"�n�a�k�e�d�_�s�i�g�n�"�>�; <�/�s�p�a�n�>�<�s�p�a�n� �c�l�a�s�s�=�"�n�a�k�e�d�_�a�u�r�a�l�"�>�(�èlŠ)�<�/�s�p�a�n�>�placebo N = Ó0ë00 or 1.0%) out of 29Ñ0ü0Ä0Õ0¡0é0Ã0É0 (GARDASIL N = 15,706; AAHS control N = Ó0ë0,0Õ0¡0é0Ã0É0<�s�p�a�n� �c�l�a�s�s�=�"�n�a�k�e�d�_�s�i�g�n�"�>�; <�/�s�p�a�n�>�<�s�p�a�n� �c�l�a�s�s�=�"�n�a�k�e�d�_�a�u�r�a�l�"�>�(�èlŠ)�<�/�s�p�a�n�>�or saline placebo N = 594) individuals (9- through 45-year-old girls and women<�s�p�a�n� �c�l�a�s�s�=�"�n�a�k�e�d�_�s�i�g�n�"�>�; <�/�s�p�a�n�>�<�s�p�a�n� �c�l�a�s�s�=�"�n�a�k�e�d�_�a�u�r�a�l�"�>�(�èlŠ)�<�/�s�p�a�n�>�and 9- through(��N)�6-year-old boys and men) reported a serious systemic adverse reaction. 　　Of the entire stud9�population (29Ñ0ü0Ä0Õ0¡0é0Ã0É0 individuals), 0.04% of the reported serious systemic adverse reactions were judged to be vaccine related by the study investigator. The mos4�frequently (frequenc9�of 4 cases or greater with either GARDASIL, AAHS control, saline placebo, or the total of all three) reported serious systemic adverse reactions, regardless of causality, were: Headache [0.02% GARDASIL Ê0Î0 cases) vs. 0.(�åe)�.�.�AAHS control (2 cases)], 　　Gastroenteritis [0.(�åe)�.�.�GARDASIL (2 2 cases) vs. 0.02% AAHS control (�]N)� cases)], 　　Appendicitis [0.Ô0³0.�.�GARDASIL (5 cases) vs. 0.01% AAHS control (1 case)], 　　Pelvic inflammatory disease [0.(�åe)�.�.�GARDASIL (2 2 cases) vs. 0.03% AAHS control (4 cases)], Urinar9�trac4�infection [0.01% GARDASIL (�]N)� cases) vs. 0.(�åe)�.�.�AAHS control (2 cases)], 　　Pneumonia [0.01% GARDASIL (�]N)� cases) vs. 0.(�åe)�.�.�AAHS control (2 cases)], 　　Pyelonephritis [0.01.�.�GARDASIL (2 cases) vs. 0.02% AAHS control Ê0Î0 cases)], 　　Pulmonary embolism [0.01% GARDASIL (�]N)� cases) vs. 0.(�åe)�.�.�AAHS control (2 cases)]. 　　One case (0.006.�.�GARDASIL<�s�p�a�n� �c�l�a�s�s�=�"�n�a�k�e�d�_�s�i�g�n�"�>�; <�/�s�p�a�n�>�<�s�p�a�n� �c�l�a�s�s�=�"�n�a�k�e�d�_�a�u�r�a�l�"�>�(�èlŠ)�<�/�s�p�a�n�>�0.0% AAHS control or saline placebo) of bronchospasm<�s�p�a�n� �c�l�a�s�s�=�"�n�a�k�e�d�_�s�i�g�n�"�>�; <�/�s�p�a�n�>�<�s�p�a�n� �c�l�a�s�s�=�"�n�a�k�e�d�_�a�u�r�a�l�"�>�(�èlŠ)�<�/�s�p�a�n�>�and 2 cases (0.01% GARDASIL; 0.0.�.�AAHS control or saline placebo) of asthma were reported as serious systemic adverse reactions that occurred following an9�vaccination visit. 　　In addition, there was 1 individual in the clinical trials, in the grou0�that received GARDASIL, who reported two injection-site serious adverse reactions (injection-site pain and injection-site join4�movement impairment). 以下機械翻訳（DeepL）： 全試験集団ã«ãŠã‘ã‚‹é‡ç¯¤ãªå‰¯ä½œç”¨ 　臨床試験全体ã§ã€ŒN9,(�>y)�3å（GARDASIL N=15,706ã€AAHS対照N³3,(�åe)�3ã€ç”Ÿç†é£Ÿå¡©æ°´ãƒ—ラセボN=594）中258å（GARDASIL N=(�*h)�8ã€0.8%ã€ãƒ—ラセボN³30ã€L.0%）ã‹ã‚‰é‡åº¦ã®å…¨èº«æ€§å‰¯ä½œç”¨ãŒå ±å‘Šã•ã‚ŒãŸï¼ˆ9～45歳女å­ã€ãŠã‚ˆã³9ï½pS6歳男å­ã€ç”·å­ã¯å¯¾è±¡å¤–ã¨ã—ãŸï¼‰ã€‚ 　全試験å‚加者ï¼]N9,(�>y)�3å）ã®ã†ã¡ã€æ²»é¨“責任医師ãŒãƒ¯ã‚¯ãƒãƒ³ã¨é–¢é€£ã™ã‚‹ã¨åˆ¤æ–­ã—ãŸé‡ç¯¤ãªå…¨èº«æ€§å‰¯ä½œç”¨ã®å ±å‘Šã¯0.04ï¼…ã§ã—ãŸã€‚因果関係をå•ã‚ãšã€æœ€ã‚‚é »ç¹ã«å ±å‘Šã•ã‚ŒãŸï¼ˆGARDASILã€AAHSコントロールã€ç”Ÿç†é£Ÿå¡©æ°´ãƒ—ラセボã®ã„ãšã‚Œã‹ã€ã¾ãŸã¯3ã¤ã®åˆè¨ˆã§4例以上ã®é »åº¦ï¼‰é‡ç¯¤ãªå…¨èº«æ€§å‰¯ä½œç”¨ã¯ã€ä»¥ä¸‹ã®ã¨ãŠã‚Šã§ã—ãŸã€‚ 　頭痛［0.(�åe)�.�.�GARDASILï¼c�a�l�例） vs. 0.02% AAHS対照（2例）］〠　胃腸炎［0.02% GARDASIL（3例ï¼9�vs. 0.(�åe)�.�.�AAHS対照ï¼]N例）］〠　虫垂炎［0.Ô0³0.�.�GARDASIL（5例） vs. 0.02% AAHS対照（1例）］ã€2�Ô0³0.�.�GARDASIL（5例） vs. 0.01% AAHS対照（1例）]〠　骨盤内炎症性疾患 [0.02% GARDASIL（3例ï¼9�vs. 0.Ô0³0.�.�AAHS対照（4例）]〠　尿路感染ç—7�[0.01%GARDASILï¼]N例） vs. 0.03% AAHS対照（1例）]ã€2�GARDASILï¼]N例）vs AAHS対照（2例）0.02%］〠　肺炎［GARDASIL（2例）vs AAHS対照ï¼]N例）0.01%］〠　腎盂腎炎［GARDASILï¼]N例）vs AAHS対照（3例）0.02%］〠　肺塞栓症［GARDASIL（2例）vs AAHS対照ï¼]N例）0.01%ï¼½ãŒæŒ™ã’られã¾ã™ã€‚ 　ã¾ãŸã€ã„ãšã‚Œã‹ã®æŽ¥ç¨®å¾Œã«ç™ºç¾ã—ãŸé‡ç¯¤ãªå…¨èº«æ€§å‰¯ä½œç”¨ã¨ã—ã¦ã€æ°—管支痙攣1例（GARDASIL 0.006% AAHS対照ã¾ãŸã¯ç”Ÿç†é£Ÿå¡©æ°´ãƒ—ラセム�š0.0%）ãŠã‚ˆã³å–˜æTS例（GARDASIL 0.01% AAHS対照ã¾ãŸã¯ç”Ÿç†é£Ÿå¡©æ°´ãƒ—ラセボ）ãŒå ±å‘Šã•ã‚Œã¦ã„る。 　ã¾ãŸã€è‡¨åºŠè©¦é¨“ã«ãŠã„ã¦ã€GARDASIL投与群ã«1åã€æ³¨å°„部ä½ã®é‡ç¯¤ãªå‰¯ä½œç”óS件（注射部ä½ç–¼ç—›ã€æ³¨å°„部ä½é–¢ç¯€é‹å‹•éšœå®³ï¼‰ãŒå ±å‘Šã•ã‚Œã¦ã„ã¾ã™ã€‚ </blockquote> <span style="color:cornflowerblue;">â—†Ã_span>Forster, Victoria 　20(� g)�0828　,「å­å®®é ¸ãŒã‚“検診ã¨HPVワクãƒãƒ³ã€ç™½äººå¥³æ€§ã®æ™®åŠçŽ‡ãŒä½Žã„米国ã€ã€€ã€ŽForbes JAPANã€.　<a href="httpsa_/forbesjapan.com/articletzdetail/499Ó0ë0(�W)�/1/1">[外部サイト]</a> <blockquote>æ–°ãŸãªèª¿æŸ»ã‹ã‚‰ã¯ã€ç±³å›½ã§é€²è¡ŒæœŸã®å­å®®é ¸ï¼ˆã‘ã„）ãŒã‚“ã¨è¨ºæ–­ã•ã‚Œã‚‹æ•°ã®å¹´é–“上昇率ãŒã€ç™½äººå¥³æ€§ã®é–“ã§æœ€ã‚‚高ã‹ã£ãŸã“ã¨ãŒåˆ¤æ˜Žã—ãŸã€‚åˆæœŸæ®µéšŽã®å­å®®é ¸ãŒã‚“ã®è¨ºæ–­æ•°ã¯1å¹´ã«ã¤ãç´W.6ï¼…ã®å‰²åˆã§æ¸›ã£ã¦ãã¦ã„ã‚‹ãŒã€é€²è¡ŒæœŸã§è¨ºæ–­ã‚’å—ã‘る人ã®æ•°ã¯å¹´é–“1.5ï¼…ã®å‰²åˆã§å¢—ãˆã¦ã„ã¦ã€ç ”究者を困惑ã•ã›ã¦ã„る。Ã_blockquote> <blockquote>研究者らã¯è«–æ–‡ã®ä¸­ã§ã€Œæ¤œè¨ºã¨ãƒ¯ã‚¯ãƒãƒ³æŽ¥ç¨®ãŒã‚ã‚‹ã«ã‚‚ã‹ã‹ã‚らãšã€éŽåŽ»18å¹´é–“ã§é éš”病期ã®å­å®®é ¸ãŒã‚“ãŒæ¸›ã£ã¦ã„る人種・民æ—集団や米国内ã®åœ°åŸŸã€å¹´é½¢é›†å›£ã¯ä¸€ã¤ã‚‚存在ã—ãªã„ã€ã¨è¿°ã¹ã¦ã„る。</blockquote> <blockquote>研究者らã¯ã€å…¨ã¦ã®äººç¨®ã®é–“ã§é€²è¡Œå­å®®é ¸ãŒã‚“ã®è¨ºæ–­ãŒå¢—ãˆã¦ã„ã‚‹è¦å› ã«ã¤ã„ã¦ç›´æŽ¥çµè«–を出ã›ã¦ã„ãªã„ã‚‚ã®ã®ã€è‚¥æº€çŽ‡ã®å¢—加やåˆç”£å¹´é½¢ã®é«˜é½¢åŒ–ãŒã“ã†ã—ãŸã‚¿ã‚¤ãƒ—ã®å­å®®é ¸ãŒã‚“ã®å¢—加ã«å¯„与ã—ã¦ã„ã‚‹ã‹ã‚‚ã—ã‚Œãªã„ã¨ç¤ºå”†ã—ãŸã€‚Ã_blockquote> <blockquote>研究者らã¯è«–æ–‡ã®ä¸­ã§ã€Œå­å®®é ¸ãŒã‚“ã®DS％以上ã¯HPVãŒå¼•ãèµ·ã“ã—ã¦ã„る。白人女性ã®é–“ã§ãƒ¯ã‚¯ãƒãƒ³æŽ¥ç¨®çŽ‡ãŒä½Žã„ã“ã¨ã¨ã‚¬ã‚¤ãƒ‰ãƒ©ã‚¤ãƒ³ã«æ²¿ã£ãŸæ¤œè¨ºãŒè¡Œã‚ã‚Œã¦ã„ãªã„ã“ã¨ãŒã€ç™½äººå¥³æ€§ã®é–“ã§é éš”転移ã®å¢—加率ãŒé«˜ã¾ã‚Šã¤ã¤ã‚る傾å‘を引ãèµ·ã“ã—ã¦ã„ã‚‹å¯èƒ½æ€§ãŒã‚ã‚‹ã€ã¨è¿°ã¹ã¦ã„る。 ã¾ãŸç ”究者らã¯ã“ã®ç ”究çµæžœã‹ã‚‰ã€é»’人やヒスパニック系ã®å¥³æ€§ã®é–“ã§æ¤œè¨ºã®æ©Ÿä¼šãŒå°‘ãªã„ã“ã¨ãŒé éš”転移ã®è¨ºæ–­çŽ‡ãŒä»–より高ã„状æ³ã«ã¤ãªãŒã£ã¦ã„ã‚‹ã¨ã„ã†è€ƒãˆæ–¹ãŒç–‘å•è¦–ã•ã‚Œã‚‹ã¨è£œè¶³ã—ã¦ã„る。Ã_blockquote> <h3>â–˜016年以å‰ã®æŽ²è¼‰æƒ…å ±</h3> â—†2016/0r^10　「学校ã¸è¡ŒããŸã„――宮頸ãŒã‚“ワクãƒãƒ³ã¨å°‘女ãŸã¡ã€ï¼ˆä»®ï¼‰ ＊大熊ã•ã‚“より 未æ¥ã¸ã®ä¸å®‰ï½žå­å®®é ¸ãŒã‚“ワクãƒãƒ³ã¨å°‘女ãŸã¡ 「å­å®®é ¸ã‚¬ãƒ³ãƒ¯ã‚¯ãƒãƒ³ã€ã¨ç§°ã™ã‚‹è–¬æ¶²ã®æŽ¥ç¨®ã‚’å—ã‘ãŸå°‘女ãŸã¡ã®å¤šããŒã€ 中学ã€é«˜æ ¡ã‚’å’業ã™ã‚‹å¹´ä»£ã«ãªã‚Šã¾ã—ãŸã€‚ æ¿€ã—ã„ç—›ã¿ã‚„ã—ã³ã‚Œã€ã•ã‚‰ã«ã€è¨˜æ†¶éšœå®³ã‚‚発症ã™ã‚‹ä¾‹ãŒç›¸æ¬¡ãŽã€ 通学ã§ããšç•™å¹´ã‚’余儀ãªãã•ã‚Œã‚‹å°‘女ã¯å°‘ãªãã¨ã‚ñ35人ã«ä¸Šã‚Šã¾ã™ã€‚ 「学校ã«è¡Œã‘ãšå‹é”ã«ã‚‚会ãˆãªããªã£ãŸã€ã€‚å°†æ¥ã‚’悲観ã™ã‚‹å°‘女ãŸã¡ã®åˆ‡å®Ÿãªæ€ã„を〠ＮＨＫ大阪放é€å±€ãŒå–æã—ã€ãょã†ã®æ·±å¤œã®ç·åˆãƒ†ãƒ¬ãƒ“ 「ＮＥＸＴ　未æ¥ã®ãŸã‚ã«ã€ã§æ”¾é€ã•ã‚Œã¾ã™ã€‚ 関西ã§ã—ã‹ã¿ã‚‰ã‚Œãªã‹ã£ãŸã€Œã‹ã‚“ã•ã„熱視線ã€ã®è©•åˆ¤ãŒé«˜ã〠ã“ã‚Œã«ã€ã•ã‚‰ã«è¿½åŠ å–æã—ãŸç•ªçµ„。 タイトルã¯ã€Œå­¦æ ¡ã¸è¡ŒããŸã„　～å­å®®é ¸ãŒã‚“ワクãƒãƒ³ã¨å°‘女ãŸã¡ï½žï¼ˆä»®ï¼‰ã€ã§ã™ã€‚ ＮＨＫç·åˆã€€ï¼™æ—¥æ°´æ›œæ·±å¤œã€æ­£å¼ã«ã¯10æ—¥åˆå‰ï¼æ™‚10分～ï¼æ™‚40分。詳細ã¯ä»¥ä¸‹ã‚’。 <a href="http:å]www4.nhk.or.jp/next-mira}v">httpa_/www4.nhk.or.j:ynext-mirai/</a> â—†å­å®®é ¸ãŒã‚“（cervical cancer）ワクãƒãƒ³ã®çµŒéŽï¼ˆ20Ó0ë0å¹´6朅5日　京都新èžæœåˆŠï¼“é¢ã‹ã‚‰ï¼‰(�)�009å¹´10月　厚生労åƒçœãŒã‚°ãƒ©ã‚¯ã‚½ãƒ»ã‚¹ãƒŸã‚¹ã‚¯ãƒ©ã‚¤ãƒ³ç¤¾ã®å­å®®é ¸ãŒã‚“ワクãƒãƒ³ã€Œã‚µãƒ¼ãƒãƒªãƒƒã‚¯ã‚¹ã€ã‚’åˆæ‰¿èª(�)�011å¹´7月　厚労çœãŒMSD社ã®ãƒ¯ã‚¯ãƒãƒ³ã€Œã‚¬ãƒ¼ãƒ€ã‚·ãƒ«ã€ã‚’承èª(�)�013å¹´3月　ワクãƒãƒ³æŽ¥ç¨®ã‚’ã€åŽŸå‰‡ç„¡æ–™ã®ã€Œå®šæœŸæŽ¥ç¨®ã€ã®å¯¾è±¡ã¨ã—ã¦è¿½åŠ ã™ã‚‹æ”¹æ­£äºˆé˜²æŽ¥ç¨®æ³•ãŒå›½ä¼šã§æˆç«‹ 20Ó0ë0å¹´4朅日　ワクãƒãƒ³ãŒå®šæœŸæŽ¥ç¨®ã«(�)�013å¹´4月8日　民間団体ãŒé‡ã„å¥åº·è¢«å®³ã«è‹¦ã—む中高生ãŒå‡ºã¦ã„ã‚‹ã¨ã—ã¦ã€æŽ¥ç¨®ä¸­æ­¢ã‚’求ã‚る嘆願書を厚労çœã«æ出(�)�013å¹´5月16日　1968件ã®å‰¯ä½œç”¨ãŒå ±å‘Šã•ã‚ŒãŸã“ã¨ã‹ã‚‰ã€åŽšåŠ´çœã®å°‚門部会ã¯ãƒ¯ã‚¯ãƒãƒ³æŽ¥ç¨®ã¨å¥åº·è¢«å®³ã«é–¢é€£ãŒã‚ã‚‹ã‹ã©ã†ã‹ã‚’調査ã™ã¹ãã ã¨æ„見(�)�013å¹´6月14日　厚労çœã¯ã€ç©æ¥µçš„ã«æŽ¥ç¨®ã‚’呼ã³æŽ›ã‘ã‚‹ã“ã¨ã‚’一時中止ã™ã‚‹ã‚ˆã†å…¨å›½ã®è‡ªæ²»ä½“ã«å‹§å‘Š 　…… â—†å­å®®é ¸ãŒã‚“予防ワクãƒãƒ³å…¬è²»åŠ©æˆæŽ¨é€²å®Ÿè¡Œå§” 　<a href="httpsa_/twitter.com/hpvvaccination">httpsa_/twitter.com/hpvvaccination</a> ◆全国å­å®®é ¸ãŒã‚“ワクãƒãƒ³è¢«å®³è€…連絡会 　<a href="kyuukeigan.fem.jp.".">http:å]shikyuukeigan.fem.jp/</a> ◆全国å­å®®é ¸ãŒã‚“ワクãƒãƒ³è¢«å®³è€…連絡会・ツィッター 　<a href="httpsa_/twitter.com/shikyuukeigan01">https:å]twitter.coÛwshikyuukeigan01</a> ◆『ã¿ã‹ã‚Šã‚“ã®ã•ã•ã‚„ã――å­å®®é ¸ãŒã‚“ワクãƒãƒ³è¢«å®³ã®ãƒ–ログ〠　<a href="httpa_/ameblo.jpÔ0¯0ë0fujiko.".">http:å]ameblo.j:y3fujikówÃ_a> â—†<a href="../d/fms.htm">線維筋痛症</a> â–  â—N01^(�*h)�/16　「緊急報å‘+�å­å®®é ¸ãŒã‚“ワクãƒãƒ³æŽ¥ç¨®å¾Œã®éšœå®³ã€ 　ＮＨＫ・Ｅテレ『ãƒãƒ¼ãƒˆãƒãƒƒãƒˆï¼´ï¼¶ã€W014å¹´(�*h)�朅6日（ç«æ›œï¼‰20ES0～ 12月Õ0¡0é0Ã0É0日（ç«æ›œï¼‰ 　「ãƒãƒ¼ãƒˆãƒãƒƒãƒˆTVã€ã«18æ­³ã®å¥³æ€§ã‹ã‚‰å¯„ã›ã‚‰ã‚ŒãŸãƒ¡ãƒ¼ãƒ«ã€‚ 　「左å´ã®æ‰‹è¶³ãŒå…¨ãå‹•ã‹ã™äº‹ãŒå‡ºæ¥ãšã€ä»–ã«ã‚‚記憶障害ã§ã‚ã£ãŸã‚Šã€æ¯Žæ—¥å½“ãŸã‚Šå‰ã®æ§˜ã«ã‚ã‚‹é ­ç—›ã§å¯ãŸãã‚Šã«ãªã£ã¦ã—ã¾ã„ã€å­¦æ ¡ã«ã‚‚ãªã‹ãªã‹è¡Œã‘ãšã«ã„ã¾ã™ã€‚ä»–ã«ã‚‚ãŸãã•ã‚“日本中ã§æ‚©ã¿è‹¦ã—ã‚“ã§ã„る人é”ãŒã„ã¾ã™ã€‚ã¿ã‚“ãªå­å®®é ¸ãŒã‚“ワクãƒãƒ³ã‚’打ã£ã¦ã‹ã‚‰ä½“ã«ç•°å¸¸ãŒå‡ºã¦ã„ã¾ã™ã€‚ãã—ã¦ã¿ã‚“ãªã¯å…ƒã®ä½“ã«æˆ»ã‚ã†ã¨å¿…æ­»ã«æ¯Žæ—¥é—˜ã£ã¦ã„ã¾ã™ã€ 　å­å®®é ¸ãŒã‚“ã®äºˆé˜²åŠ¹æžœã‚’期待ã•ã‚Œã€2009å¹´ã«æ—¥æœ¬ã§ã‚‚承èªã•ã‚ŒãŸã€Œå­å®®é ¸ãŒã‚“ワクãƒãƒ³ï¼ˆHPVワクãƒãƒ³ï¼‰ã€ã€‚ã“ã‚Œã¾ã§ã«10代ã®å¥³æ€§ã‚’中心ãM�P�a�30万人以上ãŒæŽ¥ç¨®ã—ã¾ã—ãŸã€‚ã—ã‹ã—ã€ãƒ¯ã‚¯ãƒãƒ³æŽ¥ç¨®å¾Œã€åŽŸå› ä¸æ˜Žã®ä½“ã®ç—›ã¿ãªã©ã®ç—‡çŠ¶ã‚’訴ãˆã‚‹æ‚£è€…ãŒç›¸æ¬¡ã„ã§ã„ã¾ã™ã€‚難病ãªã©ã®å°‚門家ãŸã¡ã¯ç‹¬è‡ªã®ç ”究ãƒãƒ¼ãƒ ã‚’ç«‹ã¡ä¸Šã’調査を開始。ワクãƒãƒ³ã®å‰¯åå¿œã®å¯èƒ½æ€§ãŒã‚る症状ãŒå…¨å›½ã§1000件以上ã«ã®ã¼ã‚Šã€æŽ¥ç¨®å¾Œï¼‘年以上ãŒéŽãŽã¦ã‹ã‚‰æ·±åˆ»ãªç—‡çŠ¶ãŒç¾ã‚Œã‚‹ã‚±ãƒ¼ã‚¹ã‚‚多ã„ã“ã¨ãŒã‚ã‹ã£ã¦ãã¾ã—ãŸã€‚ã“ã†ã—ãŸçŠ¶æ³ã‚’å—ã‘ã€åŽšç”ŸåŠ´åƒçœã‚‚ã€ç—‡çŠ¶ãŒå‡ºãŸã™ã¹ã¦ã®äººã‚’対象ã¨ã—ãŸè¿½è·¡èª¿æŸ»ã®å®Ÿæ–½ã‚’決定。�月ã«ã¯é›»è©±ç›¸è«‡çª“å£ã‚’開設ã™ã‚‹ãªã©ã€å®Ÿæ…‹æŠŠæ¡ã¸ã®å¯¾å¿œãŒå§‹ã¾ã‚Šã¾ã—ãŸã€‚ 　番組ã§ã¯ã€å½“事者や家æ—ã®åˆ‡å®Ÿãªå£°ã€æ²»ç™‚ç¾å ´ãªã©ã‚’å–æ。今も一人ã§æ‚©ã‚“ã§ã„る人ã¸ã®æƒ…å ±æ供を目的ã«ç·Šæ€¥ç”Ÿæ”¾é€ã§ä¼ãˆã¾ã™ã€‚〠◆2014/1r^10　日本医師会・日本医学会もåˆåŒã‚·ãƒ³ãƒã‚¸ã‚¦ãƒ ã€Œå­å®®é ¸ãŒã‚“ワクãƒãƒ³ã«ã¤ã„ã¦è€ƒãˆã‚‹ã€ 　<a href="httpa_/jams.med.or.j:ysymposiuÛwpdf_sympa-poster_god˜°014.pdf">http:å]jams.med.or.jp/symposium/pdf_sympo-poster_godo2014.pdfÃ_a> â—N01^09/13　「症状ã®ï¼“分ã®ï¼‘ã¯ä¸­æž¢ç¥žçµŒç³»ã€€å­å®®é ¸ãŒã‚“ワクãƒãƒ³å•é¡Œã€ 　『æœæ—¥æ–°èžã€W01^09/12 < 　<a href="httpa_/apital.asahi.coÛwarticl0unews(�W)�0140300019.html">http:å]apital.asahi.com/article/newtz201409Ó0ë000019.htmlÃ_a> 　「å­å®®é ¸ï¼ˆã‘ã„）ãŒã‚“ワクãƒãƒ³ã®æŽ¥ç¨®å¾Œã«ä½“ã®ç•°å¤‰ã‚’訴ãˆã‚‹äº‹ä¾‹ãŒç›¸æ¬¡ã„ã§ã„ã‚‹å•é¡Œã§ã€æ±äº¬åŒ»ç§‘大医学ç·åˆç ”究所長ã®è¥¿å²¡ä¹…寿樹医師らã®ç ”究ç­ã¯ï¼‘３日ã€å›½ã«å‰¯ä½œç”¨ã¨ã—ã¦å ±å‘Šã•ã‚ŒãŸç´„２５ï¼ï¼äººã®ç—‡ä¾‹ã‚’独è‡a�ﾉ調ã¹ãŸã¨ã“ã‚ã€å»¶ã¹ï¼—６７６件ã®ç—‡çŠ¶ãŒç¢ºèªã•ã‚Œã€ã†ã¡ï¼“分ã®ï¼‘ãŒä¸­æž¢ç¥žçµŒã«ã‹ã‹ã‚る症状ã¨ã¿ã‚‰ã‚Œã‚‹ã¨ç™ºè¡¨ã—ãŸã€‚ 　研究ç­ãŒé•·é‡Žå¸‚ã§é–‹ã‹ã‚Œã¦ã„る日本<a href="../d/fms.htm">線維筋痛症</a>学会ã«é–¢é€£ã—ã¦è¨˜è€…会見ã—ãŸã€‚複数ã®ç—‡çŠ¶ãŒå‡ºã¦ã„る女性ãŒå¤šãã€æœ€å¤šã¯ä¸­æž¢ç¥žçµŒã®ç—‡çŠ¶ã‚’å«ã‚€ï¼–２種類。ワクãƒãƒ³ã¨ã®å› æžœé–¢ä¿‚ã¯ä¸æ˜Žã ãŒã€ã€Œè„³å†…ã§ç•°å¤‰ãŒèµ·ãã¦ã„ã‚‹å¯èƒ½æ€§ãŒã‚ã‚‹ã€ã¨ã—ã¦ã„る。 　研究ç­ã®ãƒ¡ãƒ³ãƒãƒ¼ã¯è¥¿å²¡åŒ»å¸«ï¼ˆãƒªã‚¦ãƒžãƒãƒ»è† åŽŸã€ˆã“ã†ã’ん〉病）ã€æ¨ªæµœå¸‚大å誉教授ã§å›½éš›åŒ»ç™‚ç¦ç¥‰å¤§ç†±æµ·ç—…院長ã®æ¨ªç”°ä¿Šå¹³åŒ»å¸«ï¼ˆå°å…科）ã€æ±äº¬æ…ˆæµä¼šåŒ»ç§‘大ã€é †å¤©å ‚大ãªã©ã®ç¥žçµŒå†…科ã€æ•´å½¢å¤–科ã€ç·åˆè¨ºç™‚科ã®åŒ»å¸«ã€ç”Ÿç‰©çµ±è¨ˆå­¦ã®å°‚門家ã®è¨ˆï¼—人。 　…「続ãã¯ãƒ­ã‚°ã‚¤ãƒ³ãƒ»ã”購入後ã«èª­ã‚ã¾ã™ã€ã€ â—N01^09/12　「å­å®®é ¸ãŒã‚“ワクãƒãƒ³:é‡ã„副作用１１１２人　研究ãƒãƒ¼ãƒ ã€ 　毎日新èžã€�N014å¹´09朅2æ—¥ã€G5時00分（最終更新　09月(�*h)�日　15æ™ñ6分） 　<a href="httpa_/mainichi.jp/selecËznews/p201409(�*h)�k0000e04(�åe)�27000c.html">http:å]mainichi.j:yselect/newtzä²01402k0000e040(� g)�7000c.htmlÃ_a> 　「◇厚労çœé›†è¨ˆã®ï¼‘７６人ã®ï¼–å€ä»¥ä¸Šã« 　副作用ãŒç›¸æ¬¡ã„ã§æŽ¥ç¨®å‹§å¥¨ãŒä¸­æ­¢ã•ã‚Œã¦ã„ã‚‹å­å®®é ¸ï¼ˆã‘ã„）ãŒã‚“ワクãƒãƒ³ã«ã¤ã„ã¦ã€ä»Šå¹´ï¼“月末ã¾ã§ã«é‡ã„副作用ãŒç¢ºèªã•ã‚ŒãŸæ‚£è€…ã¯ï¼‘１１２人ã«ä¸Šã‚‹ã¨ã®åˆ†æžçµæžœã‚’ã€é›£ç—…治療研究振興財団（å‚å£åŠ›ç†äº‹é•·ï¼‰ã®ç ”究ãƒãƒ¼ãƒ ãŒã¾ã¨ã‚ãŸã€‚厚生労åƒçœãŒé›†è¨ˆã—ãŸï¼‘７６人ã®ï¼–å€ä»¥ä¸Šã«ä¸Šã‚‹ã€‚ãƒãƒ¼ãƒ ã¯ã€ŒåŽšåŠ´çœã¯ç—‡ä¾‹ã‚’ç‹­ãã¨ã‚‰ãˆéŽãŽã ã€ã¨æŒ‡æ‘˜ã€èª¿æŸ»æ–¹æ³•ã®è¦‹ç›´ã—を求ã‚ã¦ã„る。１３日ã‹ã‚‰é•·é‡Žå¸‚ã§å§‹ã¾ã‚‹æ—¥æœ¬<a href=".Û](ufms.htm">線維筋痛症Ã_a>学会ã§å ±å‘Šã™ã‚‹ã€‚ 　å­å®®é ¸ãŒã‚“ワクãƒãƒ³ã¯ï¼’ï¼ï¼ï¼™å¹´ï¼‘２月ã‹ã‚‰ä»Šå¹´ï¼“月末ã¾ã§ã«ç´„３３８万人ãŒæŽ¥ç¨®ã—ã€ç´„２５ï¼ï¼äººã®å‰¯ä½œç”¨å ±å‘ŠãŒå¯„ã›ã‚‰ã‚ŒãŸã€‚厚労çœã®æœ‰è­˜è€…検討会ã¯ã€ç™ºç†±ã‚„失神ãªã©å®‰å…¨ä¸Šã®å¿ƒé…ã¯ãªã„ã¨åˆ¤æ–­ã—ãŸç—‡ä¾‹ã‚’除ãã€é‹å‹•éšœå®³ãªã©ã®ï¼‘７６人を詳ã—ã„分æžãŒå¿…è¦ãªé‡ã„副作用ã¨åˆ¤æ–­ã—ãŸã€‚ãã®ä¸Šã§ã€åŽŸå› ã¯ãƒ¯ã‚¯ãƒãƒ³ãã®ã‚‚ã®ã§ã¯ãªãã€æ³¨å°„ã®ç—›ã¿ã‚„ä¸å®‰ãŒå¼•ãèµ·ã“ã™ã€Œå¿ƒèº«ã®åå¿œã€ã«ã‚ˆã‚‹ã¨çµè«–付ã‘ãŸã€‚ 　一方ã€åŒè²¡å›£ã®ãƒãƒ¼ãƒ ã¯ç´„２５ï¼ï¼äººã®ç—‡ä¾‹ã«ã¤ã„ã¦ã€æ•‘急æ¬é€ã®å¿…è¦æ€§ã‚„後éºç—‡ã®æã‚Œãªã©ã‚’分æžã—ãŸçµæžœã€åŠæ•°è¿‘ã„１１１２人をé‡ã„副作用ã¨åˆ¤å®šã—ãŸã€‚多ã‹ã£ãŸã®ã¯ä¸­æž¢ç¥žçµŒéšœå®³ï¼ˆã‘ã„れんã€æ­©è¡Œéšœå®³ã€è¨˜æ†¶åŠ›ã®ä½Žä¸‹ãªã©ï¼‰â–½è¦–力やè´åŠ›ã®æ„Ÿè¦šå™¨éšœå®³â–½åºƒç¯„囲ã®ç—›ã¿??�ﾈã©ã§ã€ç—‡çŠ¶ãŒé‡ãªã£ãŸã‚Šå¤‰åŒ–ã—ãŸã‚Šã™ã‚‹ã‚±ãƒ¼ã‚¹ã‚‚多ã‹ã£ãŸã€‚ 　ãƒãƒ¼ãƒ ã«ã¯ç¥žçµŒå†…科ã€å°å…科ã€ç²¾ç¥žç§‘ãªã©ã®è‡¨åºŠåŒ»ç´„１ï¼äººãŒå‚加。ãƒãƒ¼ãƒ ã®åŒ»å¸«ãŒå®Ÿéš›ã«æ²»ç™‚ã—ãŸï¼”４人ã¯ã€æŽ¥ç¨®ã‹ã‚‰é‡ã„症状ãŒå‡ºã‚‹ã¾ã§ã®å¹³å‡æœŸé–“ãŒç´„８．５カ月ã ã£ãŸã€‚「接種後１カ月以上ã—ã¦ã‹ã‚‰ã®ç™ºç—‡ã¯å› æžœé–¢ä¿‚ãŒè–„ã„ã€ã¨ã™ã‚‹åŽšåŠ´çœæ¤œè¨Žä¼šã®è¦‹è§£ã¨ã¯ç•°ãªã‚‹çµæžœã«ãªã£ãŸã€‚ 　ãƒãƒ¼ãƒ ãƒªãƒ¼ãƒ€ãƒ¼ã®è¥¿å²¡ä¹…寿樹（ãã™ã）・æ±äº¬åŒ»ç§‘大医学ç·åˆç ”究所長ã¯ã€Œä¸€é€£ã®ç—‡çŠ¶ã¯ã€å¿ƒèº«å応よりもã€ãƒ¯ã‚¯ãƒãƒ³ã«å«ã¾ã‚Œã‚‹å…疫補助剤ã«åå¿œã—ã¦è„³ç¥žçµŒãŒç‚Žç—‡ã‚’èµ·ã“ã—ã¦ã„ã‚‹ã¨è§£é‡ˆã—ãŸæ–¹ãŒåˆç†çš„ã ã€ã¨æŒ‡æ‘˜ã™ã‚‹ã€‚日本医学会ãªã©ã«åƒã掛ã‘ã€æ²»ç™‚指é‡ã®ç­–定を急ãã¨ã„ã†ã€‚ 　厚労çœçµæ ¸æ„ŸæŸ“症課ã®æ‹…当者ã¯ã€Œï¼‘７６人ã¯è¿½è·¡èª¿æŸ»ã‚’ã™ã‚‹ãŒã€ãれ以外ã®ç—‡ä¾‹ã®å†èª¿æŸ»äºˆå®šã¯ãªã„。副作用ã®æƒ…å ±åŽé›†ã¯å ±å‘Šã®é …目を増やã™ãªã©å¼·åŒ–ã™ã‚‹ã€ã¨è©±ã—ã¦ã„る。ã€æ¸…æ°´å¥äºŒã€‘〠◆2014/0P_08　コロンビアã§ã‚‚å­å®®é ¸ç™Œãƒ¯ã‚¯ãƒãƒ³è¢«å®³ 　<a href="http:å]elangelopolita.com/index.php/component/kr^item/124-es-histeria-colectiva-o-son-efectos-secundarios-de-la-vacuna-contra-el-vph">http:å]elangelopolita.com/index.php/component/kr^item/124-es-histeria-colectiva-o-son-efectos-secundarios-de-la-vacuna-contra-el-vph</a> â—†2014/0 _27　ä¼èª¬ã®åŒ»å¸«ã‚’è¿Žãˆã¦ã€Žå­å®®é ¸ãŒã‚“ワクãƒãƒ³ã€è¢«å®³ã‚·ãƒ³ãƒ 薬害オンブズパースン会議事務局長ã®æ°´å£çœŸå¯¿ç¾Ž ã•ã‚“ã‹ã‚‰ï¼š 英国ã®è‡¨åºŠè–¬ç†å­¦è€…ã§ã€è–¬å®³ã‚¹ãƒ¢ãƒ³äº‹ä»¶ã§æ—¥æœ¬ã®è¢«å®³è€…ã®ãŸã‚ã«å°½åŠ›ã—ã€ã‚³ã‚¯ãƒ©ãƒ³ãƒ»ã‚»ãƒ³ã‚¿ï¼ãªã©ã®æ´»å‹•ã‚’通ã˜ã¦å¤šãã®äººã€…ã«å½±éŸ¿ã‚’与ãˆï¼˜ï¼˜æ­³ã®ä»Šã‚‚世界å„地ã«æ‹›ã‹ã‚Œã¦è¬›æ¼”活動をã—ã¦ã„る欧州医学界ã®ä¼èª¬çš„人物ã€ã‚¢ãƒ³ãƒ‰ãƒ«ãƒ¼ãƒ»ãƒ˜ãƒ«ã‚¯ã‚¹ãƒã‚¤ãƒžãƒ¼åŒ»å¸«ï¼¨ï¼°ï¼¶ãƒ¯ã‚¯ãƒãƒ³ï¼ˆå­å®®é ¸ãŒã‚“ワクãƒãƒ³ï¼‰è¢«å®³ã«ã¤ã„ã¦ã€ã„ã¡æ—©ã調査ãƒãƒ¼ãƒ ã‚’ç«‹ã¡ä¸Šã’ãŸè¥¿å²¡ä¹…寿樹教授（æ±äº¬åŒ»ç§‘大学医学ç·åˆç ”究所所長）をゲストã«æ‹›ãã€ï¼¨ï¼°ï¼¶ãƒ¯ã‚¯ãƒãƒ³è¢«å®³ã‚’通ã—ã¦ã€åŒ»è–¬å“監視ã®ç¾çŠ¶ã¨èª²é¡Œã«ã¤ã„ã¦è€ƒãˆã¾ã™ã€‚ <a href="http:å]www.yakugai.gr.j:ytopics/topic.php?id=873">http:å]www.yakugai.gr.j:ytopics/topic.php?id=873</a> <a href="http:å]www.yakugai.gr.j:ytopics/fil0usymposium%202014.7(�Ñ‘)�7%20leafle¬À0140(�¡Œ)�9.pdf">http:å]www.yakugai.gr.j:ytopics/fil0usymposium%202014.7(�Ñ‘)�7%20leafle¬À0140(�¡Œ)�9.pdf</a> 7月27日（日）１３時３ï¼åˆ†ï½žï¼‘７時 æ±äº¬å¤§å­¦é‰„門記念講堂（地下鉄「本郷三ä¸ç›®ã€å¾’歩１ï¼åˆ†ã€ã€Œæ±å¤§å‰ã€å¾’歩１５分） å‚加費無料・事å‰ç”³è¾¼ä¸è¦ãƒ»åŒæ™‚通訳付 医薬å“監視ï¼è¢«å®³å®Ÿæ…‹èª¿æŸ»å ±å‘Šï¼åˆ©ç›Šç›¸åå•ã‚’ã‚ãるパãƒãƒ«ãƒ‡ã‚£ã‚¹ã‚«ãƒƒã‚·ãƒ§ãƒ³ã‚‚。 â—N01^07(�W)�0　「å­å®®é ¸ãŒã‚“å¾åœ§ã‚’ã‚ã–ã™å°‚門家会議ã€ã«ãƒ¯ã‚¯ãƒãƒ³ãƒ¡ãƒ¼ã‚«ãƒ¼å…ƒéƒ¨é•· 　時事通信 7æœ]N0æ—¥(æ—¥) 　<a href="httpa_/headlines.yahoo.co.jp/hl?a=20140720-00000Ô0³06-jij-soci">httpa_/headlines.yahoo.co.jp/hl?a=20140720-00000Ô0³06-jij-sociÃ_a> 　「医師やå¼è­·å£«ã§ã¤ãる薬害オンブズパースン会議ãTS0æ—¥ã¾ã§ã«ã€å­å®®é ¸ï¼ˆã‘ã„）ãŒã‚“ã¨ãƒ¯ã‚¯ãƒãƒ³ã®å•“発活動を行ã†ã€Œå­å®®é ¸ãŒã‚“å¾åœ§ã‚’ã‚ã–ã™å°‚門家会議ã€ï¼ˆè­°é•·ãƒ»é‡Žç”°èµ·ä¸€éƒŽå‰è¿‘畿大学長）ã§ã€ãƒ¯ã‚¯ãƒãƒ³ãƒ¡ãƒ¼ã‚«ãƒ¼ã®ã‚°ãƒ©ã‚¯ã‚½ãƒ»ã‚¹ãƒŸã‚¹ã‚¯ãƒ©ã‚¤ãƒ³ï¼ˆGSK）ã®å…ƒéƒ¨é•·ãŒæ´»å‹•ã—ã¦ã„ã‚‹ã¨æŒ‡æ‘˜ã—ã€ä»–ã«ãƒ¡ãƒ¼ã‚«ãƒ¼é–¢ä¿‚者ãŒåœ¨ç±ã™ã‚‹ã‹ã‚’å°‹ã­ã‚‹è³ªå•æ›¸ã‚’é€ã£ãŸã€‚元部長ã¯GSKã§ãƒ¯ã‚¯ãƒãƒ³ãƒžãƒ¼ã‚±ãƒ†ã‚£ãƒ³ã‚°éƒ¨é•·ã‚’å‹™ã‚ãŸå¾Œã€GSK在ç±æ­´ã‚’公表ã›ãšå°‚門家会議ã§æ´»å‹•ã—ã¦ã„る。 �　専門家会議ãTS012年度ã«GSKã‹ã‚ˆ500万円ã€ã‚‚ã†ä¸€ã¤ã®ãƒ¡ãƒ¼ã‚«ãƒ¼MSDã‹ã‚‰2000万円ã®å¯„付をå—ã‘ã¦ã„ãŸã€‚オンブズã¯6月ã€ä»–ã®å¹´ã®è³‡é‡‘å—領を開示ã™ã‚‹ã‚ˆã†æ±‚ã‚る質å•æ›¸ã‚’é€ä»˜ã€‚「中立性ã«å¼·ã„ç–‘å•ãŒã‚る。メーカーã¨ã®é–¢ä¿‚ã‚’é€æ˜ŽåŒ–ã™ã¹ãã ã€ã¨æŒ‡æ‘˜ã—ã¦ã„る。ã“ã‚Œã«å¯¾ã—専門家会議ã¯ã€å…ƒéƒ¨é•·ãŒGSK退è·å¾Œã®20�å¹´1月ã‹ã‚‰ä¼šè­°ã®äº‹æ¥­ã‚’å—託ã—ã€å¯¾ä¾¡ã‚’å—ã‘å–ã£ã¦ã„ã‚‹ã¨å›žç­”。メーカーã®è³‡é‡‘å—é ˜ã¯ã€Œé–‹ç¤ºã—ã¦ã„ãªã„ã€ã¨ã—ã€ä»–ã®é–¢ä¿‚者ã®åœ¨ç±ã«ã¤ã„ã¦ã‚‚「社員ãŒå±žã—ãŸã“ã¨ã¯ãªã„ã€ã¨ç­”ãˆã‚‹ã«ã¨ã©ã¾ã£ãŸã€‚ �　ワクãƒãƒ³ã‚’接種ã—ãŸäººãŒé•·æœŸã«ã‚ãŸã‚‹ç—›ã¿ã‚’訴ãˆã€æŽ¥ç¨®å‹§å¥¨ãŒä¸€æ™‚中断ã•ã‚ŒãŸå•é¡Œã§ã€å°‚門家会議ã¯ã€ŒåŠ¹æžœã¨å®‰å…¨ãŒç¢ºèªã•ã‚Œã¦ã„ã‚‹ã€ã¨ã—ã¦å‹§å¥¨å†é–‹ã‚’求ã‚ã¦ã„る。〠â—N01^07/15　「å­å®®é ¸ãŒã‚“ワクãƒãƒ³ 広ãŒã‚‹æ³¢ç´‹ã€ 　ＮＨＫã€G5時35分　久米兵衛記者 　<a href="http:å]wwd�m�.nhk.or.jp/newtzweb_tokushùz2014_05.html">httpa_/www3.nhk.or.j:ynews/web_tokushu(�W)�014_0715.html</a> 　「å­å®®é ¸ãŒã‚“ワクãƒãƒ³ã€ã€‚ 　ã“ã®ãƒ¯ã‚¯ãƒãƒ³ã®åå‰ã‚’耳ã«ã—ãŸã“ã¨ãŒã‚る方も多ã„ã¨æ€ã„ã¾ã™ã€‚ å­å®®é ¸ãŒã‚“を予防ã§ãる「夢ã®ãƒ¯ã‚¯ãƒãƒ³ã€ã¨æœŸå¾…ã•ã‚Œã€åŽ»å¹´ï¼”月ã€æ³•å¾‹ã«åŸºã¥ã「定期接種ã€ã«è¿½åŠ ã•ã‚Œã¾ã—ãŸãŒã€ã“ã®ï¼‘å¹´ã»ã¨ã‚“ã©æŽ¥ç¨®ã‚’å—ã‘る人ãŒã„ãªã„異例ã®çŠ¶æ…‹ãŒç¶šã„ã¦ã„ã¾ã™ã€‚ 　å­å®®é ¸ãŒã‚“ワクãƒãƒ³ã‚’å·¡ã£ã¦ä½•ãŒèµ·ãã¦ã„ã‚‹ã®ã‹�A社会部ã®ä¹…米兵衛記者ãŒè§£èª¬ã—ã¾ã™ã€‚ 定期接種ã‹ã‚‰ï¼’ã‹æœˆã§ã®æŽ¥ç¨®å‹§å¥¨ä¸­æ­¢ã€€å¹´é–“ã§ãŠã‚ˆã３ï¼ï¼ï¼äººãŒæ­»äº¡ã™ã‚‹å­å®®é ¸ãŒã‚“。 　「ヒトパピローマウイルスã€ã¨å‘¼ã°ã‚Œã‚‹ã‚¦ã‚¤ãƒ«ã‚¹ã«æ€§è¡Œç‚ºãªã©ã‚’通ã˜ã¦æ„ŸæŸ“ã—ã€é•·æœŸé–“ã€æ„ŸæŸ“ã—ãŸçŠ¶æ…‹ãŒç¶šãã¨å­å®®é ¸ãŒã‚“ã«ãªã‚‹ã¨è¨€ã‚ã‚Œã¦ã„ã¾ã™ã€‚ ã€€ãƒ‹ãƒ¥ãƒ¼ã‚¹ç”»åƒ ã€€ãƒ¯ã‚¯ãƒãƒ³ã‚’接種ã™ã‚Œã°å…¨ä½“ã®ï¼•å‰²ã‹ã‚‰ï¼—割程度ã®ç¨®é¡žã®ã‚¦ã‚¤ãƒ«ã‚¹ã¸ã®æ„ŸæŸ“を防ãŽã€ãŒã‚“ã«ãªã‚‹ãƒªã‚¹ã‚¯ã‚’減らã›ã‚‹ã¨ã—ã¦ã€åŽšç”ŸåŠ´åƒçœã¯åŽ»å¹´ï¼”月ã€å°å­¦ï¼–年生ã‹ã‚‰é«˜æ ¡ï¼‘年生ã¾ã§ã®å¥³å­ã‚’対象ã«æ³•å¾‹ã«åŸºã¥ã定期接種ã«è¿½åŠ ã—ã¾ã—ãŸã€‚ 　ã¨ã“ã‚ãŒã€æŽ¥ç¨®ã‚’å—ã‘ãŸäººãŒç›¸æ¬¡ã„ã§ä½“ã®ç—›ã¿ã‚’訴ãˆã€åŽšç”ŸåŠ´åƒçœã¯ã€Œãƒ¯ã‚¯ãƒãƒ³æŽ¥ç¨®ã¨ã®å› æžœé–¢ä¿‚ãŒå¦å®šã§ããªã„ã€ã¨ã—ã¦ã€åƒ…ã‹ï¼’ã‹æœˆå¾Œã®åŽ»å¹´ï¼–月ã€æŽ¥ç¨®ã‚’ç©æ¥µçš„ã«å‘¼ã³ã‹ã‘ã‚‹ã®ã‚’中止ã—ã¾ã—ãŸã€‚ 　厚生労åƒçœã®å¯¾å¿œã‚’å—ã‘ã¦ã€å…¨å›½ã®è‡ªæ²»ä½“もワクãƒãƒ³æŽ¥ç¨®ã‚’案内ã™ã‚‹ãƒãƒ©ã‚·ã®é€ä»˜ã‚’å–ã‚Šã‚„ã‚ã‚‹ãªã©å‘¼ã³ã‹ã‘を控ãˆã‚‹ã‚ˆã†ã«ãªã‚Šã€æŽ¥ç¨®ã‚’å—ã‘る人ã¯å…¨å›½ã§ã‚‚ã»ã¨ã‚“ã©ã„ãªããªã‚Šã¾ã—ãŸã€‚ 症状ã®åŽŸå› ã¯ï¼Ÿ 　呼ã³ã‹ã‘を中止ã—ã¦ï¼‘年。 　厚生労åƒçœã¯ã€ç ”究ç­ã‚’設ã‘ã¦ç—‡çŠ¶ã¨ãƒ¯ã‚¯ãƒãƒ³æŽ¥ç¨®ã¨ã®å› æžœé–¢ä¿‚を調ã¹ã¦ãã¾ã—ãŸã€‚ ã“ã‚Œã¾ã§ã«ãƒ¯ã‚¯ãƒãƒ³ã‚’接種ã—ãŸäººã¯æŽ¨å®šã§ï¼“３８万人。 　ã“ã®ã†ã¡é‡ã„症状を訴ãˆãŸã®ã¯ï¼‘７６人ã§ã€ï¼•ä¸‡å›žæŽ¥ç¨®ã™ã‚‹ã¨ï¼‘回ã®å‰²åˆã§ç—‡çŠ¶ãŒå‡ºã‚‹è¨ˆç®—ã§ã™ã€‚ ã€€ãƒ‹ãƒ¥ãƒ¼ã‚¹ç”»åƒ ã€€ã“ã†ã—ãŸç—‡çŠ¶ã«ã¤ã„ã¦ã€å›½ã®å°‚門家会議ã¯ã“ã¨ã—１月ã€ãƒ¯ã‚¯ãƒãƒ³ã¯ç­‹è‚‰ã«æ³¨å°„ã™ã‚‹ãŸã‚å¼·ã„ç—›ã¿ã‚’ä¼´ã†ã¨ã—ãŸã†ãˆã§ã€Œãƒ¯ã‚¯ãƒãƒ³ãã®ã‚‚ã®ãŒåŽŸå› ã§ã¯ãªãã€æŽ¥ç¨®ã®éš›ã®ä¸å®‰ã‚„ストレスãªã©å¿ƒç†çš„ãªè¦å› ã«ã‚ˆã£ã¦å¼•ãèµ·ã“ã•ã‚Œã‚‹â€œå¿ƒèº«ã®åå¿œâ€ã ã€ã¨ã„ã†è¦‹è§£ã‚’示ã—ã¾ã—ãŸã€‚ 　実際ã€ç ”究ç­ãŒã“ã®è¦‹è§£ã«åŸºã¥ã„ã¦ã‚«ã‚¦ãƒ³ã‚»ãƒªãƒ³ã‚°ãªã©ã®æ²»ç™‚ã‚’è¡Œã£ãŸï¼—ï¼äººã®æ‚£è€…ã®ã†ã¡ï¼—割近ã„人ã§ç—‡çŠ¶ã®æ”¹å–„ãŒè¦‹ã‚‰ã‚ŒãŸã¨ã—ã¦ã„ã¾ã™ã€‚ ãã®ä¸€æ–¹ã§ã€ç—‡çŠ¶ãŒæ”¹å–„ã—ã¦ã„ãªã„患者もã„ã¾ã™ã€‚ ã€€ãƒ‹ãƒ¥ãƒ¼ã‚¹ç”»åƒ ã€€ç¥žå¥ˆå·çœŒã«ä½ã‚€ä¸­å­¦ï¼“年生ã®å‰å·ä½³é‡Œã•ã‚“ã¯ã€ãŠã¨ã¨ã—å­å®®é ¸ãŒã‚“ワクãƒãƒ³ã‚’接種ã—ãŸã‚ã¨ã€å…¨èº«ã«å¼·ã„ç—›ã¿ã®ç—‡çŠ¶ãŒç¾ã‚Œè‡ªç”±ã«æ­©ãã“ã¨ãŒé›£ã—ããªã‚Šã¾ã—ãŸã€‚ 　１１ã®åŒ»ç™‚機関を転々ã¨ã—ã€ãƒ¯ã‚¯ãƒãƒ³ã®å½±éŸ¿ãŒç–‘ã‚れるã¨è¨ºæ–­ã•ã‚Œã¾ã—ãŸã€‚ 　今ã¯ã»ã¨ã‚“ã©å­¦æ ¡ã«é€šãˆãªããªã£ã¦ã„ã¾ã™ã€‚ 　å‰å·ã•ã‚“ã¯ã€Œå‡ºå¸­æ—¥æ•°ã‚‚足りãšã€å‹‰å¼·ã‚‚ã§ãã¦ã„ãªã„ã‹ã‚‰ã€é«˜æ ¡ã«è¡Œãã®ã¯é›£ã—ã„ã®ã§ã¯ãªã„ã‹ã€ã¨å°†æ¥ã¸ã®ä¸å®‰ã‚’語ã£ã¦ã„ã¾ã™ã€‚ “心身ã®åå¿œâ€ã«ç–‘å•ã®å£°ã‚‚ 　“心身ã®åå¿œâ€ã ã‘ã§ã¯èª¬æ˜Žã—ãã‚Œãªã„ã¨æŒ‡æ‘˜ã™ã‚‹å°‚門家もã„ã¾ã™ã€‚ 　厚生労åƒçœã®ç ”究ç­ã®ãƒ¡ãƒ³ãƒãƒ¼ã§ä¿¡å·žå¤§å­¦ç—…院ã®æ± ç”°ä¿®ä¸€åŒ»å¸«ã¯ã€ã“ã‚Œã¾ã§ãƒ¯ã‚¯ãƒãƒ³æŽ¥ç¨®å¾Œã®ç—›ã¿ãªã©ã‚’訴ãˆã‚‹ï¼•ï¼äººã®æ‚£è€…を診察ã—ã¦ãã¾ã—ãŸã€‚ ã€€ãƒ‹ãƒ¥ãƒ¼ã‚¹ç”»åƒ ã€€ç¥žçµŒãŒå¯†é›†ã™ã‚‹æŒ‡å…ˆã‚’é›»å­é¡•å¾®é¡ã§è©³ã—ã調ã¹ã‚‹ã¨ã€ç—›ã¿ã‚’æ„Ÿã˜ã‚‹ç¥žçµŒã®ä¸€éƒ¨ãŒé»’ã変色ã—ã¦æå‚·ã—ã¦ã„ãŸã¨ã„ã†ã“ã¨ã§ã™ã€‚ 　ãã“ã§ã€ç¥žçµŒã®å›žå¾©ã‚’促ã™è–¬ãªã©ã‚’投与ã—ãŸã¨ã“ã‚ã€ï¼—５％ã®æ‚£è€…ã§ç—‡çŠ¶ãŒæ”¹å–„ã—ãŸã¨è¨€ã„ã¾ã™ã€‚ 　池田医師ã¯ã€Œå¿ƒèº«ã®åå¿œã§ã¯ãªãã€ç¥žçµŒã®éšœå®³ãŒç—›ã¿ã‚’引ãèµ·ã“ã—ã¦ã„ã‚‹ã®ã§ã¯ãªã„ã‹ã€ã¨æŒ‡æ‘˜ã—ã¦ã„ã¾ã™ã€‚ 　ã¾ãŸã€é•·å¹´é›£ç—…を研究ã—ã¦ããŸæ±äº¬åŒ»ç§‘大学医学ç·åˆç ”究所ã®è¥¿å²¡ä¹…寿樹所長もã€å¿ƒèº«ã®åå¿œã§èª¬æ˜Žã™ã‚‹ã®ã¯ç„¡ç†ãŒã‚ã‚‹ã®ã§ã¯ãªã„ã‹ã¨è€ƒãˆã¦ã„ã¾ã™ã€‚ ã€€ãƒ‹ãƒ¥ãƒ¼ã‚¹ç”»åƒ ã€€ã“ã‚Œã¾ã§ã«è¨ºå¯Ÿã—ãŸï¼’５人ã®æ‚£è€…ã®ç—‡çŠ¶ã‚’分æžã—ãŸçµæžœã€ä½“ã®ç—›ã¿ã ã‘ã§ãªãã€ç–²åŠ´æ„Ÿã‚„ã€è¨˜æ†¶åŠ›ã‚„読解力ã®ä½Žä¸‹ãªã©ã€ï¼’ï¼ç¨®é¡žã«ã‚‚åŠã¶ç—‡çŠ¶ãŒç¢ºèªã§ããŸã¨ã„ã†ã“ã¨ã§ã™ã€‚ 西岡所長ã¯ã€Œã“ã‚Œã¾ã§ã®æ¦‚念ã§ã¯æ‰ãˆãã‚Œãªã„éžå¸¸ã«å¤šæ§˜ãªç—‡çŠ¶ãŒè¦‹ã¤ã‹ã£ã¦ã„る。ã•ã¾ã–ã¾ãªç—‡çŠ¶ã‚’ワクãƒãƒ³ã«é–¢é€£ã—ãŸã‚‚ã®ã¨æ‰ãˆã¦ã€åŽŸå› ã‚’解明ã—ã¦ã„ãå¿…è¦ãŒã‚ã‚‹ã€ã¨æŒ‡æ‘˜ã—ã¦ã„ã¾ã™ã€‚ 　ã“ã†ã—ãŸæŒ‡æ‘˜ã«å¯¾ã—ã€åŽšç”ŸåŠ´åƒçœã®æ‹…当者ã¯ã€Œä½“ã®ç—›ã¿ä»¥å¤–ã«ã‚‚ã•ã¾ã–ã¾ãªç—‡çŠ¶ã‚’訴ãˆã‚‹æ‚£è€…ãŒã„ã‚‹ã®ã¯æŠŠæ¡ã—ã¦ã„ã‚‹ãŒã€ä»Šã¾ã§é›†ã‚ãŸãƒ‡ãƒ¼ã‚¿ã‹ã‚‰ã¯ãƒ¯ã‚¯ãƒãƒ³æŽ¥ç¨®ã¨ã®å› æžœé–¢ä¿‚を示ã™è¨¼æ‹ ã¯è¦‹ã¤ã‹ã£ã¦ã„ãªã„ã€2�今後ã€æ–°ãŸãªãƒ‡ãƒ¼ã‚¿ãŒé›†ã¾ã‚Œã°ã€æ”¹ã‚ã¦æ¤œè¨¼ã—ãŸã„ã€ã¨è©±ã—ã¦ã„ã¾ã™ã€‚ 戸惑ã†ä¿è­·è€…ãŸã¡ã€€æŽ¥ç¨®ã®å‘¼ã³ã‹ã‘を中止ã—ã¦ã‹ã‚‰ï¼‘年。 　厚生労åƒçœã¯ã€Œãƒ¯ã‚¯ãƒãƒ³ã®æ„義ã¨ãƒªã‚¹ã‚¯ã‚’å分ã«ç†è§£ã—ãŸã†ãˆã§ã€ä¿è­·è€…ã¯å­ã©ã‚‚ã«æŽ¥ç¨®ã•ã›ã‚‹ã‹ã©ã†ã‹åˆ¤æ–­ã—ã¦ã»ã—ã„ã€ã¨ã—ã¦ã„ã¾ã™ã€‚ 　ã—ã‹ã—ä¿è­·è€…ã®é–“ã§ã¯ã€å›½ã‚„専門家ã®è¦‹è§£ãŒå®šã¾ã£ã¦ã„ãªã„ãªã‹ã§åˆ¤æ–­ã‚’委ã­ã‚‰ã‚Œã‚‹ã“ã¨ã«æˆ¸æƒ‘ã„ãŒåºƒãŒã£ã¦ã„ã¾ã™ã€‚ ã€€ãƒ‹ãƒ¥ãƒ¼ã‚¹ç”»åƒ ã€€ç¥žå¥ˆå·çœŒè—¤æ²¢å¸‚ã®ï¼“人姉妹ã®æ¯è¦ªã¯ãŒã‚“を予防ã§ãã‚‹ãªã‚‰ã¨ã€ã¾ãšé•·å¥³ã¨æ¬¡å¥³ã«æŽ¥ç¨®ã•ã›ã€é«˜æ ¡ç”Ÿã®ä¸‰å¥³ã«ã‚‚接種をå—ã‘ã•ã›ã‚‹äºˆå®šã§ã—ãŸã€‚ 　三女ã¯ã™ã§ã«å¿…è¦ãªï¼“回ã®æŽ¥ç¨®ã®ã†ã¡ï¼’回ã¾ã§çµ‚ãˆã¦ã„ã¾ã—ãŸãŒã€ä»Šå›žã®å•é¡Œã‚’å—ã‘ã¦ã€æœ€å¾Œã®æŽ¥ç¨®ã‚’１年以上見é€ã£ã¦ã„ã¾ã™ã€‚ ã€€ãƒ‹ãƒ¥ãƒ¼ã‚¹ç”»åƒ ã€€æ¯è¦ªã¯ã€ŒåŠ¹æžœãŒã‚ã‚‹ãªã‚‰æŽ¥ç¨®ã‚’å—ã‘ã•ã›ãŸã„ãŒã€å¨˜ã«ä¸‡ä¸€ã®ã“ã¨ãŒã‚ã£ãŸã‚‰ã¨æ€ã†ã¨�Sé…ã ã€‚打ã£ãŸã»ã†ãŒã„ã„ã®ã‹æ‰“ãŸãªã„ã»ã†ãŒã„ã„ã®ã‹ã€æ—©ãçµè«–を出ã—ã¦ã»ã—ã„ã€ã¨è©±ã—ã¦ã„ã¾ã—ãŸã€‚ 急ãŒã‚Œã‚‹æ¤œè¨¼ã¨æ²»ç™‚法ã®ç¢ºç«‹ 　ã“ã®ï¼‘å¹´ã§ãƒ¯ã‚¯ãƒãƒ³ã‚’巡る症状ã«ã¤ã„ã¦ç ”究ã¯é€²ã‚“ã§ã„ã¾ã™ãŒã€æŽ¥ç¨®ã¨ã®å› æžœé–¢ä¿‚ãŒè§£æ˜Žã•ã‚Œã¦ã„ãªã„ã“ã¨ã‚‚ã‚ã£ã¦ã€æŽ¥ç¨®ã®å‘¼ã³ã‹ã‘ã‚’å†é–‹ã™ã¹ãã‹ã©ã†ã‹ã€çµè«–ã¯ç°¡å˜ã«ã¯å‡ºãã†ã«ã‚ã‚Šã¾ã›ã‚“。 　厚生労åƒçœã«ã¯ï¼’ã¤ã®èª²é¡Œã«ã¤ã„ã¦å¯¾å¿œã‚’急ã„ã§ã»ã—ã„ã¨æ€ã„ã¾ã™ã€‚ 　ã¾ãšã¯ã€ãƒ¯ã‚¯ãƒãƒ³ã‚’接種ã—ãŸã‚ã¨é‡ã„症状ã«è‹¦ã—ã‚€å­ã©ã‚‚ãŸã¡ãŒä¸€åˆ»ã‚‚æ—©ãå…ƒã®ç”Ÿæ´»ã‚’å–り戻ã›ã‚‹ã‚ˆã†ã€æ²»ç™‚法を確立ã™ã‚‹ã“ã¨ã€‚ 　ãã—ã¦ã€ä¿è­·è€…ã‚„å­ã©ã‚‚ãŸã¡ãŒä¸å®‰ã‚’æ„Ÿã˜ãªã„よã†ã€ç—›ã¿ã‚‚å«ã‚ãŸã•ã¾ã–ã¾ãªç—‡çŠ¶ã¨ãƒ¯ã‚¯ãƒãƒ³æŽ¥ç¨®ã¨ã®å› æžœé–¢ä¿‚を徹底的ã«æ¤œè¨¼ã—ã¦ã„ãå¿…è¦ãŒã‚ã‚‹ã¨æ€ã„ã¾ã™ã€‚ã€ï¼ˆå…¨æ–‡ï¼‰ 　…… â—N01^(�åe)�(�W)�6　「å­å®®é ¸ãŒã‚“ワクãƒãƒ³ä¸­æ­¢è¨´ãˆã€éƒ½å†…ã§å›½éš›ã‚·ãƒ³ãƒã€€ã€Œã‚¢ãƒ«ãƒŸãŒå‰¯ä½œç”¨åŽŸå› ã€å°‚門家指摘〠　æ±äº¬æ–°èpS014å¹´2月26æ—¥ æœåˆŠ 　<a href="http:å]www.tokya-np.co.jp/article/nationaîvnews/CK20140(� g)�02000(�*h)�1.html">httpa_/www.tokyo-np.co.j:yarticl0unational/newtzCK2014(�åe)�26(�åe)�0001.html</a> 　「多ãã®å‰¯ä½œç”¨ãŒå ±å‘Šã•ã‚Œã¦ã„ã‚‹å­å®®é ¸ï¼ˆã‘ã„）ãŒã‚“ワクãƒãƒ³ã«ã¤ã„ã¦ã€å›½å†…外ã®åŒ»å­¦è€…らãŒäºŒå五日ã€æ±äº¬éƒ½å†…ã§å›½éš›ã‚·ãƒ³ãƒã‚¸ã‚¦ãƒ ã‚’é–‹ãã€æŽ¥ç¨®ã®ä¸­æ­¢ã‚’訴ãˆãŸã€‚厚生労åƒçœã®æœ‰è­˜è€…専門部会ã¯ä¸€æœˆã€å‰¯ä½œç”¨ã¯æ³¨å°„ã®ç—›ã¿ã¸ã®æ‚£è€…ã®ä¸å®‰ãŒå¼•ãèµ·ã“ã™ã€Œå¿ƒèº«ã®åå¿œã€ãŒåŽŸå› ã¨çµè«–付ã‘ãŸãŒã€åŒ»å­¦è€…らã¯ã€ãƒ¯ã‚¯ãƒãƒ³ã®åŠ¹æžœã‚’高ã‚ã‚‹ãŸã‚ã«å«ã¾ã‚Œã‚‹ç‰¹æ®Šãªã‚¢ãƒ«ãƒŸãƒ‹ã‚¦ãƒ ãŒå¼•ãèµ·ã“ã—ã¦ã„ã‚‹ã¨æŒ‡æ‘˜ã—ãŸã€‚ 　パリ大ã®ãƒ•ãƒ©ãƒ³ã‚½ãƒ¯ãƒ»ã‚ªãƒ¼ã‚·ã‚¨æ•™æŽˆï¼ˆç¥žçµŒç­‹è‚‰ç—…ç†å­¦ï¼‰ã¯ã€ãƒ¯ã‚¯ãƒãƒ³ã‚’注射ã™ã‚‹ã¨ç­‹è‚‰å†…ã§ç™½è¡€çƒã®ä¸€ç¨®ã®ã€Œãƒžã‚¯ãƒ­ãƒ•ã‚¡ãƒ¼ã‚¸ã€ãŒéŽå‰°ã«é›†ã¾ã‚Šã€ã‚¢ãƒ«ãƒŸãƒ‹ã‚¦ãƒ ã‚’å–り込んã§åˆ†è§£ã§ããªã„ã¾ã¾å…¨èº«ã¸åºƒãŒã£ã¦ç‚Žç—‡ã‚’èµ·ã“ã™ã¨ã—ã€ä¸€éƒ¨ã¯è„³ã«ãŸã¾ã‚Šã€ç¥žçµŒã‚„èªçŸ¥ã®éšœå®³ã®åŽŸå› ã«ãªã‚‹ã¨èª¬æ˜Žã—ãŸã€‚ 　シン・ãƒãƒ³ãƒ»ãƒªãƒ¼ç±³ã‚¨ãƒ¼ãƒ«å¤§å…ƒå‡†æ•™æŽˆï¼ˆç—…ç†å­¦ï¼‰ã¯ã€å­å®®é ¸ãŒã‚“を引ãèµ·ã“ã™ã‚¦ã‚¤ãƒ«ã‚¹ã®ï¼¤ï¼®ï¼¡ãŒã‚¢ãƒ«ãƒŸãƒ‹ã‚¦ãƒ ã«å¸ç€ã—ã€äººä½“ã«æ¿€ã—ã„自己å…疫疾患を引ãèµ·ã“ã™ã¨ã®è¦‹è§£ã‚’示ã—ãŸã€‚ 　ワクãƒãƒ³æŽ¥ç¨®å¾Œã«æ€¥æ­»ã—ãŸä¸‰äººã®å°‘女ã®è„³ã‚’調ã¹ãŸã‚«ãƒŠãƒ€ã®ãƒ–リティッシュ・コロンビア大学ã®ãƒ«ãƒã‚¸ãƒ£ãƒ»ãƒˆãƒ ãƒ«ã‚¸ã‚§ãƒŽãƒ“ック研究助手ã¯ã€ã‚·ãƒ³ãƒã‚¸ã‚¦ãƒ å¾Œã®ä¼šè¦‹ã§ã€Œã“ã‚Œã»ã©æ¿€çƒˆãªå‰¯ä½œç”¨ãŒä¸–界中ã§èµ·ãã¦ã„ã‚‹ã®ãŒç¾å®Ÿã€‚ã™ã¹ã¦ã®å›½ã§æŽ¥ç¨®ã‚’å³åˆ»ä¸­æ­¢ã™ã‚‹ã¹ãã ã€ã¨è©±ã—ãŸã€‚ 　厚労çœã¯äºŒåå…­æ—¥åˆå¾Œã€å°‚門部会を開ãã€ç¾åœ¨ä¸­æ­¢ã—ã¦ã„る接種勧奨をå†é–‹ã™ã‚‹ã‹æ¤œè¨Žã™ã‚‹ã€‚åŒæ—¥åˆå‰ã€ã‚·ãƒ³ãƒã‚¸ã‚¦ãƒ ã«å‚加ã—ãŸåŒ»å­¦è€…も呼んã§æ„見をèžã場を設ã‘ã‚‹ãŒã€å°‚門部会ã®è­°è«–ã«å映ã•ã›ã‚‹ã‹ã¯åˆ†ã‹ã‚‰ãªã„ã¨ã—ã¦ã„る。ã€ï¼ˆå…¨æ–‡ï¼‰ ◆「å­å®®é ¸ãŒã‚“ワクãƒãƒ³æŽ¥ç¨®è€…調査ã€å›žç­”ã®ï¼”割「体調変化ã€ã€ 　æœæ—¥æ–°èžã€�N014å¹´2月24æ—¥07時19分 　<a href="httpa_/www.asahi.com/articletzAS{G4K7JG2GUTIL01L.html">httpa_/www.asahi.com/articletzAS{G4K7JG2GUTIL01L.htmlÃ_a> ã€€ã€Œæ–Žè—¤æ™ºå­ ã€€å­å®®é ¸ï¼ˆã‘ã„）ãŒã‚“ワクãƒãƒ³æŽ¥ç¨®å¾Œã«é•·æœŸçš„ãªç—›ã¿ãªã©ã‚’訴ãˆã‚‹äººãŒç›¸æ¬¡ãŽã€å›½ãŒæŽ¥ç¨®ã®æŽ¨å¥¨ã‚’中止ã—ãŸå•é¡Œã§ã€ï¼–自治体ãŒç‹¬è‡ªã«æŽ¥ç¨®è€…ã®è¿½è·¡èª¿æŸ»ã‚’ã—ãŸã¨ã“ã‚ã€ã„ãšã‚Œã‚‚４割å‰å¾Œã®äººãŒä½•ã‚‰ã‹ã®ä½“調変化ãŒã‚ã£ãŸã¨å›žç­”ã—ã¦ã„ãŸã“ã¨ãŒã‚ã‹ã£ãŸã€‚接種推奨ã®å†é–‹ã‚’視野ã«å…¥ã‚Œã‚‹ï¼’ï¼–æ—¥ã®å›½ã®æ¤œè¨Žä¼šã‚’å‰ã«ã€æ‚£è€…や専門家ã‹ã‚‰ã¯åŽŸå› ç©¶æ˜Žã‚’求ã‚る声ãŒä¸ŠãŒã£ã¦ã„る。 　□「全員ã®è¿½è·¡èª¿æŸ»ã‚’〠　神奈å·çœŒèŒ…ケ崎市ã¯ã€ï¼’ï¼ï¼‘１年３月～１３年１ï¼æœˆã«æŽ¥ç¨®ã—ãŸå°å­¦ï¼–å¹´ã‹ã‚‰å¤§å­¦ç”Ÿã¾ã§ã®è¨ˆï¼•ï¼’７５人ã«ã‚¢ãƒ³ã‚±ãƒ¼ãƒˆã‚’é€ã‚Šã€ï¼’３８２人ã‹ã‚‰å›žç­”ã‚’å¾—ãŸã€‚接種後ã«ä½“調ã®å¤‰åŒ–ãŒã‚ã£ãŸã¨ç­”ãˆãŸã®ã¯ï¼™ï¼’１人（３８・７％）。「注射部ã®ç—›ã¿ãªã©ã€ï¼—ï¼ãƒ»ï¼™ï¼…ã€ã€Œä½“ã®ã ã‚‹ã•ãªã©ã€ï¼‘１・１％ã€ã€Œæ‰‹è¶³ã®ç—›ã¿ã€ï¼“・７％ã€ã€Œå¤±ç¥žã€ï¼ãƒ»ï¼–ï¼…ãªã©ã®ç—‡çŠ¶ãŒã‚ã‚Šã€èª¿æŸ»æ™‚点ã§ç—‡çŠ¶ãŒç¶šã„ã¦ã„ãŸäººã¯ï¼‘５人ã ã£ãŸã€‚ 　ã“ã†ã—ãŸä½“調変化ã¯åºƒç¾©ã®å‰¯ä½œç”¨ã«å½“ãŸã‚‹ã€‚ãã‚Œã¾ã§åŒå¸‚ãŒæŠŠæ¡ã—ã¦ã„ãŸå‰¯ä½œç”¨ãŒå‡ºãŸäººæ•°ã¯ï¼•äººã€‚担当者ã¯ã€Œã‚„ã£ã¨å…¨ä½“åƒãŒã¤ã‹ã‚ãŸã€ã¨è©±ã™ã€‚ � ログインã—ã¦ç¶šãを読む 無料登録ã—ã¦ç¶šãを読む　残り:1910文字ï¼æœ¬æ–‡ï¼šÕ0¡0é0Ã0É0(� T)�文字　無料会員ã¯ï¼‘日３本ã¾ã§ã€æœ‰æ–™ä¼šå“¡ã¯ä½•æœ¬ã§ã‚‚ãŠèª­ã¿ã„ãŸã ã‘ã¾ã™ã€‚〠■ 　※以下ã¯æ–°ã—ã„ã‚‚ã®ãŒä¸‹ ◆全国å­å®®é ¸ãŒã‚“ワクãƒãƒ³è¢«å®³è€…連絡会 　<a href="http:å]shikyuukeigan.fem.jp.".">http:å]shikyuukeigan.fem.jp/</a> â—†20Ó0ë0/1ñ]28　「å­å®®é ¸ãŒã‚“ワクãƒãƒ³å‰¯ä½œç”¨ã€ŒN件　４～７月〠　日本経済新èžã€€20Ó0ë0/1ñ]28 19:55 　<a href="http:å]www.nikkei.com/article/DGXNASD{AS4E_Y3A(�åe)�1C1CR800ñ]">httpa_/www.nikkei.coÛwarticl0uDGXNASDG2804E_1�¹pA0CRAS00/</a> 　「å­å®®é ¸ï¼ˆã‘ã„）ãŒã‚“ワクãƒãƒ³æŽ¥ç¨®å¾Œã«æ…¢æ€§çš„ãªç—›�ï¾ãŒç”Ÿã˜ã‚‹å‰¯ä½œç”¨ãŒå ±å‘Šã•ã‚Œã¦ã„ã‚‹å•é¡Œã§ã€åŽšç”ŸåŠ´åƒçœã¯28æ—¥ã€ï¼”月ã‹ã‚‰ï¼—月末ã«å‰¯ä½œç”¨ã®å ±å‘Šã4l件ã‚ã£ãŸã“ã¨ã‚’明らã‹ã«ã—ãŸã€‚ã“ã®ã†ã¡å®šæœŸæŽ¥ç¨®ãŒå§‹ã¾ã£ãŸï¼”月以é™ã«æŽ¥ç¨®ã—ãŸæ‚£è€…ã‹ã‚‰ã®è¨´ãˆã¯(�*h)�9件。åŒçœã®å°‚門部会ã«å ±å‘Šã—ãŸã€‚ 　報告ã«ã‚ˆã‚‹ã¨ã€ãƒ¯ã‚¯ãƒãƒ³ã‚’製造・販売ã™ã‚‹ï¼’社ã‹ã‚‰83件ã€åŒ»ç™‚æ©Ÿé–¢ã‹ã‚AS08件ã®å‰¯ä½œç”¨å ±å‘ŠãŒãã‚Œãžã‚Œå¯„ã›ã‚‰ã‚ŒãŸã€‚医療機関ã®ã†ã¡ã€å…¨èº«ã®ç—›ã¿ã‚’ä¼´ã†ãªã©åŒ»å¸«ãŒé‡ç¯¤ã¨åˆ¤æ–­ã—ãŸã‚±ãƒ¼ã‚¹ã¯87件ã‚ã£ãŸã€ N009å¹´(�*h)�月ã®ãƒ¯ã‚¯ãƒãƒ³è²©å£²é–‹å§‹ã‹ã‚‰ä»Šå¹´ï¼—月ã¾ã§ã®å‰¯ä½œç”¨å ±å‘Šã¯è¨ˆ(� g)�59件ã¨ãªã£ãŸã€‚ 　å­å®®é ¸ãŒã‚“ã¯ä»Šå¹´ï¼”月ã‹ã‚‰ãƒ¯ã‚¯ãƒãƒ³ãŒåŽŸå‰‡ç„¡æ–™ã¨ãªã‚‹å®šæœŸäºˆé˜²æŽ¥ç¨®ã«åŠ ã‚ã£ãŸã€‚ワクãƒãƒ³ã¯ã€Œã‚µãƒ¼ãƒãƒªãƒƒã‚¯ã‚¹ã€ã¨ã€Œã‚¬ãƒ¼ãƒ€ã‚·ãƒ«ã€ã®ï¼’種類。接種後ã«åŽŸå› ä¸æ˜Žã®ç—›ã¿ã‚„ã‘ã„れんãªã©å‰¯ä½œç”¨ãŒç–‘ã‚れる報告ãŒç›¸æ¬¡ã„ã ãŸã‚ã€åŽšåŠ´çœã¯ï¼–月ã€æŽ¥ç¨®å‹§å¥¨ã®ä¸€æ™‚中止を決ã‚ãŸã€‚〠◆20Ó0ë0/1ñ]28　「å­å®®é ¸ãŒã‚“ワクãƒãƒ³:é‡ã„副作用報告１４３件〠　読売新èž(��N)�01z^10(�W)�8 　<a href="httpa_/www.yomiuri.co.jp/nationaîvnews(�W)�01ª(�åe)�8-OYfT01426.htm">httpa_/www.yomiuri.co.jp/nationaîvnews(�W)�01ª(�åe)�8-OYfT01426.htmÃ_a> 　「å­å®®é ¸ã‘ã„ãŒã‚“ワクãƒãƒ³ã®æŽ¥ç¨®å¾Œã«é‡ã„副作用ãŒå‡ºã¦ã„ã‚‹å•é¡Œã§åŽšç”ŸåŠ´åƒçœã¯ï¼’８日ã€ä»Šå¹´ï¼”月ã‹ã‚‰ï¼—月末ã¾ã§ã«ï¼‘４３件ã®é‡ã„副作用報告ãŒã‚ã£ãŸã“ã¨ã‚’明らã‹ã«ã—ãŸã€‚［…］〠◆薬害オンブズパースン会議　20Ó0ë0/1r^25 「「å­å®®é ¸ãŒã‚“ワクãƒãƒ³ã€ï¼ˆï¼¨ï¼°ï¼¶ãƒ¯ã‚¯ãƒãƒ³ï¼‰ã®è²»ç”¨å¯¾åŠ¹æžœã«é–¢ã™ã‚‹è¦‹è§£ã€ 　全文：<a href="httpa_/www.yakugai.gr.jp/topictzfile/hpvkenkai.pdf">httpa_/www.yakugai.gr.jp/topictzfile/hpvkenkai.pdfÃ_a> 　è¦æ—¨ï¼š<a href="httpa_/www.yakugai.gr.jp/topictztopic.php?id=8Õ0é0ó0">httpa_/www.yakugai.gr.jp/topictztopic.php?id=8Õ0é0ó0Ã_a> 　当会議ã¯ã€ï¼’ï¼ï¼‘３年１２月２５日付ã§ã€ã€Œå­å®®é ¸ãŒã‚“ワクãƒãƒ³ã€ï¼ˆï¼¨ï¼°ï¼¶ãƒ¯ã‚¯ãƒãƒ³ï¼‰ã®è²»ç”¨å¯¾åŠ¹æžœã«é–¢ã™ã‚‹è¦‹è§£ã‚’公表ã—ã¾ã—ãŸã€‚ 　以下ã¯ã€ãã®è¦æ—¨ã§ã™ï¼ˆå…¨æ–‡ã¯ã€æœ«å°¾è³‡æ–™æ¬„をクリックã—ã¦ã”覧ãã ã•ã„）。 １ã€0�å­å®®é ¸ãŒã‚“ワクãƒãƒ³ã¯ã€ï¼’ï¼ï¼‘３年４月ã«å®šæœŸæŽ¥ç¨®åŒ–ã•ã‚Œã¾ã—ãŸãŒã€å®šæœŸæŽ¥ç¨®åŒ–決定ã«å½“ãŸã£ã¦ã¯ã€åŽšç”ŸåŠ´åƒçœåŽšç”Ÿç§‘学審議会感染症分科会予防接種部会ã«ãŠã„ã¦ã€ãƒ¯ã‚¯ãƒãƒ³ã®æœ‰åŠ¹æ€§ã¨å®‰å…¨æ€§ã«åŠ ãˆè²»ç”¨å¯¾åŠ¹æžœã‚‚é‡è¦ãªè¦ç´ ã¨ã—ã¦è€ƒæ…®ã•ã‚Œã¾ã—ãŸã€2� 　ã¨ã“ã‚ãŒã€ä½œæ¥­ãƒãƒ¼ãƒ å ±å‘Šæ›¸ã«ãŠã„ã¦æ–‡çŒ®ãƒ¬ãƒ“ューã®å¯¾è±¡ã¨ã—ãŸè«–æ–‡ã®ã†ã¡ã€�\ã«æ•´ç†ã—ã¦ã¾ã§ç´¹ä»‹ã—ã¦ã„る国内先行研究ã®ï¼‘ã¤ã«ã¤ã„ã¦ã€ãƒ¯ã‚¯ãƒãƒ³ã®è£½é€ è²©å£²ãƒ¡ãƒ¼ã‚«ãƒ¼ã§ã‚るグラクソ・スミスクライン社ã®ç¤¾å“¡ãŒåŸ·ç­†ã—ã¦ã„ãŸã«ã‚‚ã‹ã‹ã‚らãšã€ãã®äº‹å®ŸãŒè«–æ–‡ã«æ˜Žè¨˜ã•ã‚Œã¦ã„ãªã‹ã£ãŸã“ã¨ãŒæ˜Žã‚‰ã‹ã«ãªã‚Šã¾ã—ãŸã€‚ 　ã“ã‚Œã«å¯¾ã—ã€ã‚°ãƒ©ã‚¯ã‚½ãƒ»ã‚¹ãƒŸã‚¹ã‚¯ãƒ©ã‚¤ãƒ³ç¤¾ã¯ã€å ±é“ã«ã‚ˆã‚Œã°ã€è«–文発表ã®ä»•æ–¹ã®ä¸é©åˆ‡ã•ã¯èªã‚ãªãŒã‚‰ã€å†…容ã«ã¯å•é¡ŒãŒãªã„旨をコメントã—ã¦ã„ã¾ã™ã€2� ï¼’ 　ã—ã‹ã—ã€å†…容ã«ã‚‚å•é¡ŒãŒã‚ã‚Šã¾ã™ã€‚ 　ＨＰＶワクãƒãƒ³ã¯ã€ï¼‘ï¼–åž‹ã¨ï¼‘８型ã®ï¼¨ï¼°ï¼¶ã«ã—ã‹åŠ¹æžœãŒã‚ã‚Šã¾ã›ã‚“。ã“ã®ä¸¡åž‹ãŒå ã‚る割åˆï¼ˆè”“延率）を仮ã«ç´„５ï¼ï½žï¼—ï¼ï¼…ã¨è¦‹ã‚‹ã¨ã—ã¦ã‚‚ã€å®šæœŸæŽ¥ç¨®åŒ–ã«ã‚ˆrるワクãƒãƒ³æŽ¥ç¨®çŽ‡ãŒï¼‘ï¼ï¼ï¼…ã«ãªã‚‹ã¨ã„ã†ã“ã¨ã¯ã‚ã‚Šãˆãšã€ãƒ¯ã‚¯ãƒãƒ³ãŒæŽ¥ç¨®è€…全員ã«æœ‰åŠ¹æ€§ã‚’発æ®ã™ã‚‹ã‚ã‘ã§ã¯ã‚ã‚Šã¾ã›ã‚“ã‹ã‚‰ã€ãƒ¯ã‚¯ãƒãƒ³ã®åŠ¹æžœã¯è”“延率を下回るã¯ãšã§ã™ã€‚ã¾ãŸã€ãã‚‚ãã‚‚ã€ï¼¨ï¼°ï¼¶ãƒ¯ã‚¯ãƒãƒ³ã®åŠ¹æžœã¨ã—ã¦è¨¼æ˜Žã•ã‚Œã¦ã„ã‚‹ã®ã¯ã€ç•°å½¢æˆã‚’防止ã™ã‚‹åŠ¹æžœã®ã¿ã§ã€å­å®®é ¸ãŒã‚“ãã®ã‚‚ã®ã‚’防ã効果ã¯è¨¼æ˜Žã•ã‚Œã¦ã„ã¾ã›ã‚“。異形æˆé˜²æ­¢ã«ã¤ã„ã¦ã‚‚最長ã§ï¼™å¹´é–“ã®ãƒ‡ãƒ¼ã‚¿ã—ã‹ã‚ã‚Šã¾ã›ã‚“。 　ã«ã‚‚ã‹ã‹ã‚らãšã€ä¸Šè¨˜ã®è«–æ–‡ã¯ã€ãƒ¯ã‚¯ãƒãƒ³ã«ã‚ˆã£ã¦å­å®®é ¸ãŒã‚“ã®ç½¹æ‚£ã‚„死亡を７ï¼ï¼…以上減少ã•ã›ã‚‹ã¨ã„ã†å‰æã«ç«‹ã¡ã€ã—ã‹ã‚‚ã€ï¼’ï¼ä»£ã‹ã‚‰ï¼“ï¼ä»£ã®å¥³æ€§ã®ç«‹å ´ã«ç«‹ã£ãŸæ¤œè¨Žã§ã‚ã‚‹ã¨ã—ã¦ã€ãƒ¯ã‚¯ãƒãƒ³ã®æŽ¥ç¨®è²»ç”¨ã‚’ゼロã¨ã—ã¦è¨ˆç®—ã—ã¦ã„ã¾ã™ã€2� 　ã“ã®ã‚ˆã†ãªå‰æã§ã®è²»ç”¨å¯¾åŠ¹æžœæŽ¨è¨ˆã¯ã€ã‚°ãƒ©ã‚¯ã‚½ãƒ»ã‚¹ãƒŸã‚¹ã‚¯ãƒ©ã‚¤ãƒ³ç¤¾ã®ç¤¾å“¡ã¨ã—ã¦è‡ªç¤¾ã«æœ‰åˆ©ãªçµè«–ã‚’å°ŽããŸã‚ã«è¡Œã£ãŸåã‚Šã§ã‚ã‚‹ã¨ã„ã†ä»–ã¯ãªãã€ã—ã‹ã‚‚本æ¥ã®æ‰€å±žã§ã‚ã‚‹ä¼æ¥­åã‚’ä¼ã›ã¦å…¬è¡¨ã—ãŸã®ã§ã™ã‹ã‚‰ã€ã“ã‚Œã¯å…¨ä½“ã¨ã—ã¦æ„図的ãªæ“作ã§ã‚ã‚‹ã¨è©•ã•ã‚Œã¦ã‚‚致ã—æ–¹ã‚ã‚Šã¾ã›ã‚“ã€2� 　ãªãŠã€åŽšåŠ´çœã®å°å§”員会ã®ä½œæ¥­ãƒãƒ¼ãƒ ãŒè¡¨ã¾ã§ä½œæˆã—ã¦ç´¹ä»‹ã—ãŸå›½å†…è«–æ–‡ã¯ï¼“ã¤ã§ã€ä¸Šè¨˜ã®è«–æ–‡ã®ä»–ã«ï¼’ã¤ã‚ã‚Šã¾ã™ãŒã€ã„ãšã‚Œã«ã¤ã„ã¦ã‚‚ã€ã‚°ãƒ©ã‚¯ã‚½ãƒ»ã‚¹ãƒŸã‚¹ã‚¯ãƒ©ã‚¤ãƒ³ç¤¾ã®ãƒ¯ã‚¯ãƒãƒ³äº‹æ¥­ã‚’扱ã†ã‚°ãƒ«ãƒ¼ãƒ—会社ã®ç¤¾å“¡ãŒåŸ·ç­†ã«åŠ ã‚ã£ã¦ã„ã¾ã™ã€2� ３ã€0�費用対効果ã®æŽ¨è¨ˆã®å‰æã¨ãªã‚‹ãƒ¯ã‚¯ãƒãƒ³ã®åŠ¹æžœã‚’éŽå¤§ã«è©•ä¾¡ã—ã¦ã„ã‚‹ã¨ã„ã†å•é¡Œç‚¹ã¯ã€åŽšç”ŸåŠ´åƒçœã®äºˆé˜²æŽ¥ç¨®éƒ¨ä¼šã®å°å§”員会報告書ã«ã‚‚ã‚ã¦ã¯ã¾ã‚Šã¾ã™ã€2� 　å°å§”員会報告書ã¯ã€ŒåŒ»ç™‚経済的ãªè©•ä¾¡ã«ã¤ã„ã¦ã¯ã€ãƒ¯ã‚¯ãƒãƒ³ã®é•·æœŸçš„ãªåŠ¹æžœã®æŒç¶šæœŸé–“ãŒæ˜Žç¢ºã«ãªã£ã¦ã„ãªã„ã“ã¨ã‹ã‚‰ã€ï¼‘３歳女å­ã«æŽ¥ç¨®ã—ãŸãƒ¯ã‚¯ãƒãƒ³ãŒç”Ÿæ¶¯æœ‰åŠ¹ã§ã‚ã‚‹ã¨ä»®å®šã—ã¦ã€è²»ç”¨åŠ¹æžœåˆ†æžã‚’è¡Œã£ãŸå ´åˆã€LQALYç²å¾—ã‚ãŸã‚Šç´„ï¼’ï¼ï¼‘万円ã¨æŽ¨è¨ˆã•ã‚Œã€è²»ç”¨å¯¾åŠ¹æžœã¯è‰¯å¥½ã¨è€ƒãˆã‚‰ã‚ŒãŸã€‚ã€ã¨ã—ã¦ã„�é©ï¾Œã§ã™ã€2� 　ワクãƒãƒ³ã®åŠ¹æžœæŒç¶šæœŸé–“ãŒä¸æ˜Žã§ã‚ã‚‹ã‹ã‚‰ã€ç”Ÿæ¶¯æœ‰åŠ¹ã¨ä»®å®šã™ã‚‹ã¨ã„ã†ã®ã¯ã€è‘—ã—ã„飛èºã§ã‚ã‚Šåˆç†æ€§ã‚’欠ã„ã¦ã„ã¾ã™ã€‚ 　ＨＰＶワクãƒãƒ³ãŒå­å®®é ¸ãŒã‚“を減少ã•ã›ã‚‹åŠ¹æžœã¯ã€ŒæœŸå¾…ã•ã‚Œã‚‹ã€ã¨ã—ã‹ã„ãˆãªã„一方ã§ã€ãƒ¯ã‚¯ãƒãƒ³æŽ¥ç¨®ã¾ã§ã¯å¥åº·ã§é€šå­¦ã—ã¦ã„ãŸå°‘女é”ãŒã€é€šå­¦ã§ããªããªã‚‹ã€è»Šæ¤…å­ã§ã®ç”Ÿæ´»ã‚’余儀ãªãã•ã‚Œã‚‹ã€å°†æ¥ã®å¤¢ã‚’諦ã‚ã–ã‚‹ã‚’å¾—ãªããªã‚‹ã¨ã„ã£ãŸæ·±åˆ»ãªè¢«å®³ãŒç¾ã«ç™ºç”Ÿã—ã¦ã„ã¾ã™ã€‚ã¨ã“ã‚ãŒã€ã“ã†ã—ãŸè¢«å®³ã«é–¢ã—ã¦ç”Ÿã˜ã‚‹åŒ»ç™‚費や経済的ãªæ失ã¯ã€è²»ç”¨å¯¾åŠ¹æžœã®æŽ¨è¨ˆã§ã¯ä¸€åˆ‡è€ƒæ…®ã®å¯¾è±¡ã¨ãªã£ã¦ã„ã¾ã›ã‚“。 　ワクãƒãƒ³ã¯ã€å¥åº·ãªäººã«æŽ¥ç¨®ã™ã‚‹ã‚‚ã®ã§ã™ã‹ã‚‰ã€æ¥µã‚ã¦é«˜ã„安全性ãŒå¿…è¦ã§ã™ã€‚ＨＰＶワクãƒãƒ³ã¯ã€æœ‰åŠ¹æ€§ã¨å±é™ºæ€§ã®ãƒãƒ©ãƒ³ã‚¹ã‚’失ã—ã¦ãŠã‚Š ã€è²»ç”¨å¯¾åŠ¹æžœã®ç‚¹ã§ã‚‚é‡å¤§ãªå•é¡ŒãŒã‚ã‚Šã¾ã™ã€‚ 　当会議ã¯ã€ï¼’ï¼ï¼‘３年９月２５日付ã§ã€Œã€Žå­å®®é ¸ãŒã‚“ワクãƒãƒ³ï¼ˆãƒ’トパピローマウイルスワクãƒãƒ³ï¼‰ã€ã«é–¢ã™ã‚‹è¦æœ›æ›¸ã€(�を公表ã—ã€å®šæœŸæŽ¥ç¨®ã®ä¸­æ­¢ç­‰ã‚’求ã‚ã¦ã„ã¾ã™ãŒã€æ”¹ã‚ã¦å®šæœŸæŽ¥ç¨®ã®ä¸­æ­¢ã‚’求ã‚ã¾ã™ã€‚ 　ã¾ã—ã¦ã€ç©æ¥µæŽ¨å¥¨å†é–‹ãªã©æ–­ã˜ã¦ã™ã‚‹ã¹ãã§ã¯ã‚ã‚Šã¾ã›ã‚“ â—†20Ó0ë0/1r^15　「体中ã«æ¿€ç—›ãƒ»è»Šã„ã™ç”Ÿæ´»â€¦å­å®®é ¸ãŒã‚“ワクãƒãƒ³ã€è¢«å®³ç¶šã〠　æœæ—¥æ–°èpS013å¹´(�*h)�朅5æ—¥Ó0ë0æ™ N5分 　<a href="http:å]www.asahi.coÛwarticles/TKY20Ó0ë0(�*h)�150006.html">http:å]www.asahi.coÛwarticles/TKY20Ó0ë0(�*h)�150006.html</a> 　写真：図版電話相談ã«å¿œã˜ã‚‹è¢«å®³è€…連絡会事務局長ã®æ± ç”°åˆ©æµãƒ»æ—¥é‡Žå¸‚è­°ï¼æ—¥é‡Žå¸‚平山１ä¸ç›® �「ã€æ–Žè—¤æ™ºå­ã€‘å­å®®é ¸ï¼ˆã‘ã„）ãŒã‚“ワクãƒãƒ³æŽ¥ç¨®å¾Œã®å¥åº·è¢«å®³ãŒã€ä»Šã‚‚広ãŒã£ã¦ã„る。３月末ã«ç™ºè¶³ã—ãŸã€Œå…¨å›½å­å®®é ¸ãŒã‚“ワクãƒãƒ³è¢«å®³è€…連絡会ã€ï¼ˆæ¾è—¤ç¾Žé¦™ä»£è¡¨ã€æ—¥é‡Žå¸‚）ã«å…¨å›½ã‹ã‚‰å¯„ã›ã‚‰ã‚ŒãŸç›¸è«‡ã¯ã€ä»Šæœˆã¾ã§ã«ç´„８ï¼ï¼ä»¶ã€‚国ãŒã€ŒæŽ¥ç¨®ã‚’勧ã‚ã‚‹ã®ã‚’ã„ã£ãŸã‚“åœæ­¢ã™ã‚‹ã€ã¨æ±ºã‚ã¦ç´„åŠå¹´ã€‚今後ã®æ–¹é‡ã‚’話ã—åˆã†ï¼’５日ã®å›½ã®æ¤œè¨Žä¼šã‚’å‰ã«ã€ç¾çŠ¶ã‚’追ã£ãŸã€‚ 　□全身ã«æ¿€ç—›ã€é »ç¹ãªå¤±ç¥ž 　都内ã®é«˜æ ¡ï¼‘å¹´ã®ç”Ÿå¾’（１５）ã¯ä¸­å­¦ï¼’å¹´ã§æŽ¥ç¨®ã—ãŸæ•°æ—¥å¾Œã€è¶³é¦–ã®ç—›ã¿ã‚’æ„Ÿã˜ãŸã€‚æ¯è¦ªï¼ˆï¼”４）ã¯é‹å‹•éƒ¨ã®ã›ã„ã¨è€ƒãˆã€ï¼’回目を接種ã•ã›ãŸã€‚ãã®å¤œã‹ã‚‰ã€ä½“ã®ã‚ã¡ã“ã¡ã«é‹­ã„ç—›ã¿ãŒèµ°ã‚‹ã‚ˆã†ã«ãªã£ãŸã€‚ 　ç·åˆç—…院ã§æ¤œæŸ»ã‚’é‡ã­ãŸãŒã€ç•°å¸¸ã¯èªã‚られãšã€ã€Œç²¾ç¥žçš„ãªã‚‚ã®ã§ã¯ã€ã¨è¨€ã‚れ傷ã¤ã„ãŸã€‚今ã®ä¸»æ²»åŒ»ã«ãªã‚Šã€ã€Œé›£æ²»æ€§ç–¼ç—›ï¼ˆã¨ã†ã¤ã†ï¼‰ã€ã¨è¨ºæ–­ã•ã‚ŒãŸã€‚ 　通ã£ã¦ã„ãŸä¸­é«˜ä¸€è²«æ ¡ã«ã¯ã€æ¯è¦ªãŒè»Šã§é€è¿Žã—ã€é…刻や早退をã—ãªãŒã‚‰ã‚‚通ã†ã€‚ã—ã‹ã—ã€å¤‰ã‚らãªã„体調ã«æ¯è¦ªã¯ã€Œå¿ƒãŒæŠ˜ã‚Œã¦ã€ã“ã®å­ã¨ä¸€ç·’ã«æ­»ã®ã†ã‹ã¨æ€ã£ãŸã€ã¨æ‰“ã¡æ˜Žã‘る。高校ã§ã¯ã€ä½“育ãªã©ã„ãã¤ã‹ã®å˜ä½ãŒè¶³ã‚‰ãªã„ãŒã€å­¦æ ¡ãŒè£œè¬›ãªã©ã§é…æ…®ã—ã¦ãれるã®ãŒæ•‘ã„ã ã¨ã„ã†ã€‚ 　都内ã®äºˆå‚™æ ¡ç”Ÿï¼ˆï¼‘９）ã¯ã‚»ãƒ³ã‚¿ãƒ¼è©¦é¨“å‰ã«å—ã‘ãŸæŽ¥ç¨®ã§ä½“調ãŒæ‚ªåŒ–。高校ã®éšŽæ®µã§å¤±ç¥žã—ã¦æ•‘急æ¬é€ã•ã‚Œã¦å…¥é™¢ã—ã€å¼è­·å£«ã‚’ã‚ã–ã—ã¦å‹‰å¼·ã—ã¦ã„ãŸå¤§å­¦å—験を断念ã—ãŸã€‚［ログインã—ã¦ç¶šãを読む］ â—†20Ó0ë0/1r^27　「å­å®®é ¸ãŒã‚“ワクãƒãƒ³å•é¡Œã€åŠæ•°ã¯æŽ¥ç¨®å¾Œã®ç—›ã¿å›žå¾©ã€ 　æœæ—¥æ–°èž20Ó0ë0å¹´12月27æ—¥06時54分 　<a href="httpa_/www.asahi.com/articletzASF0TK2�9�01ª(� g)�50400.html">httpa_/www.asahi.com/articletzASF0TK2�9�01ª(� g)�50400.htmlÃ_a> 　「å­å®®é ¸ï¼ˆã‘ã„）ãŒã‚“ワクãƒãƒ³æŽ¥ç¨®å¾Œã«è…•ã‚„足ã«ç—›ã¿ã‚’訴ãˆã‚‹äººãŒç›¸æ¬¡ã„ã å•é¡Œã§ã€åŽšç”ŸåŠ´åƒçœã¯ï¼’５日ã€æ‚£è€…９７人ã®ã†ã¡åŠæ•°ã¯å›žå¾©ã¾ãŸã¯ç—‡çŠ¶ãŒè»½ããªã£ãŸã“ã¨ã‚’明らã‹ã«ã—ãŸã€‚専門医ã®ã„る医療施設を全国ã«ï¼‘７カ所整ãˆã¦ãŠã‚Šã€å°‚門家ã¯ã€Œæ—©æœŸã®æ²»ç™‚ã‚’å—ã‘ã‚Œã°ã€æ”¹å–„ã—ã‚„ã™ã„ã€ã¨æŒ‡æ‘˜ã€‚厚労çœã¯ï¼‘月以é™ã®æ¤œè¨Žä¼šã§ã€ãƒ¯ã‚¯ãƒãƒ³ã®æŽ¨å¥¨ã‚’å†é–‹ã™ã‚‹ã‹åˆ¤æ–­ã™ã‚‹è¦‹é€šã—ã ã€‚ 　ã“ã®æ—¥é–‹ã‹ã‚ŒãŸå‰¯ä½œç”¨ã®æ¤œè¨Žä¼šã§å…¬è¡¨ã—ãŸã€‚今後ã€æœªè§£æ±ºã®èª²é¡Œã‚„接種ã®ãƒªã‚¹ã‚¯ãªã©ã®è«–点をã¾ã¨ã‚る。 　厚労çœã«ã‚ˆã‚‹ã¨ã€é•·æœŸã«ã‚ãŸã‚‹è…•ã‚„足ã€é ­ãªã©ã®ç—›ã¿ã®å ±å‘Šã¯ãƒ¯ã‚¯ãƒãƒ³è²©å£²å¾Œã‹ã‚‰ä»Šå¹´ï¼™æœˆã¾ã§ã§è¨ˆï¼™ï¼—人。１ï¼æœˆã®å‰æ¤œè¨Žä¼šã‹ã‚‰ï¼’６人増ãˆãŸã€‚ãŸã ã€ï¼™ï¼—人ã®ã†ã¡ï¼‘２人ã¯æŽ¥ç¨®ä»¥å¤–ã®åŽŸå› ãŒç–‘ã‚ã‚ŒãŸã€‚４９人ã¯å›žå¾©ã‹è»½å¿«ã—ãŸãŒã€ã»ã‹ï¼”８人ã¯æœªå›žå¾©ã¾ãŸã¯çµŒéŽãŒä¸æ˜Žã ã£ãŸã€‚［ログインã—ã¦ç¶šãを読む］〠◆2014/0þ]20　平æˆï¼’５年度第７回厚生科学審議会予防接種・ワクãƒãƒ³åˆ†ç§‘会副å応検討部会ã€å¹³æˆï¼’５年度第８回薬事・食å“衛生審議会医薬å“等安全対策部会安全対策調査会　資料 　<a href="http:å]www.mhlw.go.jp/stf/shing}v0000Ô0³0(�yr)�20.html">http:å]www.mhlw.go.jp/stf/shing}v0000Ô0³0(�yr)�20.html</a> â—†2014/0þ]　「ワクãƒãƒ³å¾Œç—›ã¿ã€ã€Œå¿ƒèº«é¢ãŒå½±éŸ¿ã€ã€€å­å®®é ¸ãŒã‚“ã§æ¤œè¨Žä¼šã€ ã€�N014å¹´1月æ—¥05時00分 　<a href="httpa_/www.asahi.com/articletzDA3S10Ø0ë0Ä05865.html">http:å]www.asahi.coÛwarticles/DÛ0ü0ë0e0935865.htmlÃ_a> 　「å­å®®é ¸ï¼ˆã‘ã„）ãŒã‚“ワクãƒãƒ³æŽ¥ç¨®å¾Œã«è…•ã‚„足ã«é•·æœŸçš„ãªç—›ã¿ã‚’訴ãˆã‚‹äººãŒç›¸æ¬¡ã„ã å•é¡Œã§ã€åŽšç”ŸåŠ´åƒçœã®æ¤œè¨Žä¼šã¯ï¼’ï¼æ—¥ã€ç—‡çŠ¶ã®å¤šãã¯æŽ¥ç¨®ã«ã‚ˆã‚‹ç—›ã¿ã‚„è…«ã‚Œã§å¿ƒèº«ã®å応を引ãèµ·ã“ã•ã‚Œã€æ…¢æ€§åŒ–ã—ãŸã¨ã®è€ƒãˆã§ä¸€è‡´ã—ãŸã€‚ワクãƒãƒ³æˆåˆ†ãŒç›´æŽ¥ã®åŽŸå› ã«ãªã£ãŸå¯èƒ½æ€§ã«ã¤ã„ã¦ã¯ã€Œç§‘学的知見ã¯ãªã„ã€ã¨å¦å®šã€‚接種推奨ãŒå†é–‹ã•ã‚Œã‚‹å¯â€¦ã€€ï¼»ãƒ­ã‚°ã‚¤ãƒ³ã—ã¦ç¶šãを読む］〠◆薬害オンブズパースン・メールマガジン　No.36 � 　　　　　　　　　　　　　 　　　　　　　 2014.1(�Ñ‘)�2 発行 � 　　　　　　　　　　薬害オンブズパースン会議 � 　　　　　　　　　　　　 <a href="http:å]www.yakugai.gr.jp">http:å]www.yakugai.gr.jp</a> 　å­å®®é ¸ãŒã‚“ワクãƒãƒ³ã«é–¢ã™ã‚‹ï¼’ï¼ï¼‘４年１月２ï¼æ—¥ã®åŽšåŠ´çœå¯©è­°ä¼šã«ã¤ã„㦠　２ï¼ï¼‘４年１月２ï¼æ—¥ã«é–‹å‚¬ã•ã‚ŒãŸåŽšç”ŸåŠ´åƒçœã®å¯©è­°ä¼šï¼ˆâ€»ï¼‘）ã¯ã€å­å®®é ¸ãŒã‚“ワクãƒãƒ³æŽ¥ç¨®å¾Œã«å¤šæ•°ç™ºç”Ÿã—ã¦ã„る広範ãªç–¼ç—›ã¾ãŸã¯é‹å‹•éšœå®³ã«ã¤ã„ã¦ã€é‡ã‚’刺ã—ãŸç–¼ç—›ã®åˆºæ¿€ã‚„ä¸å®‰ãŒæƒ¹èµ·ã—ãŸå¿ƒèº«ã®åå¿œã§ã‚ã‚Šã€ãƒ¯ã‚¯ãƒãƒ³ã®æˆåˆ†ãŒåŽŸå› ã§ã¯ãªã„ã¨ã—ã¾ã—ãŸãŒã€ç¾æ™‚点ã§ã“ã®ã‚ˆã†ãªçµè«–ã‚’å°Žãã®ã¯èª¤ã‚Šã§ã™ã€‚ 　ã“ã®çµè«–ã¯ã€è€ƒãˆã‚‰ã‚Œã‚‹åŽŸå› ã¨ã—ã¦ã€1)神経学的疾患「N)中毒ã€3)å…ç–«åå¿œã€4)心身ã®å応を検討ã—ã€L)～3)ã‚’å¦å®šã—ã¦å°Žã„ãŸã‚‚ã®ã§ã™ã€‚ãã®éš›ã€L)～3)ã®åŽŸå› ã§ã¯èª¬æ˜Žã§ããªã„症例ãŒä¸€éƒ¨ã«å­˜åœ¨ã™ã‚‹ã“ã¨ã‚’根拠ã«ãã®åŽŸå› ã‚’å¦å®šã™ã‚‹ã¨ã„ã†æ‰‹æ³•ãŒã¨ã‚‰ã‚Œã¦ã„ã¾ã™ã€‚ 　ãŸã¨ãˆã°ã€ã€Œç¥žçµŒç–¾æ‚£ã«ã‚ˆã‚‹ä¸éšæ„é‹å‹•ã¯ä¸€èˆ¬ã«æ„識的ã«æ­¢ã‚られãªã„ã¯ãšã§ã‚ã‚‹ãŒã€æŽ¡è¡€æ™‚ã«ã¯ä¸éšæ„é‹å‹•ãŒåŽã¾ã‚‹ç—‡ä¾‹ãŒã‚ã‚‹ã€ã¨ã—ã¦ã€ãã®ã‚ˆã†ãªç—‡ä¾‹ã®å‰²åˆã‚‚示ã•ãªã„ã¾ã¾ã€ç¥žçµŒå­¦çš„疾患をå¦å®šã™ã‚‹æ ¹æ‹ ã®ä¸€ã¤ã¨ã—ã¦ã„ã¾ã™ã€‚ã—ã‹ã—ã€å¤šæ§˜ãªç—‡çŠ¶ã‚’示ã—ã¦ã„ã‚‹ã™ã¹ã¦ã®å‰¯å応症例ãŒåŒä¸€ã®åŽŸå› ã§ç”Ÿã˜ã¦ã„ã‚‹ã¨ã™ã‚‹æ ¹æ‹ ã¯ãªã„ã®ã§ã™ã‹ã‚‰ã€èª¬æ˜Žã§ããªã„症例ãŒä¸€éƒ¨ã«å­˜åœ¨ã™ã‚‹ã‹ã‚‰ã¨ã„ã£ã¦ã€èª¬æ˜Žã§ãã‚‹ãã®ä»–多ãã®ç—‡ä¾‹ã¾ã§ç¥žçµŒå­¦çš„疾患ã§ã¯ãªã„ã¨è¦‹ã‚‹ã“ã¨ã¯ã§ãã¾ã›ã‚“。 　ã“ã®ã‚ˆã†ãªæ¤œè¨Žæ‰‹æ³•ãŒéžç§‘学的ã§ã‚ã‚‹ã“ã¨ã¯æ˜Žã‚‰ã‹ã§ã™ã€‚厚労çœç ”究ç­ä»£è¡¨ã®æ± ç”°ä¿®ä¸€ä¿¡å·žå¤§æ•™æŽˆã‚‚ã€ã€Œå¿ƒç†çš„ã€ç¤¾ä¼šçš„ãªè¦å› ã ã‘ã§å…¨ã¦ã‚’説明ã™ã‚‹ã®ã¯å›°é›£ã§ã¯ãªã„ã‹ã€ã¨ã‚³ãƒ¡ãƒ³ãƒˆã—ã¦ã„ã¾ã™ï¼ˆâ€»ï¼’）。 　ã“ã®ç‚¹ã‚’ã¯ã˜ã‚ã€å­å®®é ¸ãŒã‚“ワクãƒãƒ³ã®ã‚ˆã†ãªæ–°è–¬ã§ã¯ã“ã‚Œã¾ã§ã«ãªã„タイプã®å‰¯åå¿œãŒç™ºç”Ÿã—ã¦ã„ã‚‹å¯èƒ½æ€§ãŒã‚ã‚‹ã«ã‚‚ã‹ã‹ã‚らãšã€ã€Œé€šå¸¸ã®åŒ»å­¦çš„見地ã€ã‚’根拠ã«æŽ¥ç¨®å¾Œï¼‘ヶ月以上ã—ã¦ã‹ã‚‰å‰¯åå¿œãŒå‡ºç¾ã—ãŸç—‡ä¾‹ã®å› æžœé–¢ä¿‚を安易ã«å¦å®šã™ã‚‹ãªã©ã€ä»Šå›žã®å¯©è­°ä¼šã®è­°è«–ã«ã¯å¤šãã®å•é¡ŒãŒã‚ã‚Šã¾ã™ï¼ˆâ€»ï¼“）�Bã¯ã˜ã‚ã‹ã‚‰çµè«–ã‚ã‚Šãã®å¯©è­°ã§ã‚ã‚Šã€å¤šæ§˜ãªå‰¯å応症例ã®åŽŸå› ç©¶æ˜ŽãŒé‚ã’られãŸã¨ã¯åˆ°åº•ã„ã†ã“ã¨ãŒã§ãã¾ã›ã‚“。 　厚労çœç ”究ç­ã«ã‚ˆã‚‹æ²»ç™‚体制ãŒçµ„ã¾ã‚ŒãŸå¾Œã‚‚ã€æœªã ã«åŠæ•°ã‚‚ã®è¢«å®³è€…ãŒæ²»ç™’ã›ãšå‰¯åå¿œã«è‹¦ã—ã‚“ã§ã„ã¾ã™ã€‚å分ãªç§‘学的検討を行ã‚ãšã«çµè«–を急ã審議会ã®å§¿å‹¢ã¯ã€å‰¯å応被害ã«è‹¦ã—む少女ãŸã¡ã«å¯¾ã—ã¦ã‚‚ãã‚ã‚ã¦ä¸èª å®Ÿã§ã‚ã‚Šã€åŽŸå› ç©¶æ˜ŽãŒãªã•ã‚Œãªã„ã¾ã¾æŽ¥ç¨®å‹§å¥¨ã‚’å†é–‹ã™ã‚Œã°ã€ã•ã‚‰ã«å¤šãã®è¢«å®³è€…ãŒç™ºç”Ÿã™ã‚‹ã“ã¨ã¯æ˜Žã‚‰ã‹ã§ã™ã€‚ 　次回審議会以é™ã€å‰¯åå¿œã®åŽŸå› ã«ã¤ã„ã¦ã‚らãŸã‚ã¦å分ãªå¯©è­°ã‚’è¡Œã†ã‚ˆã†æ±‚ã‚ã¾ã™ã€‚ （※１）平æˆï¼’５年度第７回厚生科学審議会予防接種・ワクãƒãƒ³åˆ†ç§‘会副å応検討部会ã€å¹³æˆï¼’５年度第８回薬事・食å“衛生審議会医薬å“等安全対策部会安全対策調査会 （※２）平æˆï¼’６年１月２１日信濃毎日新èžæœåˆŠ （※３）当会議ã¯ã€ãã®ä»–ã®å•é¡Œç‚¹ã‚‚å«ã‚ãŸã‚ˆã‚Šè©³ã—ã„分æžã‚’ã‚らãŸã‚ã¦å…¬è¡¨ã™ã‚‹äºˆå®šã§ã™ã€‚ ☆ã“ã®ãƒ¡ãƒ¼ãƒ«ãƒžã‚¬ã‚¸ãƒ³ã®è»¢é€ã¯è‡ªç”±ã§ã™ã€‚ 　新è¦ç™»éŒ²ã¯ã“ã¡ã‚‰ 　　â†o�<a href="http:å]f.blayn.jp/sÛw:y‹utf.php?id=yakugai">http:å]f.blayn.jp/sÛw:y‹utf.php?id=yakugai</a> ☆é…ä¿¡ã®åœæ­¢ã‚’希望ã•ã‚Œã‚‹æ–¹ã¯ã€ã“ã¡ã‚‰ã§æ‰‹ç¶šãã‚’è¡Œãªã£ã¦ãã ã•ã„。 　　→ <a href="httpa_/f.blayn.j:ysm/p/f/tf.php?id=yakugai">httpa_/f.blayn.j:ysm/p/f/tf.php?id=yakugaiÃ_a> 　薬害オンブズパースン会議・タイアップグループ 　ã€�N0-0(�åe)�2　æ±äº¬éƒ½æ–°å®¿åŒºæ–°å®¿1-14-4　AMビル4階 　TEL : 03（Õ0£0ü0È050）007　　FAX : 03（Õ0é0ó0Ø0¯0¿0ü0ë0）7080 　<a href="httpa_/www.yakugai.gr.jp.".">http:å]www.yakugai.gr.j:yÃ_a> 　Mail : infoã‚ã£ã¨yakugai.gr.jp â—†2014/0r^06　「「痛ã¿ã¯å¿ƒèº«ã®åå¿œã€çµè«–ã«æŠ—議　å­å®®é ¸ãŒã‚“ワクãƒãƒ³ã€ 　æœæ—¥æ–°èž2014å¹3�9�月6æ—-N1時16分 　<a href="httpa_/www.asahi.com/articletzAS{65SYBG26UTILÔ0³0H.html">httpa_/www.asahi.com/articletzAS{65SYBG26UTILÔ0³0H.htmlÃ_a> 　「å­å®®é ¸ï¼ˆã‘ã„）ãŒã‚“ワクãƒãƒ³æŽ¥ç¨®å¾Œã«é•·æœŸçš„ãªç—›ã¿ã‚’訴ãˆã‚‹äººãŒç›¸æ¬¡ãŽã€å›½ãŒæŽ¥ç¨®ã®æŽ¨å¥¨ã‚’中止ã—ã¦ã„ã‚‹å•é¡Œã§ã€åŽšç”ŸåŠ´åƒçœã®æ¤œè¨Žä¼šãŒç—›ã¿ã®åŽŸå› ã‚’「心身ã®åå¿œã€ã¨çµè«–ã¥ã‘ãŸã“ã¨ã«å…¨å›½ã®è¢«å®³è€…や支æ´è€…ãŒï¼–æ—¥ã€æŠ—è­°ã—ãŸã€‚ç´„ï¼’ï¼ï¼äººãŒå‚議院議員会館ã§ã€ŒæŽ¥ç¨®æŽ¨å¥¨ã®å†é–‹ã‚ã‚Šãã®çµè«–ã ã€ã¨å£°ã‚’上ã’ãŸã€‚ 　「全国å­å®®é ¸ãŒã‚“ワクãƒãƒ³è¢«å®³è€…連絡会ã€ãªã©ãŒä¸»å‚¬ã—ã€èŒ¨åŸŽçœŒã®ä¸­å­¦ï¼’å¹´ã®ç”Ÿå¾’ã¯ã€ŒåŒ»è€…ã«ãªã‚‹å¤¢ã‚’æ¨ã¦ãšã«ãŒã‚“ã°ã£ã¦ã„ã‚‹ãŒã€èº«ä½“ãŒè¨€ã†ã“ã¨ã‚’ãã‹ãªã„。気ã®ã›ã„ã ã¨è¨€ã‚ã‚Œã€ã¨ã¦ã‚‚æ‚”ã—ã„ã€ã¨è¨´ãˆãŸã€‚「薬害オンブズパースン会議ã€ã®æ°´å£çœŸå¯¿ç¾Žå¼è­·å£«ã¯ã€Œã‚¹ãƒ¢ãƒ³ã‚„サリドマイド薬害ã§ã‚‚未知ãªã‚‹ç–¾æ‚£ãŒèµ·ããŸã€‚æ–°ã—ã„ワクãƒãƒ³ã«ã¯æœªçŸ¥ã®å‰¯åå¿œãŒèµ·ã“ã‚Šã†ã‚‹ã¨ã„ã†ç†è§£ãŒãªã„ã€ã¨æ‰¹åˆ¤ã—ãŸã€‚ 　被害者を支æ´ã™ã‚‹ç¥žå¥ˆå·çœŒå¤§å’Œã€éŽŒå€‰ã€æ„›çŸ¥çœŒç¢§å—ã€ç†Šæœ¬çœŒåˆå¿—ã®å„市議もå‚加。å„市ã§å…¨æŽ¥ç¨®è€…ã«ã‚¢ãƒ³ã‚±ãƒ¼ãƒˆã—ãŸã¨ã“ã‚ã€ã„ãšã‚Œã‚‚４割å‰å¾Œã®äººã«ä½“調異常ãŒèµ·ãã¦ã„ã‚‹ã“ã¨ãŒå ±å‘Šã•ã‚ŒãŸã€‚「全国調査をã™ã¹ãã ã€ã¨è¨´ãˆãŸã€‚〠â—N01^(�åe)�/17　ã€è–¬å®³ã‚ªãƒ³ãƒ–ズパーソン：水å£çœŸå¯¿ç¾Žã€‘å­å®®é ¸ãŒã‚“ワクãƒãƒ³å‰¯å応検討部会ã®æ ¹æœ¬çš„ãªå•é¡Œç‚¹ 　<a href="http:å]www.youtube.coÛwwatch?v=D_TzlAMSiWA">http:å]www.youtube.coÛwwatch?v=D_TzlAMSiWA</a> ◆薬害オンブズパースン会議ã€�N014-(�åe)�(�(g)�4　「æ„見書 ＨＰＶワクãƒãƒ³ï¼ˆå­å®®é ¸ãŒã‚“ワクãƒãƒ³ï¼‰ã«é–¢ã™ã‚‹åŽšç”ŸåŠ´åƒçœã®å¯©è­°çµæžœæ‰¹åˆ¤ ï¼æŽ¥ç¨®ã®ç©æ¥µçš„勧奨ã®å†é–‹ã«å¼·ãå対ã™ã‚‹ï¼ã€ã‚’æ出 　<a href="http:å]www.yakugai.gr.j:ytopics/topic.php?id=86.".".">http:å]www.yakugai.gr.j:ytopics/topic.php?id=860</a> 　ＨＰＶワクãƒãƒ³ï¼ˆå­å®®é ¸ãŒã‚“ワクãƒãƒ³ï¼‰ã«é–¢ã™ã‚‹æ¤œè¨Žéƒ¨ä¼šã®å¯©è­°çµæžœã¯ã€çµè«–ã‚ã‚Šãã§ã‚ã‚Šéžç§‘学的ã§ã‚ã‚‹ ～接種ã®ç©æ¥µçš„勧奨ã®å†é–‹ã¯ã™ã¹ãã§ã¯ãªã„～ 　当会議ã§ãTS014å¹´1月20æ—¥ã«è¡Œã‚ã‚ŒãŸåŽšç”Ÿç§‘学審議会予防接種・ワクãƒãƒ³åˆ†ç§‘会副å応検討部会ãŒã€HPVワクãƒãƒ³ï¼ˆå­å®®é ¸ãŒã‚“ワクãƒãƒ³ï¼‰ã®æŽ¥ç¨®å¾Œã«èµ·ãã¦ã„る全身ã®ç—›ã¿ã‚„é‹å‹•éšœå®³ãªã©ã®ç—‡ä¾‹ã«ã¤ã„ã¦ã€ã„ãšã‚Œã‚‚ â€å¿ƒèº«ã®å応†ã§ã‚ã‚‹ã¨ã„ã†æ–¹å‘ã§çµè«–ã‚’ã¾ã¨ã‚よã†ã¨ã—ã¦ã„ã‚‹ã“ã¨ã«ã¤ã„ã¦ã€æ£æ„çš„ã§éžç§‘学的ã§ã‚ã‚‹ã¨ã—ã¦ã€æœ¬æ—¥ï¼ˆ2014å¹3�9�æœ]N4日）æ„見書を厚生労åƒå¤§è‡£ã€ãŠã‚ˆã³æ¤œè¨Žéƒ¨ä¼šã«å¯¾ã—ã¦æ出ã—ã¾ã—ãŸã€‚ 　æ„見書ã®ä¸»ãªå†…容ã¯ä»¥ä¸‹ã®é€šã‚Šã§ã™ã€‚ １　検討部会ã¯æ£æ„çš„ã§éžç§‘学的ãªæ¤œè¨Žã‚’ã—ã¦ãŠã‚Šä¸å½“ 　ãã®ç†ç”±ã¯ â‘ æ–°è¦ãƒ¯ã‚¯ãƒãƒ³ã§ã‚ã‚‹HPVワクãƒãƒ³ã®å‰¯ä½œç”¨ãŒã€å˜ä¸€ã®æ©Ÿåºã«ã‚ˆã£ã¦ç”Ÿã˜ã‚‹ã¨ã„ã†ç§‘学的根拠ã®ãªã„å‰æã«ç«‹ã£ã¦åˆ†æžã—ã¦ã„ã‚‹ã€2� â‘¡ã•ã¾ã–ã¾ãªç—‡çŠ¶ã®åŽŸå› ã‚’検討ã™ã‚‹ã«ã‚ãŸã‚Šã€ã€Œå¿ƒèº«ã®åå¿œã€ä»¥å¤–ã®ä»®èª¬ã«å¯¾ã—ã¦ã¯ã€èª¬æ˜Žå›°é›£ãªç—‡ä¾‹ç­‰ãŒä¸€éƒ¨ã«ã‚ã‚‹ã¨ã„ã†ç†ç”±ã§å¦å®šã—ã¦ã„ã‚‹ã®ã«å¯¾ã—ã¦ã€ã€Œå¿ƒèº«ã®åå¿œã€ä»®èª¬ã«å¯¾ã—ã¦ã¯ä¸€éƒ¨ã«èª¬æ˜Žå›°é›£ãªç—‡ä¾‹ç­‰ãŒã‚ã£ã¦ã‚‚ãれをèªã‚ã‚‹ã¨ã„ã†æ£æ„çš„ãªè«–法�?・gã—ã€çµè«–ã‚ã‚Šãã®æ¤œè¨Žã‚’ã—ã¦ã„ã‚‹ã€2� ③「通常ã®åŒ»å­¦çš„見地ã€ã‚’ã‚‚ã¨ã«åˆ¤æ–­ã—ã€æ–°ã—ã„医薬å“ã§ã¯æ—¢çŸ¥ã®çŸ¥è¦‹ã§ã¯èª¬æ˜Žã§ããªã„副作用ãŒèµ·ãã‚‹å¯èƒ½æ€§ãŒã‚ã‚‹ã“ã¨ã‚’無視ã—ã¦ã„る。éŽåŽ»ã®æ•°ã€…ã®è–¬å®³ã®æ•™è¨“を忘れãŸæ¤œè¨Žã¨è¨€ã‚ã–ã‚‹ã‚’å¾—ãªã„ã€2� ④本格的ã§ç§‘学的ãªç–«å­¦èª¿æŸ»ã‚’è¡Œã‚ãšã€ã“ã‚Œã¾ã§ã«å¾—られãŸã„ã‚ã°æ°·å±±ã®ä¸€è§’ã¨ã„ã†ã¹ã副作用ã«é–¢ã™ã‚‹æƒ…報をもã¨ã«å…¨ä½“ã‚’è«–ã˜ã€æŽ¥ç¨®ã¨ã®å› æžœé–¢ä¿‚ã‚’å¦å®šã—よã†ã¨ã—ã¦ã„ã‚" ç­‰ã®ç†ç”±ã§ã™ã€‚ ２　定期接種ã¯ä¸­æ­¢ã™ã¹ã(� 　従æ¥ã‹ã‚‰å½“会議ãŒä¸»å¼µã—ã¦ã„ã‚‹ã¨ãŠã‚Šã€ã“ã®HPVワクãƒãƒ³ã«ã¯ã€å®Ÿéš›ã«æŽ¥ç¨®ã«ã‚ˆã£ã¦å­å®®ãŒã‚“ã®ç™ºç”Ÿã‚’防ã„ã ã¨ã„ã†åŒ»å­¦çš„エビデンスã¯ãªãã€ã•ã¾ã–ã¾ãªå‰¯ä½œç”¨ãƒªã‚¹ã‚¯ã¨æ¯”較衡é‡ã™ã‚‹ãŸã‚ã®ã€ŒæŽ¥ç¨®ã«ã‚ˆã‚‹åˆ©ç›Šã€ãŒæ˜Žç¢ºã§ã¯ã‚ã‚Šã¾ã›ã‚“ã®ã§ã€å®šæœŸæŽ¥ç¨®ã¨ã—ã¦å…¨å›½ã®å¯¾è±¡å¹´é½¢ã®å°‘女全員ã«æŽ¥ç¨®ã‚’勧奨ã™ã‚‹ã ã‘ã®æ ¹æ‹ ãŒä¸è¶³ã—ã¦ã„ã¾ã™ã€‚予防接種法ã®è¶£æ—¨ã‹ã‚‰è€ƒãˆã¦ã‚‚ã€å®šæœŸæŽ¥ç¨®ã¯ä¸­æ­¢ã™ã¹ãã ã¨è€ƒãˆã¾ã™ã€2� ３　å分ãªæƒ…å ±æä¾›ã¯ã§ããšã€ç©æ¥µå‹§å¥¨ã®ä¸€æ™‚å·®ã—控ãˆã®ç†ç”±ã¯è§£æ¶ˆã•ã‚Œã¦ã„ãªã4� 　ã¾ã—ã¦ã€æŽ¥ç¨®ã®ç©æ¥µå‹§å¥¨ã‚’å†é–‹ã™ã‚‹ã¹ãã§ã¯ã‚ã‚Šã¾ã›ã‚“。厚労çœãŒã€æŽ¥ç¨®ã®ç©æ¥µå‹§å¥¨ã®ä¸€æ™‚å·®ã—控ãˆã®ç†ç”±ã¨ã—ãŸã€Œå分ã«æƒ…å ±æä¾›ã§ããªã„状æ³ã«ã‚ã‚‹ã“ã¨ã€ã¯ã€ä»Šã‚‚変ã‚ã‚ŠãŒãªã„ã‹ã‚‰ã§ã™ã€‚ ４　自己決定権を侵害ã™ã‚‹ãŠãã‚ŒãŒã‚ã‚" 　ç¾æ™‚点ã§ã¯ã€HPVワクãƒãƒ³ã«é–¢ã—ã¦ã€æœ¬äººã¨ä¿è­·è€…ãŒã€æŽ¥ç¨®ã‚’å—ã‘ã‚‹ã‹ã©ã†ã‹ã‚’é¸æŠžã™ã‚‹ã†ãˆã§å¿…è¦ãªæƒ…報をæä¾›ã™ã‚‹ã“ã¨ã¯ã§ããšã€ã‚¤ãƒ³ãƒ•ã‚©ãƒ¼ãƒ ãƒ‰ãƒ»ã‚³ãƒ³ã‚»ãƒ³ãƒˆã‚’ä¿éšœã™ã‚‹ã“ã¨ã¯ã€å®Ÿè³ªä¸Šä¸å¯èƒ½ã§ã™ã€‚ã«ã‚‚ã‹ã‹ã‚らãšã€ï¼¨ï¼°ï¼¶ãƒ¯ã‚¯ãƒãƒ³ã‚’定期接種ã®å¯¾è±¡ã¨ã—ã¦æŽ¥ç¨®ã®åŠªåŠ›ç¾©å‹™ã‚’課ã™ã‚‹ã“ã¨ã¯ã€è‡ªå·±æ±ºå®šæ¨©ã®ä¾µå®³ã«ã¤ãªãŒã‚‹ãŠãã‚ŒãŒã‚ã‚Šã¾ã™ã€2� ã“ã®ç‚¹ã‹ã‚‰ã‚‚ã€ï¼¨ï¼°ï¼¶ãƒ¯ã‚¯ãƒãƒ³ã®å®šæœŸæŽ¥ç¨®ã¯ä¸­æ­¢ã™ã¹ãã§ã‚ã‚Šã€ã¾ã—ã¦æŽ¥ç¨®ã®ç©æ¥µæŽ¨å¥¨ã‚’å†é–‹ã™ã‚‹ã¹ãã§ã¯ã‚ã‚Šã¾ã›ã‚“ã€2� 当会議HPã§ã¯ã€æœ¬æ„見書ã®ã»ã‹ã€ä»¥ä¸‹ã®è¦æœ›æ›¸ç­‰ã‚‚ã•ã‚Œã¦ã„ã¾ã™ã®ã§ã€ä¸‹è¨˜ã€Œé–¢é€£è³‡æ–™ãƒ»ãƒªãƒ³ã‚¯ç­‰ã€æ¬„よりã”å‚ç…§ãã ã•ã„ã€2� 「å­å®®é ¸ãŒã‚“ワクãƒãƒ³ã€ï¼ˆãƒ’トパピローマウイルスワクãƒãƒ³ï¼‰ã«é–¢ã™ã‚‹è¦æœ›æ›¸ å­å®®é ¸ãŒã‚“ワクãƒãƒ³ã«é–¢ã™ã‚‹æœ¬å½“ã®ï¼±ï¼†ï¼¡ 「å­å®®é ¸ãŒã‚“ワクãƒãƒ³ã€ï¼ˆï¼¨ï¼°ï¼¶ãƒ¯ã‚¯ãƒãƒ³ï¼‰ã®è²»ç”¨å¯¾åŠ¹æžœã«é–¢ã™ã‚‹è¦‹è§£ </div> ＊増補：<a href=".Û]ø|nr05.htm">中井 良平</a>(20(� g)�~) <di6�class="s">REV: …(��N)�01ª208, 09, .. 2014(�åe)�26, 28 … 0917, (�*h)�16, 20(� g)�0830, … 20Õ0¡0é0Ã0É0Ô0³0, †N(�åe)�30705-18, <hr> â—‡<a href=".Û](uf02.htm">医療éŽèª¤ã€åŒ»ç™‚事故ã€çŠ¯ç½ªâ€¦Ã_a>　 â—‡<a href="../d/c09.htm">ãŒã‚“（癌・ガン）Ã_a>　 â—‡<a href="../d/r06.htm">患者ã®æ¨©åˆ©</a>　 â—‡<a href=".Û](usm.htm">医療社会学</a>　 â—‡<a href=".Û](ums.htm">医療ã¨ç¤¾ä¼š</a>　 â—‡<a href=".Û](ul.htm">生存・生活Ã_a>　 Ã_div> <di6�class="sr"><a href="#top">TOP</a>　<a href="http:å]www.arsvi.com">HOME (http:å]www.arsvi.com)Ã_a>â—‡</div> <button id="page-top" class="page-top">Ã_button> <script type="texËzjavascript" src=".Û]js/import.js">Ã_script> </body>Ã_html> <�/�d�i�v�>�<�d�i�v� �c�l�a�s�s�=�"�n�a�k�e�d�_�c�t�r�l�"�>� �<�f�o�r�m� �a�c�t�i�o�n�=�"�/�i�n�d�e�x�.�c�g�i�/�c�o�n�t�r�a�s�t�"� �m�e�t�h�o�d�=�"�g�e�t�"� �n�a�m�e�=�"�g�a�t�e�"�>� �<�p�>�<�a� �h�r�e�f�=�"�h�t�t�p�:�/�/�a�l�t�s�t�y�l�e�.�a�l�f�a�s�a�d�o�.�n�e�t�"�>�A�l�t�S�t�y�l�e�<�/�a�>� �k0ˆ0c0f0 YÛcU0Œ0_0Ú0ü0¸0 �<�a� �h�r�e�f�=�"�h�t�t�p�:�/�/�w�w�w�.�a�r�s�v�i�.�c�o�m�/�d�/�h�p�v�v�.�h�t�m�"�>�(�-�&�g�t�;�ª0ê0¸0Ê0ë0)�<�/�a�>� �/� �<�l�a�b�e�l�>�¢0É0ì0¹0:� �<�i�n�p�u�t� �t�y�p�e�=�"�t�e�x�t�"� �n�a�m�e�=�"�n�a�k�e�d�_�p�o�s�t�_�u�r�l�"� �v�a�l�u�e�=�"�h�t�t�p�:�/�/�w�w�w�.�a�r�s�v�i�.�c�o�m�/�d�/�h�p�v�v�.�h�t�m�"� �s�i�z�e�=�"�2�2�"� �/�>�<�/�l�a�b�e�l�>� �<�l�a�b�e�l�>�â0ü0É0:� �<�s�e�l�e�c�t� �n�a�m�e�=�"�n�a�k�e�d�_�p�o�s�t�_�m�o�d�e�"�>� �<�o�p�t�i�o�n� �v�a�l�u�e�=�"�d�e�f�a�u�l�t�"�>�Ç0Õ0©0ë0È0<�/�o�p�t�i�o�n�>� �<�o�p�t�i�o�n� �v�a�l�u�e�=�"�s�p�e�e�c�h�"�>�ó—ðXÖ0é0¦0¶0<�/�o�p�t�i�o�n�>� �<�o�p�t�i�o�n� �v�a�l�u�e�=�"�r�u�b�y�"�>�ë0Ó0ØNM0<�/�o�p�t�i�o�n�>� �<�o�p�t�i�o�n� �v�a�l�u�e�=�"�c�o�n�t�r�a�s�t�"� �s�e�l�e�c�t�e�d�=�"�s�e�l�e�c�t�e�d�"�>�M‘r‚ÍSâŽ<�/�o�p�t�i�o�n�>� �<�o�p�t�i�o�n� �v�a�l�u�e�=�"�l�a�r�g�e�r�-�t�e�x�t�"�>�‡eW[áb'Y<�/�o�p�t�i�o�n�>� �<�o�p�t�i�o�n� �v�a�l�u�e�=�"�m�o�b�i�l�e�"�>�â0Ð0¤0ë0<�/�o�p�t�i�o�n�>� �<�/�s�e�l�e�c�t�>� �<�i�n�p�u�t� �t�y�p�e�=�"�s�u�b�m�i�t�"� �v�a�l�u�e�=�"�hˆ:y"� �/�>� �<�/�p�>� �<�/�f�o�r�m�>� �<�/�d�i�v�>� � � �